

Poractant Alfa

**CUROSURF<sup>®</sup>**

Natural inspiration



# **CLINICAL AND EXPERIMENTAL RESEARCH ON CUROSURF<sup>®</sup> AND RELATED TOPICS**

## **BIBLIOGRAPHY**

### **1985 - 2002**

Prof. Christian P. Speer, MD, FRCPE  
University Children's Hospital  
Würzburg, Germany

Prof. Tore Curstedt, MD, PhD  
Karolinska Hospital  
Department of Clinical Chemistry  
Stockholm, Sweden

Prof. Henry L. Halliday, MD, FRCP, FRCPE  
Royal Maternity Hospital  
Perinatal Medicine  
Belfast, UK

Prof. Bengt Robertson, MD, PhD, FRCPE  
Karolinska Hospital  
Department of Pathology  
Stockholm, Sweden

**CONTENT**

	Page
Preface	3
Original Articles	5
Review Articles	41
Books and Supplements	61
Book Chapters and Extended Abstracts	62
Abstracts	82
Proceedings	128

**PREFACE**

Surfactant replacement for respiratory distress syndrome is a good example of "evidence-based" medicine, evolving from animal experiments in the early 70's to the first babies successfully treated in clinical pilot studies about 10 years later. The efficacy of this new treatment was soon confirmed in large randomized clinical trials, showing rapid improvement in gas exchange, reduced incidence of air leak problems and lowered mortality. Several subsequent trials have addressed dosage and timing of surfactant treatment and new formulas for exogenous surfactant were introduced as soon as the basic principles of this new therapeutic approach were established. In recent years collaboration between pharmaceutical industry and university research teams has generated abundant information on the functional roles of various surfactant components in the lungs, especially in the neonatal period, and on the potential of surfactant therapy in various forms of lung disease. It has been claimed that surfactant therapy is one of the most extensively studied interventions in neonatal medicine. Detailed pharmacological documentation is available for several of the surfactant substitutes on the market, including Curosurf<sup>®</sup>, a modified surfactant isolated from minced porcine lungs.

In the present volume we have listed over 1400 publications dealing with Curosurf<sup>®</sup> and related topics in the time period 1984-2002. The list is almost certainly incomplete but may nevertheless serve as a source of references to specific information on the product as well as general aspects of the surfactant system in health and disease.

CHRISTIAN P. SPEER  
TORE CURSTEDT  
HENRY L. HALLIDAY  
BENGT ROBERTSON

May 1995

**PREFACE**

The physical and physiological properties of Curosurf<sup>®</sup>, a highly effective porcine surfactant containing only polar lipids and hydrophobic proteins, have been studied extensively in recent years. Most of this work has been carried out by a network of neonatologists and basic scientists, originally known as the Collaborative European Multicenter Study Group. This group has completed several international multicenter trials of Curosurf<sup>®</sup> treatment for neonatal respiratory distress syndrome, as well as extensive collaborative experimental work on biochemical, biophysical and physiological problems related to the pulmonary surfactant system. The original network has expanded in recent years and now also includes units in Israel, North America, Brazil and China. Annual workshops have been organized since 1986, and the proceedings of some of these meetings have been published in *Biology of the Neonate*. In the present volume, we have listed references to all original papers, review articles, book chapters, and abstracts published on Curosurf<sup>®</sup> and related topics by members of this group during the period 1985-1994. Papers resulting from collaboration with other teams have also been included. Although a large number of publications were identified, the list may still be incomplete. For obvious reasons, these publications largely deal with one particular surfactant preparation. Nevertheless, a number of fundamental problems are addressed and we believe the information represented by this bibliography is of interest to all investigators involved in surfactant research. The 760 listed papers are the impressive result of ten years of intensive work, fuelled by widespread enthusiastic support for this new therapy and by the joy and benefits of international collaboration.

CHRISTIAN P. SPEER

HENRY L. HALLIDAY

BENGT ROBERTSON

## ORIGINAL ARTICLES

Ainsworth SB, Beresford MW, Milligan DW, Shaw NJ, Matthews JN, Fenton AC, Ward Platt MP.

Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial.

Lancet 2000; 355: 1387-1392

Ainsworth SB, Milligan DW.

Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review.

Am J Respir Med 2002; 1: 417-433

Alfonso LF, Arnaiz A, Alvarez FJ, Baquoquan QQ, Díez-Pardo JA, Valls i Soler A, Tovar JA.

Lung hypoplasia and surfactant system immaturity induced in the fetal rat by prenatal exposure to Nitrofen.

Biol Neonate 1996; 69: 94-100

Almaas R, Robertson B, Linderholm B, Lundberg E, Saugstad OD, Moen A.

Reversal of meconium inhibition of pulmonary surfactant by ferric chloride, copper chloride, and acetic acid.

Am J Respir Crit Care Med 2000;162: 1789-1794

Alvarez FJ, Alfonso LF, Gastiasoro E, López Heredia J, Valls i Soler A.

Efectividad de la administración de surfactante natural exógeno en el fallo respiratorio experimental inducido por lavados pulmonares en ratas adultas.

Med Intensiva 1994; 18: 61-66

Alvarez FJ, Alfonso LF, Gastiasoro E, López-de-Heredia J, Valls i Soler A.

The effects of multiple small doses of exogenous surfactant on experimental respiratory failure induced by lung lavage in rats.

Acta Anesthesiol Scand 1995; 39: 970-974

Alvirefic Z, Elbourne D, European Union Antenatal TRH Network Steering Committee.

Thyrotropin releasing hormone and corticosteroids prior to preterm labour: a survey of current practice in nine European countries.

Eur J Obstet Gynecol Reprod Biol 1996; 68: 43-45

Alfirevic Z, Boer K, Brocklehurst P, Buimer M, Elbourne D, Kok J, Tansey S.

Two trials of antenatal thyrotropin releasing hormone for fetal maturation: stopping before due date. The antenatal TRH trial and the Thyroneth trial groups.

Br J Obstet Gynaecol 1999; 106: 898-906

Amato M, Hüppi P, Schneider H.

Neonatal IgE levels after surfactant replacement therapy. Preliminary observations.

Neonatalogica 1990; 2: 115-116

- Amato M, Hüppi P, Markus D, Herschkowitz N.  
Neurological function of immature babies after surfactant replacement therapy.  
*Neuropediatrics* 1991; 22: 43-44
- Amato M, Hüppi P, Markus D.  
Prevention of symptomatic patent ductus arteriosus with ethamsylate in babies treated with exogenous surfactant.  
*J Perinatol* 1993; 13: 2-7
- Amato M, Sun B, Robertson B.  
Ethamsylate and lung permeability in ventilated immature newborn rabbits.  
*Biol Neonate* 1994; 65: 103-107
- Amato M, Hüppi P, Markus D.  
Differential leucocyte count in babies treated with natural surfactant.  
*Am J Perinatol* 1994; 11: 33-36
- Amato M, Schürch S, Bachofen H, Burri PH.  
Effect of acidosis on bilirubin-lipid extract surfactant interaction.  
*Biol Neonate* 1995; 68: 301-307
- Amato M, Schürch S, Grunder R, Bachofen H, Burri PH.  
Influence of bilirubin on surface tension properties of porcine lipid extract and synthetic lung surfactant.  
*Arch Dis Child* 1996; 75: F1-F6
- Anceschi MM, Robertson B, Broccucci L, Barbati A, Grossmann G, Hedenborg L, Lundberg E, Petrelli A, Zaccardo G, Cosmi EV.  
Immunochemical and immunohistochemical evaluation of lung permeability in ventilated newborn rabbits.  
*Exp Lung Res* 1990; 16: 593-605
- Andersson M, Curstedt T, Jörnvall H, Johansson J.  
An amphipathic motif common to tumourolytic polypeptide NK-lysin and pulmonary surfactant polypeptide SP-B.  
*FEBS Lett* 1995; 362: 328-332
- Apostolidou I, Touloumi G, Papagaroufalis C.  
Factors associated with periventricular-intraventricular hemorrhage in premature neonates with severe respiratory distress syndrome treated with surfactant.  
*Ann Clin Paediatr Univ Atheniensis* 1994; 41: 303-308
- Bachofen H, Schürch S, Gerber U.  
Effects of fixatives on function of pulmonary surfactant.  
*J Appl Physiol* 2002; 93: 911-916

- Bahlmann H, Sun B, Nilsson G, Curstedt T, Robertson.  
Aerosolized surfactant in lung-lavaged adult rats: lung morphology and factors influencing the therapeutic response.  
*Acta Anaesthesiol Scand* 2000; 44: 612-622
- Balling K, Eschen CC, Verder H.  
Neonatal mortalitet og morbiditet ved svangerskabslængde mindre end 30 fulde uger for børn behandlet primært på et centralsygehus. Efterundersøgelse af en uselekteret, konsekutiv patientgruppe.  
*Ugeskr Læger* 2001; 163: 1058-1061
- Barsotti M, Chundu V, Slivka S, Stevens J, Hallman M.  
Effects of exogenous surfactant substitution on hemodynamics.  
*Lung* 1996; 174: 255-268
- Baur FM, Brenner B, Goetze-Speer B, Neu S, Speer CP.  
Natural porcine surfactant (Curosurf<sup>®</sup>) downregulates mRNA of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and TNF- $\alpha$  Type II receptor in lipopolysaccharide-stimulated monocytes.  
*Pediatr Res* 1998; 44: 32-36
- Bell AH, Skov L, Lundstrøm K, Saugstad OD, Greisen G.  
Cerebral blood flow and plasma hypoxanthine in relation to surfactant treatment.  
*Acta Paediatr* 1994; 83: 910-914
- Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B, Schollin J.  
Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome.  
*Acta Paediatr* 2000; 89: 460-464
- Berggren P, Curstedt T, Grossmann G, Nilsson R, Robertson B.  
Physiological activity of pulmonary surfactant with low protein content; effect of enrichment with synthetic phospholipids.  
*Exp Lung Res* 1985; 8: 29-51
- Berggren P, Lachmann B, Curstedt T, Grossmann G, Robertson B.  
Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress syndrome induced by repeated lung lavage.  
*Acta Anaesthesiol Scand* 1986; 30: 321-328
- Berggren P, Eklind J, Linderholm B, Robertson B.  
Bubbles and computer aided image analysis for evaluation of surfactant inhibition.  
*Biol Neonate* 1992; 61 (suppl 1): 15-20
- Berggren P, Rigaut JP, Curstedt T, Robertson B.  
Computerized image analysis of lung expansion patterns in surfactant treated immature newborn rabbits.  
*Respir Physiol* 1999; 115: 45-53

Bevilacqua G, Cosmi EV, Volante E, Parmigiani S, Gaioni L, Guerrini P, Chirico G, Curstedt T, Robertson B.

Trattamento della malattia della membrana ialine polmonare nel neonato con surfattante suppletivo.

Riv Ital Pediatr 1987; 13: 211-213

Bevilacqua G, Volante E, Parmigiani S, Cosmi EV, Gaioni L, Guerrini P, Rondini G, Curstedt T, Robertson B.

Il surfattante suppletivo nella terapia della malattia delle membrane ialine polmonari del neonato.

Neonatologia 1987; 1: 124-134

Bevilacqua G, Halliday H, Parmigiani S, Robertson B, Monici-Prete P, Tubman R, Valls i Soler A and members of the Collaborative European Multicenter Study Group.

Randomized multicentre trial with porcine natural surfactant for moderately severe neonatal respiratory distress syndrome.

J Perinat Med 1993; 21: 329-340

Bevilacqua G, Parmigiani S, Robertson B on behalf of the trial participants.

Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomized trial.

J Perinat Med 1996; 24: 609-620

Bevilacqua G, Chernev T, Parmigiani S, Yarakova N, Gaioni L, Volante E, Gambini L, Bussolati G.

Use of surfactant for prophylaxis versus rescue treatment of respiratory distress syndrome: experience from an Italian-Bulgarian trial.

Acta Biomed Ateneo Parmense 1997; 68: 47-54

Bevilacqua G.

Timing of exogenous surfactant administration in clinical practice. Report of a multi-center Italian observational study.

Acta Biomed Ateneo Parmense 2000; 71: 421-429

Björklund LJ, Vilstrup CT, Larsson A, Svenningsen NW, Werner O.

Changes in lung volume and static expiratory pressure-volume diagram after surfactant rescue treatment of neonates with established respiratory distress syndrome.

Am J Respir Crit Care Med 1996; 154: 918-923

Björklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, Vilstrup CT.

Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs.

Pediatr Res 1997; 42: 348-355

Björklund LJ, Ingimarsson J, Curstedt T, Larsson A, Robertson B, Werner O.

Lung recruitment at birth does not improve lung function in immature lambs receiving surfactant. Acta Anaesthesiol Scand 2001; 45: 986-993

- Blennow M, Jonsson B, Dahlström A, Sarman I, Bohlin K, Robertson B.  
Surfactantbehandling i kombination med CPAP minskar behovet av respiratorvård hos för tidigt födda barn med RDS.  
Läkartidningen 1999; 96:1571-1576
- Bongrani S, Fornasier M, Papotti M, Razzetti R, Robertson B.  
Lung gas volumes and expiratory time constant in immature newborn rabbits treated with natural or synthetic surfactant or detergents.  
Biol Neonate 1994; 65: 406-415
- Bongrani S, Fornasier M, Papotti M, Razzetti R, Curstedt T, Robertson B.  
Dose-response study of surfactant replacement in immature newborn rabbits.  
Prenat Neonat Med 1999; 4: 71-78
- Bouhafs RKL, Rauprich P, Herting E, Schröder A, Robertson B, Jarstrand C.  
Direct and phagocyte mediated lipid peroxidation of lung surfactant by group B streptococci. Lung 2000; 178: 317-329
- Büky B, Dévai G, Várady E, Rózavölgyi A, Kovách I, Kovács A, Jancsó G, Waldinger K, Görgényi A, Zsolnai B, Robertson B, Curstedt T.  
Treatment of severe hyaline membrane disease with surfactant (Curosurf®).  
Acta Paediatr Hung 1990; 30: 351-365
- Calkovská A, Sun B, Curstedt T, Renheim G, Robertson B.  
Combined effects of high-frequency oscillatory ventilation and surfactant therapy in experimental meconium aspiration syndrome.  
Act Anaesthesiol Scand 1999; 45: 135-145
- Clercx A, Vandenbussche G, Curstedt T, Johansson J, Jörnvall H, Ruyschaert JM.  
Structural and functional importance of the C-terminal part of the pulmonary surfactant polypeptide SP-C.  
Eur J Biochem 1995; 229: 465-472
- Collaborative European Multicenter Study Group.  
Surfactant replacement therapy for severe neonatal respiratory distress syndrome: An international randomized clinical trial.  
Pediatrics 1988; 82: 683-691

Collaborative European Multicenter Study Group.

Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome.

Eur J Pediatr 1991; 150: 433-439

Collaborative European Multicentre Study Group: Robertson B, Curstedt T, Tubman TRJ, Strayer D, Berggren P, Kok J, Koppe J, van Sonderen L, Halliday HL, McClure G, Reid M, McC, Oetomo S B, Okken A, Speer CP, Schröter W, Svenningsen N, Walti H, Relier J-P, Herin P, Parmigiani S, Bevilacqua G, Volante E, Compagnoni G, Guerini P, Rondini G, Gaioni L.

A 2 year follow-up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome.

Eur J Pediatr 1992; 151: 372-376

Corcoran JD, Berggren P, Sun B, Halliday HL, Robertson B, Curstedt T.

Comparison of surface properties and physiological effects of a synthetic and a natural surfactant in preterm rabbits.

Arch Dis Child 1994; 71: F165-F169

Corcoran JD, Sheehan O, O'Hare MMT, Halliday HL.

Tracheal surfactant protein A following treatment with Curosurf®.

Appl Cardiopulm Pathophysiol 1995; 5: 245-248

Cosmi EV, La Torre R, Di Iorio R.

Intraamniotic instillation of surfactant for prevention of neonatal respiratory distress syndrome (RDS): a preliminary report.

Appl Cardiopulm Pathophysiol 1996; 6: 3-5

Cosmi EV, La Torre R, Di Iorio R, Anceschi MM.

Surfactant administration to the human fetus in utero: a new approach to prevention of neonatal respiratory distress syndrome (RDS).

J Perinat Med 1996; 24: 191-193

Cosmi EV, La Torre R, Piazze JJ, Maranghi L, Lerro N, Bianco D, Anceschi MM.

Intraamniotic surfactant for the prevention of neonatal respiratory distress syndrome (IRDS): rationale and personal experience.

Eur J Obstet Gynecol Reprod Biol 1997; 71: 135-139

Cowan FM, Whitelaw A, Wertheim D, Silverman M.

Cerebral blood flow velocity after rapid surfactant administration.

Arch Dis Child 1991; 66: 1105-1109

Curstedt T, Jörnvall H, Robertson B, Bergman T, Berggren P.

Two hydrophobic low-molecular weight protein fractions of pulmonary surfactant; characterization and biophysical activity.

Eur J Biochem 1987; 168: 255-262

Curstedt T, Johansson J, Barros-Söderling J, Robertson B, Nilsson G, Westberg M, Jörnvall H.

Low-molecular-mass surfactant protein type 1. The primary structure of a hydrophobic 8-kDa

polypeptide with eight half-cystine residues.

Eur J Biochem 1988; 172: 521-525

Curstedt T, Johansson J, Persson P, Eklund A, Robertson B, Löwenadler B, Jörnvall H.

Hydrophobic surfactant-associated polypeptides: SP-C is a lipopeptide with two palmitoylated

cysteine residues, whereas SP-B lacks covalently linked fatty acyl groups.

Proc Natl Acad Sci USA 1990; 87: 2985-2989

Dambeanu JM, Parmigiani S, Marinescu B, Bevilacqua G.

Use of surfactant for prevention of respiratory distress syndrome in new-born infants in spontaneous breathing. A randomized multicentre clinical pilot-study.

Acta Biomed Ateneo Parmense 1997; 68: 39-45

Dehan M, Walti H, Denizot B.

Apport de surfactant exogène pour le traitement de la maladie des membranes hyalines.

Journées Parisiennes Pédiatrie, Flammarion-Médecine Sciences, Paris 1988; 292-297

De Sanctis GT, Tomkiewicz RP, Rubin BK, Schürch S, King M.

Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog.

Eur Respir J 1994; 7: 1616-1621

De Winter JP, Merth IT, Egberts J, van Bel F, Quanjer PH.

Changes of respiratory system mechanics in ventilated lungs of preterm infants with two different

schedules of surfactant treatment.

Pediatr Res 1994; 35: 541-549

De Winter JP, Merth IT, van Bel F, Egberts J, Brand R, Quanjer PH.

De effecten van surfactanttoediening op de elastische eigenschappen van het respiratoire systeem van preterme pasgeborenen.

Tijdschr Kindergeneeskde 1994; 62: 57-62

De Winter JP, Egberts J, Merth IT, Peerdeman A, van Bel F, Bakker GC, Quanjer PH.

Biochemical lung maturity, static respiratory compliance, and pulmonary gas transfer in intubated preterm infants with and without respiratory distress syndrome.

Pediatr Pulmonol 1995; 20: 152-159

Dolfin TZ, Zamir CH, Regev R, Ben-Ari J, Wollach B.

Effect of surfactant replacement therapy on the outcome of premature infants with respiratory distress syndrome.

Isr J Med Sci 1994; 30: 267-270

Egberts J.

Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation.

Biol Neonate 1992; 61: 59-65

Egberts J, de Winter JP, Sedin G, de Kleine M, Broberger U, van Bel F, Curstedt T, Robertson B.

Comparison of prophylaxis and rescue treatment with Curosurf® in neonates less than 30 weeks gestation: A randomized trial.

Pediatrics 1993; 92: 768-774

Egberts J, de Winter JP.

Meta-analyses of surfactant and bronchopulmonary dysplasia revisited.

Lancet 1994; 24; 344: 882

Egberts J, de Winter JP, van Sonderen L, van den Anker JN.

Een theoretische berekening van de kosten van de neonatale zorg na een eventueel profylactisch of therapeutisch gebruik van surfactant.

Tijdschr Kindergeneeskde 1994; 62: 97-104

Egberts J.

Theoretical changes in neonatal hospitalisation costs after the introduction of porcine-derived lung surfactant (Curosurf®).

Pharmacoeconomics 1995; 8: 324-342

Egberts J, Brand R, Walti H, Bevilacqua G, Bréart G, Gardini. F.

Mortality, severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than therapeutic administration of the surfactant Curosurf®.

Pediatrics 1997; 100: e4

Ennema JJ, Kobayashi T, Robertson B, Curstedt T.

Inactivation of exogenous surfactant in experimental respiratory failure induced by hyperoxia.

Acta Anaesthesiol Scand 1988; 32: 665-671

Fernández-Ruanova MB, Alvarez FJ, Gastiasoro E, Arnaiz A, Robertson B, Curstedt T, Valls i Soler A.

Comparison of rapid bolus instillation with simplified slow administration of surfactant in lung lavaged rats.

Pediatr Pulmonol 1998; 26: 129-134

Fiori RM, Diniz EM, Lopes JM, Goncalves AL, da Costa MT, Marino WT, Abdallah VO, Segre CA, De Carvalho M, Guimaraes WM, Margotto PR, Bevilacqua G.

Surfactant replacement therapy: a multicentric trial comparing two dosage approaches.

Acta Biomed Ateneo Parmense 1997; 68: 55-62

Fiori HH, Linderholm B, Fiori RM, Robertson B.

Computerized image analysis of bubbles in gastric aspirate for prediction of respiratory distress syndrome.

Acta Paediatr 2001; 1: 1402-1404

Floros J, Fan R, Matthews A, DiAngelo S, Luo J, Nielsen H, Dunn M, Gewolb IH, Koppe J, van Sonderen L, Farri-Kostopoulos L, Tzaki M, Rămet M, Merrill J.

Family-based transmission disequilibrium test (TDT) and case-control association studies reveal surfactant protein A (SP-A) susceptibility alleles for respiratory distress syndrome (RDS) and possible race differences.

Clin Genet 2001; 60: 178-187

Fornasier M, Puccini P, Razzetti R, Acerbi D, Bongrani S, Ventura P.

Evaluation of potentially injurious effects of exogenous surfactant lysophospholipids on the alveolar epithelium and pulmonary mechanics.

Biol Neonate 1997; 71: 337-344

Friedrich W, Schmalisch G, Haufe M, Kling R, Wauer RR.

Surface tension measurements on pharyngeal and tracheal aspirate samples from newborns without and with respiratory distress syndrome.

Biol Neonate 1996; 70: 75-83

Gadzinowski J, Rudnicki J, Sakey S, Patalan J.

Leczenie skojarzone zespołu zaburzeń oddychania u noworodków przy pomocy podania surfaktantu i przyspieszenia dojrzałości płuc noworodka - doniesienie wstępne.

(Combined treatment of RDS with surfactant and acceleration of lung maturation in newborn infants - preliminary results.)

Klin Perinat Gin 1992; suppl I: 161-162

Gadzinowski J, Szymankiewicz M, Twarowska I, Halliday HL.

Ocena leczenia surfaktantem noworodków z zespołem zaburzeń oddychania. I. Wpływ na wymianę gazową.

(Surfactant administration in neonates with respiratory distress syndrome. 1. Importance in gas exchange.)

Ginek Pol 1992; 3: 101-104

Gadzinowski J, Halliday HL, Szymankiewicz M, Rzymska I, Solawa M.

Ocena leczenia surfaktantem noworodków z zespołem zaburzeń oddychania. II. Obraz radiologiczny.

(Surfactant administration in neonates with respiratory distress syndrome. 2. Radiographic changes.)

Ginek Pol 1992; 8: 373-376

Gadzinowski J, Halliday HL, Szymankiewicz M, Bręborowicz GH, Sackey S, Sobczak E.  
Ocena leczenia surfaktantem noworodków z zespołem zaburzeń oddychania. III. Rola  
wewnątrzmacicznej stymulacji dojrzałości płuc.

(Evaluation of surfactant administration in neonates with respiratory distress syndrome.  
3. The role of intra-uterine stimulation on lung maturity.)

Ginek Pol 1993; 2: 74-77

Gan XZ, Jarstrand C, Herting E, Berggren P, Robertson B.

Effect of surfactant and specific antibody on bacterial proliferation and lung function in  
experimental pneumococcal pneumonia.

Int J Infect Dis 2001; 5: 9-18

Griffiths WJ, Gustafsson M, Yang Y, Curstedt T, Sjövall J, Johansson J.

Analysis of variant forms of porcine surfactant polypeptide-C by nano-electrospray mass  
spectrometry.

Rapid Commun Mass Spectrom 1998; 12: 1104-1114

Gross NT, Jarstrand C, Robertson B.

Treatment of experimental cryptococcus neoformans infection in newborn rabbits by  
airway instillation of specific antibody and surfactant.

Lett Appl Microbiol 2000; 31:218-222

Grossmann G, Nilsson R, Robertson B.

Scanning electron microscopy of epithelial lesions induced by artificial ventilation of the  
immature neonatal lung; the prophylactic effect of surfactant replacement.

Eur J Pediatr 1986; 145: 361-367

Grossmann G, Suzuki Y, Robertson B, Kobayashi T, Berggren P, Kurashima K, Li WZ,  
Song GW, Sun B.

Pathophysiology of neonatal lung injury induced by monoclonal antibody to surfactant  
protein B.

J Appl Physiol 1997; 82: 2003-2010

Grossmann G, Tashiro K, Kobayashi T, Suzuki Y, Matsumoto Y, Waseda Y, Akino T,  
Curstedt T, Robertson B.

Experimental neonatal respiratory failure induced by lysophosphatidylcholine: effect of  
surfactant treatment.

J Appl Physiol 1999; 86: 633-640

Gustafsson M, Curstedt T, Jörnvall H, Johansson J.

Reverse-phase HPLC of the hydrophobic pulmonary surfactant proteins - detection of a  
surfactant protein C isoform containing N<sup>ε</sup>-palmitoyllysine.

Biochem J 1997; 326: 799-806

Gustafsson M, Vandenbussche G, Curstedt T, Ruysschaert JM, Johansson J.

Surfactant protein B and mimic peptides in the function of pulmonary surfactant – answer  
(Editorial)

FEBS Lett 1998; 430: 425

Gustafsson M, Palmblad M, Curstedt T, Johansson J, Schürch S.  
Palmitoylation of a pulmonary surfactant protein-C analogue affects the surface associated lipid reservoir and film stability.  
Biochim Biophys Acta 2000; 1466: 169-178

Halliday HL, McClure BG, Reid MMcC.  
Growth and development two years after artificial surfactant replacement at birth.  
Early Hum Dev 1986; 13: 323-327

Halliday H, Robertson B, Nilsson R, Rigaut J-P, Grossmann G.  
Automated image analysis of alveolar expansion patterns in immature newborn rabbits treated with natural or artificial surfactant.  
Br J Exp Pathol 1987; 68: 727-732

Halliday HL, McCord FB, McClure BG, Reid MMcC.  
Acute effects of instillation of surfactant in severe respiratory distress syndrome.  
Arch Dis Child 1989; 64: I3-I6

Halliday HL, Robertson B.  
Letter to the Editor: Cerebral blood flow velocity changes after rapid administration of surfactant.  
Arch Dis Child 1992; 67: 470

Halliday HL.  
Introducing new cost effective treatments into the NHS. Surfactant treatment for premature babies: who cares enough to pay?  
Qual Health Care 1993; 2: 195-197

Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC and the Collaborative European Multicentre Study Group.  
Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (The Curosurf<sup>®</sup> 4 Trial).  
Arch Dis Child 1993; 66: 276-280

Halliday HL.  
Natural vs synthetic surfactants in neonatal respiratory distress syndrome.  
Drugs 1996; 51: 225-237

Halliday HL, Speer CP, Robertson B on behalf of the Collaborative Surfactant Study Group.  
Treatment of severe meconium aspiration syndrome with porcine surfactant.  
Eur J Pediatr 1996; 155: 1047-1051

Hallman M, Merritt TA, Kari A, Bry K.  
Factors affecting surfactant responsiveness.  
Ann Med 1991; 23: 693-698

- Hanssler H, Zhou C, Roll C, Wiesemann HG.  
Effekte der Surfactant-Substitution auf die Lungenfunktion Frühgeborener mit schwerem Atemnotsyndrom.  
Pädiatr Grenzgeb 1994; 32: 31-39
- Harms K, Herting E.  
Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia.  
Respiration 1994; 61: 348-352
- Haumont D, Rössle C, Clercx A, Spehl M, Biver A, Richelle M, Carpentier YA.  
Modifications of surfactant phospholipid pattern in premature infants treated with Curosurf®: Clinical and dietary correlations.  
Biol Neonate 1992; 61 (suppl 1): 37-43
- Haumont D, Waroquier L, Van Herreweghe I.  
Outcome of very low birthweight infants treated with early surfactant and early dexamethasone. Biol Neonate 1998; 74: 43-56
- Hellström-Westas L, Bell AH, Skov L, Greisen G, Svenningsen NW.  
Cerebro-electrical depression following surfactant treatment in preterm neonates.  
Pediatrics 1992; 89: 643-647
- Hermon M, Golej J, Burda G, Boigner H, Stoll E, Vergesslich K, Strohmaier W, Pollak A, Trittenwein G.  
Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit.  
Shock 2002; 17: 247-251
- Herting E, Speer CP, Harms K, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller O, McClure BG, McC Reid M, Tubman TRJ, Herin P, Noack G, Kok J, Koppe J, van Sonderen L, Laufkoetter E, Kohler W, Boenisch H, Albrecht K, Roll C, Hanssler L, Haim M, Oetomo SB, Okken A, Altfield PC, Groneck P, Kachel W, Relier JP, Walti H.  
Factors influencing morbidity and mortality in infants with severe respiratory distress syndrome treated with a single or multiple doses of a natural porcine surfactant.  
Biol Neonate 1992; 61 (suppl 1): 26-30
- Herting E, Tubman R, Halliday HL, Harms K, Speer CP, Curstedt T, Robertson B.  
Einfluß von zwei unterschiedlichen Dosierungen eines porcinen Surfactants auf den pulmonalen Gasaustausch Frühgeborener mit schwerem Atemnotsyndrom.  
Monatschr Kinderheilkd 1993; 141: 721-727
- Herting E, Gefeller O, Speer CP, Harms K, Halliday HL, Curstedt T, Robertson B.  
Intracerebral haemorrhages in surfactant treated neonates with severe respiratory distress syndrome (RDS): age at diagnosis, severity and risk factors.  
Eur J Pediatr 1994; 153: 842-849

Herting E, Jarstrand C, Rasool O, Curstedt T, Sun B, Robertson B.  
Experimental neonatal group B streptococcal pneumonia: Effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits.  
*Pediatr Res* 1994; 36: 784-791

Herting E, Jarstrand C, Rasool O, Håkansson S, Curstedt T, Robertson B.  
Effect of surfactant on nitroblue tetrazolium (NBT) reduction of polymorphonuclear leucocytes stimulated by opsonized type Ia group B streptococci.  
*Acta Paediatr* 1995; 84: 922-926

Herting E, Speer CP, Sun B, Jarstrand C, Curstedt T, Robertson B.  
Einfluß von Surfactant auf das pulmonale Entzündungsgeschehen und die Elastasefreisetzung bei experimenteller neonataler B-Streptokokken-Pneumonie.  
*Monatsschr Kinderheilkd* 1996; 144: 1319-1325

Herting E, Sun B, Jarstrand C, Curstedt T, Robertson B.  
Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia.  
*Arch Dis Child* 1997; 76: F3-F8

Herting E, Strayer DS, Jarstrand C, Sun B, Robertson B.  
Lung function and bacterial proliferation in experimental neonatal pneumonia in ventilated rabbits exposed to monoclonal antibody to surfactant protein A.  
*Lung* 1998; 176: 123-131

Herting E, Gan XZ, Rauprich P, Jarstrand C, Robertson B.  
Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B-streptococcal pneumonia.  
*Am J Respir Crit Care Med* 1999; 159: 1862-1867

Herting E, Gefeller O, Land M, van Sonderen L, Harms K, Robertson B and Members of the Collaborative European Multicenter Study Group : Koppe J, Papagaroufalis C, Porz F, Bernsau U, Kravel X, Riverola A, Sweet DG, Halliday HL, Valls-I-Soler A, Wagner M, Segerer H, Obladen M, Boenisch H, Clercx A, Dinger J, Rinaldi G, Magaldi R, Tuo P, Silvestri G, Roll C, Hannsler L, Schiffman JH, Noth R, Pralle L, Domhof S, Pichler G, Müller W, Altfeld C, Natzschka, Groneck P, Morandi F, Babnik J, Compagnoni G, Foresti B, Marraro G, Porcelli F, Motta G, Svenningsen NW, Zanardo V, Kassis M, Voyer M, Walti H, Relier JP, Bevilacqua G, Parmigiani S, Noack G, de Kliene M.  
Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. *Pediatrics* 2000; 106: 957-964

Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B.  
Resistance of different surfactant preparations to inactivation by meconium.  
*Pediatr Res* 2001; 50: 44-49

Herting E, Schiffmann JH, Roth Ch, Zaltash S, Johansson J.  
Surfactant lavage demonstrates protein fibrils in a neonate with congenital surfactant protein B deficiency.

Am J Respir Crit Care Med 2002; 166: 1292-1294

Herting E, Möller O, Schiffmann JH, Robertson B.  
Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome.

Acta Paediatr 2002; 91: 1174-1178

Huang WX, Song GW, Gan XZ.

The improvement of oxygenation of injured lungs by exogenous surfactant replacement in rats.

Chin J Pathophysiol 1999; 15: 125-127

Huang QW, Sun B, Gao F, Zhang YM, Wu Y, Zhu LW, Lindwall R.

Effects of inhaled nitric oxide and high frequency ventilation in rabbits with meconium aspiration.

Biol Neonat 1999; 76: 374-382

Ingimarsson J, Björklund LJ, Larsson A, Werner O.

The pressure at the lower inflection point has no relation to airway collapse in surfactant-treated premature lambs.

Acta Anaesthesiol Scand 2001; 45: 690-695

Jarstrand C, Wiernik A, Curstedt T, Sundqvist KG.

Lung surfactant inhibits the lipopolysaccharide induced release of oxygen radicals, enzymes and interleukin-1 from phagocytes.

Immun Infect Dis 1991; 1: 179-182

Johansson J, Curstedt T, Robertson B, Jörnvall H.

Size and structure of the hydrophobic low-molecular weight surfactant-associated polypeptide.

Biochemistry 1988; 27: 3544-3547

Johansson J, Jörnvall H, Eklund H, Christensen N, Robertson B, Curstedt T.

Hydrophobic 3.7 kDa surfactant polypeptide: structural characterization of the human and bovine forms.

FEBS Lett 1988; 232: 61-64

Johansson J, Curstedt T, Jörnvall H.

Surfactant protein B: Disulfide bridges, structural properties and kringle similarities.

Biochemistry 1991; 30: 6917-6921

Johansson J, Persson P, Löwenadler B, Robertson B, Jörnvall H, Curstedt T.

Canine hydrophobic surfactant polypeptide SP-C: A lipopeptide with one thioester-linked palmitoyl group.

FEBS Lett 1991; 281: 119-122

- Johansson J, Jörnvall H, Curstedt T.  
Human surfactant polypeptide SP-B. Disulfide bridges, C-terminal end, and peptide analysis of the airway form.  
FEBS Lett 1992; 301: 165-167
- Johansson J, Curstedt T, Robertson B.  
The proteins of the surfactant system.  
Eur Respir J 1994; 7: 372-391
- Johansson J, Szyperski T, Curstedt T, Wüthrich K.  
The NMR structure of the pulmonary surfactant-associated polypeptide SP-C in an apolar solvent contains a valyl-rich ( $\alpha$ -helix).  
Biochemistry 1994; 33: 6015-6023
- Kazzi, SNJ, Schürch S, McLaughlin KL, Romero R, Janisse J.  
Surfactant phospholipids and surface activity among pre-term infants with respiratory distress syndrome who develop bronchopulmonary dysplasia.  
Acta Paediatr 2000; 89: 1218-1225
- Kelly KP, Stenson BJ, Drummond GB.  
Randomized comparison of partial liquid ventilation, nebulized perfluorocarbon, porcine surfactant and combined treatment on oxygenation, lung mechanics and survival in rabbits after saline lung lavage.  
Intensive Care Med 2000; 26: 1523-1530
- Klamer A, Greisen G.  
Tidligere surfaktantbehandling – også til nasalCPAP behandlede, meget for tidligt fødte børn?  
Ugeskr Læger 2001; 163: 7053-7056
- Kobayashi T, Curstedt T, Grossmann G, Robertson B.  
Inhibition of exogenous surfactant in ventilated immature newborn rabbits.  
Respir Physiol 1989; 76: 1-12
- Kobayashi T, Shido A, Nitta K, Inui S, Murakami S, Robertson B.  
The critical concentration of surfactant in fetal lung liquid at birth.  
Respir Physiol 1990; 80: 181-192
- Kobayashi T, Nitta K, Curstedt T, Grossmann G, Robertson B, Suzuki Y.  
Inhibition of pulmonary surfactant-associated protein B (SP-B) by monoclonal antibody: change of surface activity.  
J Jpn Med Soc Biol Interface 1990; 21: 97-103
- Kobayashi T, Ganzuka M, Li W-Z, Grossmann G, Robertson B, Suzuki Y.  
Inhibition of pulmonary surfactant-associated protein B (SP-B) by monoclonal antibody: physiological and histological deteriorations of the lung.  
J Jpn Med Soc Biol Interface 1990; 21: 104-110

Kobayashi T, Nitta K, Ganzuka M, Inui S, Grossmann G, Robertson B.  
Inactivation of exogenous surfactant by pulmonary edema fluid.  
*Pediatr Res* 1991; 29: 353-356

Kobayashi T, Nitta K, Takahashi R, Kurashima K, Robertson B, Suzuki Y.  
Activity of pulmonary surfactant after blocking the associated SP-A and SP-B proteins.  
*J Appl Physiol* 1991; 71: 530-536

Kobayashi T, Robertson B, Grossmann G, Nitta K, Curstedt T, Suzuki Y.  
Exogenous porcine surfactant (Curosurf<sup>®</sup>) is inactivated by monoclonal antibody to the surfactant-associated hydrophobic protein SP-B.  
*Acta Paediatr* 1992; 81: 665-671

Kornacka M, Szczapa J, Szymankiewicz M, Żak L.  
Surfactant replacement therapy and intraventricular haemorrhage.  
*Klin Perinat Ginek* 1993; suppl.III: 49-54

Kovács A, Jancsó G., Kovách I, Büky B.  
Exogenous surfactant replacement therapy in neonatal respiratory distress syndrome.  
*Gyermekgyógyászat* 1991; 42: 146-155

Kovács A, Jancsó G, Büky B, Adamovich K, Alexy M, Békefi D, Bors Z, Gagyi D, Katona M, Kerekes L, Nagy A, Nobilis A, Szüts A, Zubovics L.  
Surfactant replacement therapy in neonatal respiratory distress syndrome. Hungarian multicenter trial.  
*Gyermekgyógyászat* 1993; 44: 450-459

Kovács A, Büky B.  
Comparative study of natural and artificial surfactant. Products in treatment of premature with RDS.  
*Gyermekgyógyászat* 1995; 6: 530-537

Kroner J, Hjelt K, Nielsen JE, Kardorf UB, Verderer H.  
Den neonatale mortalitet, morbiditet og senfølger hos børn med fødselsvægt mindre end 1501g eller svangerskabslængde mindre end fulde 31 uger, primært indlagt på et centralsygehus.  
*Ugeskr Læger* 1995; 157: 5707-5177

Kuint J, Reichman B, Neumann L, Shinwell ES.  
Prognostic significance of the immediate response to surfactant.  
*Arch Dis Child* 1994; 71: F170-F173

Kukkonen AK, Virtanen M, Järvenpää AL, Pokela ML, Ikonen S, Fellman V.  
Increased infection rate after porcine surfactant compared to synthetic surfactant?  
*Acta Paediatr* 2000; 89: 556-561

Lacaze-Masmonteil T.

Les surfactants artificiels avec peptides ou protéines de synthèse.  
Med Thérap Pédiatr 1998; 2: 5-14

Levene MI, Chiswick M, Field D, Forsyth S, Gamsu HR, Grant A, Greenough A, Halliday HL, Hetherington J, Hey E, Hopkins A, Jones RA, Lloyd D, MacFadyen U, Milner AD, Rennie JM, Reynolds EOR, Silverman M, Vinall P, Weindling M.  
Development of audit measures and guidelines for good practice in the management of neonatal respiratory distress syndrome.  
Arch Dis Child 1992; 67: 1221-1227

Li J, Song GW, Zhao S.

Studies on surfactant replacement therapy for experimental viral pneumonia.  
Chin J Pediatr 1997; 35 (suppl 9): 467-470

Li J, Fan X, Song GW.

A multicenter clinical trial of the surfactant replacement therapy for neonatal respiratory distress syndrome.  
Chin J Pediatr 2000; 38 (suppl 6): 1-4

Li J, Song GW, Gan XZ.

Effect of pulmonary surfactant replacement therapy on the pulmonary function in neonatal respiratory distress syndrome.  
Chin J Pract Pediatr 2001; 16 (suppl 6): 359-361

Lista G, Azzali A, Castoldi F, Compagnoni G.

Broncholaveolar lavage (BAL) with diluted porcine surfactant for lung debris in newborns.  
Acta Biomed Ateneo Parmense 2000; 71: 457-459

Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G.

Porcine-derived surfactant treatment of severe bronchiolitis.  
Acta Anaesthesiol Scand 1998; 42: 805-810

Luchetti M, Ferrero F, Gallini C, Natale A, Pigna A, Tortorolo L, Marraro G.

Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure.  
Pediatr Crit Care Med 2002; 3: 261-268

Lundstrøm KE, Greisen G.

Changes in EEG, systemic circulation and blood gas parameters following two or six aliquots of porcine surfactant.  
Acta Paediatr 1996; 85: 708-712

Luzi P, Zaccardo G, Cosmi EV, Anceschi MM.

Acute ventilation dependent expression of surfactant associated proteins.  
J Perinat Med 1991; 19: 364-369

Maksoud Filho JG, Diniz EMA, Ceccon MEJ; Galvani ALS, Chamelian AAB, Pinho ML, Vaz FAC.

Circulação extracorpórea por membrana (ECMO) em recém-nascido com insuficiência respiratória por síndrome de aspiração meconial: efeitos da administração de surfactante exógeno.

Jornal Pediatr 2001; 77 (suppl 3): 243-248

Marraro G, Casiraghi G, Riva A.

Effets d'un apport de surfactant chez deux adolescents leucémiques atteints de détresse respiratoire.

Cahiers d'Anesthésiol 1991; 39: 227-232

Marraro G, Foresti B, Casiraghi G, Monici Preti P.

Follow up of infants treated with porcine surfactant replacement for severe neonatal and infant respiratory distress syndrome: antigenic reactivity evaluation.

Drugs Exp Clin Res 1991; 17: 511-515

Marx M, Golej J, Fürst G, Hermon M, Trittenwein G.

Acute respiratory failure (ARDS) in a young child after drowning accident: therapy with exogenous surfactant and high frequency oscillatory ventilation.

Wien Klin Wochenschr. 1995; 107: 146-148

McCord FB, Curstedt T, Halliday HL, McClure BG, Reid MMcC, Robertson B.

Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome.

Arch Dis Child 1988; 63: 10-16

Moen A, Rootwelt T, Robertson B, Curstedt T, Hall C, Saugstad OD.

Hemodynamics and tissue blood flow after porcine surfactant replacement in surfactant-depleted newborn piglets.

Pediatr Res 1996; 40: 215-224

Moen A, Yu X-Q, Rootwelt T, Saugstad OD.

Acute effects on systemic and pulmonary hemodynamics of intratracheal instillation of porcine surfactant or saline in surfactant-depleted newborn piglets.

Pediatr Res 1997; 41: 486-492

Moen A, Yu W-Q, Curstedt T, Saugstad OD.

Acute effects on systemic circulation after intratracheal instillation of Curosurf<sup>®</sup> or Survanta in surfactant-depleted newborn piglets.

Acta Paediatr 1998; 87: 297-303

Moriette G, Paris-Llado J, Walti H, Escande B, Magny J-F, Cambonie G, Thiriez G, Cantagrel S, Lacaze-Masmonteil T, Storme L, Blanc T, Liet J-M, Andre C, Salanave B, Breart G.

Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome.

Pediatrics 2001; 107: 363-372

Mortensson W, Noack G, Curstedt T, Herin P, Robertson B.

Radiological observations in severe neonatal respiratory distress syndrome treated with the isolated phospholipid fraction of natural surfactant.

Acta Radiol Diagn 1987; 28: 389-394

Nilsson R, Berggren P, Curstedt T, Grossmann G, Renheim G, Robertson B.

Surfactant treatment and ventilation by high frequency oscillation in premature newborn rabbits; effect on survival, lung aeration, and bronchiolar epithelial lesions.

Pediatr Res 1985; 19: 143-147

Nilsson K, John J, Lachmann B, Robertson B, Wollmer P.

Pulmonary clearance of <sup>99m</sup>Tc-DTPA in experimental surfactant dysfunction treated with surfactant instillation.

Acta Anesthesiol Scand 1997; 41: 297-303

Nilsson G, Gustafsson M, Vandenbussche G, Veldhuizen E, Griffiths WJ, Sjövall J, Haagsman HP, Ruyschaert J-M, Robertson B, Curstedt T, Johansson J.

Synthetic peptide-containing surfactants. Evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution.

Eur J Biochem 1998; 255: 116-124

Nitta K, Kobayashi T, Inui S, Taniguchi J, Shido A, Murakami S, Robertson B, Grossmann G.

Concentration of lung edema to inhibit surfactant determined in premature rabbits.

J Jpn Med Soc Biol Interface 1989; 20: 36-41

Noack G, Berggren P, Curstedt T, Grossmann G, Robertson B.

Treatment of the neonatal respiratory distress syndrome (RDS) with isolated surfactant phospholipids.

Eur J Respir Dis 1987; 71 (suppl 153): 289-291

Noack G, Berggren P, Curstedt T, Grossmann G, Herin P, Mortensson W, Nilsson R, Robertson B.

Severe neonatal respiratory distress syndrome treated with the isolated phospholipid fraction of natural surfactant.

Acta Paediatr Scand 1987; 76: 697-705

- Noack G, Curstedt T, Grossmann G, Nilsson R, Robertson B.  
Passive expiratory flow-volume recordings in immature newborn rabbits. Effect of surfactant replacement on the time constant of the respiratory system.  
Respiration 1990; 57: 1-5
- Noack G, Mortenson W, Nilsson R, Robertson B.  
Correlations between radiological and cytological findings in early development of bronchopulmonary dysplasia.  
Eur J Pediatr 1993; 152: 1024-1029
- Noack G, Robertson B.  
Surfaktantbehandling av fullgångna nyfödda. Alternativ vid meconiumaspiration och pneumoni.  
Läkartidningen 1995; 92: 3564-3566
- Nobilis A, Somogyváry Z, Rónaszéky A, Machay T, Büky B, Robertson B.  
Early lung function changes in small premature infants after surfactant replacement with Curosurf®.  
Gyermekgyógyászat 1993; 6: 460-466
- Nohara K, Berggren P, Curstedt T, Grossmann G, Nilsson R, Robertson B.  
Correlations between physical and physiological properties of various preparations of lung surfactant.  
Eur J Respir Dis 1986; 69: 321-335
- Oetomo SB, de Ley L, Curstedt T, ter Haar JG, Schoots C, Wildevuur ChRH, Okken A.  
Distribution of endotracheally instilled surfactant protein SP-C in lung lavaged rabbits.  
Pediatr Res 1991; 29: 178-181
- Oetomo SB, Bos AF, Leij L de, Okken A, van Sonderen L, Halliday HL, Walti H.  
Immune response after surfactant treatment of newborn infants with the respiratory distress syndrome.  
Biol Neonate 1993; 64: 341-345
- O'Hare MMT, Bingham AM, McMaster C, Halahakoon WLJC, Corcoran JD, Halliday HL.  
Lyso-phosphatidylcholine and outcome of preterm babies with respiratory distress syndrome treated with surfactant.  
Early Hum Dev 1997; 49: 135-141
- O'Neill C, Malek M, Mugford M, Normand C, Tarnow-Mordi WO, Hey E, Halliday HL (the ECSURF Study Group).  
A cost analysis of neonatal care in the UK: results from a multicentre study.  
J Publ Health Med 2000; 22: 108-115

- Palmblad M, Johansson J, Robertson B, Curstedt T.  
Biophysical activity of a synthetic surfactant containing a transmembrane peptide and native surfactant protein B.  
Biochem J 1999; 339: 381-386
- Palmblad M, Gustafson M, Curstedt T, Johansson J, Schürch S.  
Surface activity and film formation from the surface associated material of artificial surfactant preparations.  
Biochim Biophys Acta 2001; 1510: 106-117
- Parmigiani S, Panza C, Bevilacqua G.  
Evolution of respiratory mechanics in preterm babies after surfactant administration in the neonatal period.  
Acta Biomed Ateneo Parmense 1997; 68: 65-73
- Pelkonen AS, Hakulinen AL, Turpeinen M, Hallman M.  
Effect of neonatal surfactant therapy on lung function at school age in children born very preterm.  
Pediatr Pulmonol 1998; 25: 182-190.
- Perrone S, Bracci R, Buonocore G.  
New biomarkers of fetal-neonatal hypoxic stress  
Acta Paediatr 2002; 38 (suppl 4): 135-138
- Plavka R, Kopecký P, Sebron V, Leiská A, Svihovec P, Ruffer J, Dokoupilová M, Zlatohlávková B, Janus V, Keszler M.  
Early versus delayed surfactant administration in extremely premature neonates with respiratory distress syndrome ventilated by high-frequency oscillatory ventilation.  
Intensive Care Med 2002; 28: 1483-1490
- Pinot F, Bachelet M, François D, Polla BS, Walti H.  
Modified natural porcine surfactant modulates tobacco smoke-induced stress response in human monocytes.  
Life Sciences 1999; 64: 125-134
- Pinot F, Walti H, Haagsman HP, Polla BS, Bachelet M.  
Curosurf® modulates cAMP accumulation in human monocytes through a membrane-controlled mechanism.  
Am J Physiol Lung Cell Mol Physiol 2000; 278: L99-L104
- Qanbar R, Cheng S, Possmayer F, Schürch S.  
Role of palmitoylation of surfactant-associated protein C in surfactant film formation and stability.  
Am J Physiol Lung Cell Mol Physiol 1996; 271: L572-L580

Quinn MW, Wild J, Dean HG, Hartley R, Rushforth JA, Puntis JWL, Levene MI.  
Randomised double-blind controlled trial of effect of morphine on catecholamine concentrations in ventilated pre-term babies.  
Lancet 1993; 342: 324-327

Rankin SJA, Tubman TRJ, Halliday HL, Johnston SS.  
Retinopathy of prematurity in surfactant treated infants.  
Brit J Ophthalmol 1992; 96: 202-204

Rauprich P, Möller O, Walter G, Herting E, Robertson B.  
Influence of modified natural or synthetic surfactant preparations on the growth of bacteria causing infections in the neonatal period.  
Clin Diag Lab Immunol 2000; 7: 817-822

Rey M, Segerer H, Kießling C, Obladen M.  
Surfactant bolus instillation: effects of different doses on blood pressure and cerebral blood flow velocities.  
Biol Neonate 1994; 66: 16-21

Richman PS, Spragg RG, Robertson B, Merritt TA, Curstedt T.  
The adult respiratory distress syndrome: first trials with surfactant replacement.  
Eur Respir J 1989; 2 (suppl 3): 109s-111s

Rigaut J-P, Robertson B.  
Quantitative evaluation of neonatal lung expansion with automated image analysis.  
Pediatr Pathol 1986; 6: 11-24

Rigaut J-P, Berggren P, Robertson B.  
Stereology, fractals and semi-fractals - the lung alveolar structure studied through a new model.  
Acta Stereol 1987; 6: 63-67

Rigaut JP, Robertson B.  
Modeles fractals en biologie.  
J Microsc Spectrosc Electron 1987; 12: 163-167

Robertson B, Berry D, Curstedt T, Grossmann G, Ikegami M, Jacobs H, Jobe A, Jones S.  
Leakage of protein in the immature rabbit lung; effect of surfactant replacement.  
Respir Physiol 1985; 61: 265-276

Robertson B.  
Pharmacological stimulation of surfactant secretion and surfactant replacement.  
Eur J Respir Dis 1985; 67 (suppl 142): 63-70

Robertson B, Rigaut J-P.  
Stereological profiles of immature neonatal lungs treated with exogenous surfactants.  
J Jap Med Soc Biol Interface 1986; 17: 181-183  
Robertson B, Curstedt T, Grossmann G, Kobayashi T, Kokubu M, Suzuki Y.

Prolonged ventilation of the premature newborn rabbit after treatment with natural or apoprotein-based artificial surfactant.

Eur J Pediatr 1988; 147: 168-173

Robertson B, Grossmann G, Jobe A, Ikegami M, Pettenazzo A, Seidner S.

Vascular to alveolar leak of iron dextran (120 kDa) in the immature ventilated rabbit lung.

Pediatr Res 1989; 25: 130-135

Robertson B, Curstedt T, Johansson J, Jörnvall H, Kobayashi T.

Structural and functional characterization of porcine surfactant isolated by liquid-gel chromatography.

Prog Respir Res 1990; 25: 237-246

Robertson B, Kobayashi T, Ganzuka M, Grossmann G, Li W-Z, Suzuki Y.

Experimental neonatal respiratory failure induced by monoclonal antibodies to the hydrophobic surfactant-associated protein SP-B.

Pediatr Res 1991; 30: 239-243

Robertson B, Speer CP.

Letter to the Editor: Questions to the judgment of OSIRIS.

Lancet 1993; 341: 172

Robertson B, Saugstad O.

Letter to the Editor: Naturlig eller syntetisk surfaktant i behandling av neonatalt andendssyndrom?

Tidsskr Nor Laegeforen 1994; 5: 114

Robertson B, Curstedt T, Herting E, Sun B, Akino T, Schäfer K.

Alveolar-to vascular leakage of surfactant protein A in ventilated immature newborn rabbits.

Biol Neonate 1995; 68: 185-190

Roll C, Knief J, Horsch S, Hanssler L.

Effect of surfactant administration on cerebral haemodynamics and oxygenation in premature infants - a near infrared spectroscopy study.

Neuropediatrics 2000; 31: 16-23

Roll C, Horsch S, Knief J, Hüsing J, Hanssler L.

Comparison of effects of endotracheal suction and surfactant administration on hemodynamics and oxygenation of premature infants - a near infrared spectroscopy study.

Z Geburtsh Neonatol 2001; 205: 104-109

Rollins M, Jenkins J, Tubman R, Corkey C, Wilson D.

Comparison of clinical responses to natural and synthetic surfactants.

J Perinat Med 1993; 21: 341-347

Rüdiger M, Köpke U, Prösch S, Rauprich M, Wauer RR, Herting E.

Effect of perfluorocarbons and perfluorocarbons/surfactant-emulsions on growth and viability of group B streptococci and Escherichia coli.  
Crit Care Med 2001; 29: 1786-1791

Rüstow B, Haupt R, Stevens P, Kunze D.  
Type II pneumocytes secrete vitamine E together with surfactant lipids.  
Am J Physiol 1993; 265: L113-L139

Saugstad OD, Tubman TRJ, Gloppestad K, Halliday HL, Øyasæter S, Curstedt T, Robertson B.  
Raised plasma hypoxanthine levels as a prognostic sign in preterm babies with respiratory distress syndrome treated with natural surfactant.  
J Perinatal Med 1992; 20: 379-385

Saugstad OD, Buø L, Johansen HT, Røise O, Aasen AO.  
Activation of the plasma kallikrein-kinin system in respiratory distress syndrome (RDS).  
Pediatr Res 1992; 32: 431-435

Saugstad OD, Danielsen K, Grønn M, Holt J, Meberg A, Silberg IE, Økland O.  
Neonatal andenødssyndrom behandlet med naturlig surfaktant. Den norske Curosurf®studien.  
Tidsskr Nor Lægefor 1993; 113: 2389-2393

Saugstad OD, Halliday HL, Robertson B, Speer CP.  
Replacement therapy with porcine natural surfactant-current status and future challenges.  
Biol Neonate 1993; 64: 269-278

Saugstad OD, Bevilacqua G, Katona M, Valls i Soler A.  
Surfactant therapy in the newborn.  
Prenat Neonat Med 2001; 6 (suppl 2): 56-59

Schiffmann JH, Harms K, Herting E, Gefeller O, Speer CP.  
Radiologische Veränderungen nach Surfactanttherapie.  
Monatsschr Kinderheilkd 1994; 142: 513-519

Schipper JA, van Sonderen L, Koppe JG, de Jongh FHC, Griffioen RW, Deen L.  
The influence of surfactant on functional residual capacity measured by nitrogen washout method in preterm newborns.  
Appl Cardiopulm Pathophysiol 1996; 6: 19-24

Schipper JA, van Sonderen L, de Jongh FHC, Koppe JG.  
The impact of surfactant replacement therapy on lung function.  
Appl Cardiopulm Pathophysiol 1998; 7: 3-7

- Scholtes U, Wiegand N, Zwirner J, Herting E.  
Influence of porcine natural modified surfactant on chemotaxis and oxidative metabolism of polymorphonuclear leucocytes.  
Immun Biol 2002; 205: 290-302
- Schröder A, Herting E, Speer CP.  
Aktivität von Superoxiddismutase und Katalase im Tracheobronchialsekret Surfactant-behandelter Frühgeborener mit Atemnotsyndrom.  
Z Geburtsh Neonatol 1999; 203: 201-206
- Schürch S, Schürch D, Curstedt T, Robertson B.  
Surface activity of lipid extract surfactant in relation to film area compression and collapse.  
J Appl Physiol 1994; 77: 974-986
- Schürch S, Qanbar R, Bachofen H, Possmayer F.  
The surface-associated surfactant reservoir in the alveolar lining layer.  
Biol Neonate 1995; 67 (suppl 1): 61-76
- Schürch S, Bachofen H, Possmayer F.  
Surface activity *in situ*, *in vivo* and in the Captive Bubble Surfactometer.  
Comparat Biochem Physiol, Part A 2001; 129: 195-207
- Segerer H, Stevens P, Schadow B, Maier R, Kattner E, Schwarz H, Curstedt T, Robertson B, Obladen M.  
Surfactant substitution in ventilated very low birthweight infants: factors related to response types.  
Pediatr Res 1991; 30: 591-596
- Segerer H, van Gelder W, Angenent FWM, van Woerkens LJPM, Curstedt T, Obladen M, Lachmann B.  
Pulmonary distribution and efficacy of exogenous surfactant in lung-lavaged rabbits are influenced by the instillation technique.  
Pediatr Res 1993; 34: 490-494
- Segerer H, Scheid A, Wagner M, Lekka M, Obladen M.  
Rapid tracheal infusion of surfactant vs. bolus instillation in rabbits: Effects on oxygenation, blood pressure and surfactant distribution.  
Biol Neonate 1996; 69: 119-127
- Sevecova D, Calkovska A, Drgova A, Javorka K  
Surfactant lung lavage in rabbits with meconium aspiration – a pilot study.  
Acta Med Mart 2001; 2: 9-14
- Sherman MP, Campell LA, Merritt TA, Shapiro DL, Long WA, Gunkel JH, Curstedt T, Robertson B.  
Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits.  
J Pediatr 1994; 125: 939-947
- Shields MD, Wales J, McCord B, Halliday HL, McClure BG.

Rapid assessment of pulmonary maturity by a drop volume method.  
J Obstet Gynaecol 1988; 8: 319-321

Shinwell ES, Zmora E, Karplus M, Leven D, Berger I.  
Surfactant replacement therapy in respiratory distress syndrome: An Israeli pilot study.  
Harefuah 1992; 123: 1-4

Silberg IE, Gronn M.  
Surfactantbehandling ved akutt lungesvikt.  
Tidsskr Nor Laegeforen 1997; 117: 1456-1458.

Skov L, Hellström-Westas L, Jacobsen T, Greisen G, Svenningsen NW.  
Acute changes in cerebral oxygenation and cerebral blood volume in preterm infants during surfactant treatment.  
Neuropediatrics 1992; 23: 126-130

Skov L, Bell A, Greisen G.  
Surfactant administration and the cerebral circulation.  
Biol Neonate 1992; 61 (suppl 1): 31-36

Song G-W, Sun B, Curstedt T, Grossmann G, Robertson B.  
Effect of amiloride and surfactant on lung liquid clearance in mechanically ventilated newborn rabbits.  
Respir Physiol 1992; 88:233-246

Song GW, Robertson B, Curstedt T, Gan XZ, Huang WX.  
Surfactant treatment in experimental Escherichia coli pneumonia.  
Acta Anaesthesiol Scand 1996; 40: 1154-1160

Speer CP, Müller U, Harms K, Schröter W, Curstedt T, Robertson B.  
Surfactant-Substitution: Kausale Therapie des Atemnotsyndroms Frühgeborener.  
Monatsschr Kinderheilkd 1988; 136: 65-70

Speer CP, Müller U, Harms K, Schröter W, Curstedt T, Robertson B.  
Surfactant-Substitution: Kausale Therapie des Atemnotsyndroms Frühgeborener.  
Deutsches Ärzteblatt 1988; 48: 3430-3434

Speer CP, Harms K, Herting E, Müller F, Schröter W, Kuhn W, Teichmann AT, Curstedt T, Robertson B.  
Surfactant-Substitution beim schweren Atemnotsyndrom Frühgeborener <1000 g.  
Geburtsh Frauenheilk 1990; 5: 359-364

Speer CP, Götze B, Robertson B, Curstedt T.  
Einfluß von natürlichem porcinen Surfactant (Curosurf®) auf die Funktion neutrophiler Granulozyten.  
Monatsschr Kinderheilkd 1990; 138: 737-741

Speer CP, Harms K, Herting K, Neumann N, Curstedt T, Robertson B.

Early versus late surfactant replacement therapy in severe respiratory distress syndrome.  
Lung 1990; 168 (suppl): 870-876

Speer CP, Götze B, Robertson B, Curstedt T.  
Phagocytic functions and TNF secretion of human monocytes exposed to natural porcine surfactant (Curosurf®).  
Pediatr Res 1991; 30: 69-74

Speer CP, Gefeller O.  
Letter to the Editor: European surfactant trial: Questions about the protocol.  
Pediatrics 1992; 90: 782

Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller O, Harms K, Herting E, McClure G, Reid M, Tubman R, Herin P, Noack G, Kok J, Koppe J, van Sonderen L, Laufkötter E, Kohler W, Boenisch H, Albrecht K, Hanssler L, Haim M, Oetomo SB, Okken A, Altfeld PC, Groneck P, Kachel W, Relier J-P, Walti H.  
Randomized European multicentre trial of surfactant replacement for severe respiratory distress syndrome: Single versus multiple dose of Curosurf®.  
Pediatrics 1992; 89: 13-20

Speer CP, Reuß D, Harms K, Herting E, Gefeller O.  
Neutrophil elastase and acute pulmonary damage in infants with severe respiratory distress syndrome.  
Pediatrics 1993; 91: 794-799

Speer CP, Gefeller O, Groneck P, Laufkötter E, Roll C, Hanssler L, Harms K, Herting E, Boenisch H, Windeler J, Robertson B.  
Randomised clinical trial of surfactant therapy for neonatal respiratory distress syndrome: comparison of two treatment regimens with natural surfactant preparations.  
Arch Dis Child 1995; 72: F8-F13

Spragg RG, Gilliard N, Richman P, Smith RM, Hite RD, Pappert D, Robertson B, Curstedt T, Strayer D.  
Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome.  
Chest 1994; 105: 195-202

Staudinger T, Bankier A, Strohmaier W, Weiss K, Locker G J, Knapp S, Röggl M, Laczika K, Frass M.  
Exogenous surfactant therapy in a patient with adult respiratory distress syndrome after near drowning.  
Resuscitation 1997; 35: 179-182

Stenson BJ, Glover RM, Parry GJ, Wilkie RA, Laing IA, Tarnow-Mordi WO.  
Static respiratory compliance in the newborn III: early changes following exogenous surfactant therapy.

Arch Dis Child 1994; 70: F19-F24

Stenson BJ, Glover RM, Wilkie RA, Laing IA, Tarnow-Mordi WO.  
Randomised controlled trial of respiratory system compliance measurements in mechanically ventilated neonates.

Arch Dis Child Fetal Neonatal Ed 1998; 78 (suppl 1): F15-19

Stevens P, Schadow B, Bartholein S, Segerer H, Obladen M.  
Surfactant protein A in the course of respiratory distress syndrome.

Eur J Pediatr 1992; 151: 596-600

Strayer DS, Hallman M, Merritt TA.  
Immunogenicity of surfactant. I. Human alveolar surfactant.

Clin Expt Immunol 1991; 83: 35-40

Strayer DS, Hallman M, Merritt TA.  
Immunogenicity of surfactant. II. Porcine and bovine surfactants.

Clin Expt Immunol 1991; 83: 41-46

Strayer DS, Robertson B.  
Surfactant as an immunogen: implications for therapy of respiratory distress syndrome.

Acta Paediatr 1992; 81: 446-447

Strayer DS, Merritt TA, Hallman M.  
Levels of surfactant-anti-surfactant immune complexes in neonatal respiratory distress syndrome correlate with subsequent development of bronchopulmonary dysplasia.

Acta Paediatr 1995; 84: 128-131

Strayer DS, Herting E, Sun B, Robertson B.  
Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo.

Am J Respir Crit Care Med 1996; 153: 1116-1122

Strohmaier W, Schlag G.  
Lung lavage with diluted surfactant is as effective as bolus treatment in a rabbit long-term aspiration model.

Appl Cardiopulm Pathophysiol 1998; 7: 17-22

Štucin-Gantar I, Babnik J, Derganc M.  
Role of surfactant inhibitors in amniotic fluid in respiratory distress syndrome.

J Perinat Med 2002; 30: 416-422

- Sun B, Kobayashi T, Curstedt T, Grossmann G, Robertson B.  
Application of a new ventilator-multi-plethysmograph system for testing efficacy of surfactant replacement in newborn rabbits.  
*Eur Respir J* 1991; 4: 364-370
- Sun B, Curstedt T, Robertson B.  
Surfactant inhibition in experimental meconium aspiration.  
*Acta Paediatr* 1993; 82: 182-189
- Sun B, Curstedt T, Song GW, Robertson B.  
Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration.  
*Biol Neonate* 1993; 63: 96-104
- Sun B, Herting E, Curstedt T, Robertson B.  
Exogenous surfactant improves lung compliance and oxygenation in adult rats with meconium aspiration.  
*J Appl Physiol* 1994; 77: 1961-1971
- Sun B, Curstedt T, Robertson B.  
Long-term cycling of surfactant films in Wilhelmy balance.  
*Reprod Fertil Dev* 1996; 8: 173-181
- Sun B, Curstedt T, Robertson B.  
Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration.  
*Am J Respir Crit Care Med* 1996; 154: 764-770
- Sun B, Curstedt T, Lindgren G, Franzen B, Alaiya AA, Calkovska A, Robertson B.  
Biophysical and physiological function of a modified porcine lung extracted surfactant enriched with surfactant protein A.  
*Eur Respir J* 1997; 10: 1967-1974
- Suzuki Y, Curstedt T, Grossmann G, Kobayashi T, Nilsson R, Nohara K, Robertson B.  
The role of the low-molecular weight ( $\leq$  to 15,000 daltons) apoproteins of pulmonary surfactant.  
*Eur J Respir Dis* 1986; 69: 336-345
- Suzuki Y, Robertson B, Fujita Y, Grossmann G.  
Respiratory failure in mice caused by a hybridoma making antibodies to the 15kDa surfactant apoprotein.  
*Acta Anaesthesiol Scand* 1988; 32: 283-289
- Suzuki Y, Robertson B, Fujita Y, Grossmann G, Kogishi K, Curstedt T.  
Lung protein leakage in respiratory failure induced by a hybridoma making monoclonal antibody to the hydrophobic surfactant-associated polypeptide SP-B.  
*Brit J Exp Pathol* 1992; 73: 325-333

Svenningsen NW, Robertson B, Andreasson B, Berggren P, Jonson B, Lindroth M.  
Endotracheal administration of surfactant in very low birth weight infants with respiratory distress syndrome.

Crit Care Med 1987; 15: 918-922

Svenningsen NW, Björklund L, Vilstrup C, Werner O.

Lung mechanics (FRC and static pressure-volume diagram) after endotracheal surfactant instillation: Preliminary observations.

Biol Neonate 1992; 61 (suppl 1): 44-47

Svenningsen NW.

Pulmonary functional residual capacity and lung mechanics in surfactant-treated infants.

Semin Perinatol 1992; 61: 181-185

Svenningsen NW, Saugstad OD.

Surfactant treatment of extremely low birth weight (ELBW) infants.

Appl Cardiopulm Pathophysiol 1996; 6: 11-17

Szymankiewicz M, Gadzinowski J, Bręborowicz GH.

Surfactant-Curosuf<sup>®</sup> administration in neonates with RDS.

Klin Perinat Ginek 1993; suppl III: 39-48

Szyperski T, Vandenbussche G, Curstedt T, Ruyschaert J-M, Wüthrich K, Johansson J.

Pulmonary surfactant-associated polypeptide C in a mixed organic solvent transforms from a monomeric  $\alpha$ -helical state into insoluble  $\beta$ -sheet aggregates.

Protein Science 1998; 7: 2533-2540

Tarnow-Mordi WO, Halliday HL, Hey E, Malek M, Mugford M, Normand C.

The economics of neonatal surfactant therapy.

MRC News 1992; 57: 16-17

Tashiro K, Kobayashi T, Robertson B.

Dextran reduces surfactant inhibition by meconium.

Acta Paediatr 2000; 89:1439-1445

Thornton CM, Halliday HL, O'Hara MD.

Surfactant replacement therapy in preterm neonates: a comparison of postmortem pulmonary histology in treated and untreated infants.

Pediatr Pathol 1994; 14: 945-953

Tubman TRJ, Halliday HL.

Surfactant treatment for respiratory distress syndrome following very prolonged rupture of membranes.

Eur J Pediatr 1990; 149: 727-729

Tubman TRJ, Halliday HL, Normand C.

Cost of surfactant replacement for severe neonatal respiratory distress syndrome: results of a randomized controlled trial.

Brit Med J 1990; 301: 842-845

Tubman TRJ, Rollins MD, Patterson C, Halliday HL.

Increased incidence of respiratory distress syndrome in babies of hypertensive mothers.

Arch Dis Child 1991; 66: 52-54

Tubman TRJ, Halliday HL, Normand C.

Economic impact of porcine surfactant replacement (Curosurf®) for severe neonatal respiratory distress syndrome.

J Perinat Med 1991; 19 (suppl 1): 403-407

Tubman TRJ, Rankin SJ, Halliday HL, Johnston SS.

Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity.

Biol Neonate 1992; 61 (suppl 1): 54-58

Valls i Soler A, Román L, Setién G, López Heredia J.

Un caso de SDR grave tratado con surfactante de origen porcino (Curosurf®)

An Esp Pediatr 1990; 33: 160-162

Valls i Soler A, Lizarraga M, López Heredia J, Román L, Hernández E, Gastiasoro E.

Effectiveness of Curosurf® for severe respiratory distress syndrome: A case control study.

Biol Neonate 1992; 61 (suppl 1): 21-25

Valls i Soler A, López Heredia J, Hernández E, Román L, Gastiasoro E, Robertson B.

Tratamiento con surfactante natural exógeno de origen porcino de recién nacidos pretérmino con síndrome del distrés respiratorio grave.

An Esp Pediatr 1992; 39: 375-381

Valls i Soler A, Wolfson MR, Kechner N, Foust R, Shaffer TH.

Ventilación líquida parcial con perfluorocarbonados. Comparación con la administración de surfactante en corderos inmaduros. I. Correlaciones fisiológicas.

An Esp Pediatr 1994; 41: 190-194

Valls i Soler A, López Heredia J, Román Echevarría L, Krauel X, San Román Martínez L, Roqués Serradilla V, Closa Monasterolo R, Simonet Salas J, Natal Pujol A, González Molina E, Martínez Santana S, Altirriba Valls O, Pantoja Bajo A, Paisán Grisolia L, Pedraz García C, Sánchez de León Arenas L.

Administración de surfactante natural exógeno en el SDR grave. Estudio multicéntrico.

An Esp Pediatr 1994; 41: 344-350

Valls i Soler A, Alfonso LF, Arnaiz A, Alvarez FJ, Tovar JA.

Pulmonary surfactant dysfunction in congenital diaphragmatic hernia. Experimental and clinical findings.

Biol Neonate 1996; 69: 318-326.

- Valls i Soler A, Wolfson MR, Kechner N, Foust R, Shaffer TE.  
Comparison of natural surfactant and brief liquid ventilation in very immature lambs.  
Clinical and physiological correlates.  
*Biol Neonate* 1996; 69: 275-283
- Valls i Soler A, López de Heredia J, Fernández MB, Gastiasoro Cuesta E and Spanish Surfactant Collaborative Group.  
A simplified surfactant dosing procedure in respiratory distress syndrome: the "Side-hole" randomized study.  
*Acta Paediatr* 1997; 86: 747-751
- Valls i Soler A, Fernández-Ruanova MB, López de Heredia J, Román Etxebarria L, Rodríguez-Soriano J and Spanish Surfactant Collaborative Group.  
A randomized comparison of surfactant dosing via a dual-lumen endotracheal tube in respiratory distress syndrome.  
*Pediatrics* 1998; 101(4):E4
- Van Bel F, de Winter JP, Wijnands HBG, van de Bor M, Egberts J, Robertson B.  
Cerebral and aortic blood flow velocity patterns in preterm infants receiving prophylactic surfactant treatment.  
*Acta Paediatr Scand* 1992; 81: 504-510
- Van Sonderen L.  
Het toedienen van surfactant in de longen van prematuren, lijdend aan een ernstig IRDS.  
*Tijdschrift voor Verloskundigen* 1987; 10: 311-312
- Vandenbusche G, Clercx A, Curstedt T, Johansson J, Jörnvall H, Ruyschaert JM.  
Structure and orientation of the surfactant-associated protein C in a lipid bilayer.  
*Eur J Biochem* 1992; 203: 201-209
- Vandenbusche G, Clercx A, Curstedt T, Johansson J, Jörnvall H, Ruyschaert JM.  
Secondary structure and orientation of the surfactant protein SP-B in a lipid environment. A Fourier transform infrared spectroscopy study.  
*Biochemistry* 1992; 31: 9169-9176
- Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbesen F, Greisen G, Hobolth N, Holm V, Jacobsen T, Johansen KH, Kamper J, Lange A, Mølgaard C, Nathan E, Nielsen F, Pedersen-Bjergaard L, Peitersen B, Robertson B, Skov L, Svenningsen N, Tegllund L.  
Surfaktantbehandling af nyfødte med respiratorisk distress-syndrom primært behandlet med nasalt kontinuerligt positivt luftvejstryk. En pilotundersøgelse.  
*Ugeskr Læger* 1992; 154: 2136-2139

Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrøm K, Jacobsen T, The Danish-Swedish Multicenter Study Group.

Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome.

N Engl J Med 1994; 331: 1501-1555

Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B, Agertoft L, Grytter C, Djernes B, Nathan E, Pryds O, Hertel J, Peitersen B, Pedersen-Bjergaard L, Berg A, Vrang C, Christensen MF, Johansen K, Eschen C, Kroner J, Reinholdt J, Bertelsen A.

Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation.

Pediatrics 1999; 103(2):E24

Victorin LH, Deverajan LV, Curstedt T, Robertson B.

Surfactant replacement in spontaneously breathing babies with hyaline membrane disease; a pilot study.

Biol Neonate 1990; 58: 121-126

Vilstrup C, Björklund L, Larsson A, Lachmann B, Werner O.

Functional residual capacity and ventilation homogeneity in mechanically ventilated small neonates.

J Appl Physiol 1992; 73: 276-283

Wagner M H., Koch H, Scheid A, Obladen M, Segerer H.

Circulatory changes after surfactant bolus instillation in lung-lavaged adult rabbits.

Exp Lung Res 1996; 22: 667-676

Wagner M H, Sonntag J, Strauß E, Obladen M.

Complement and contact activation related to surfactant response in respiratory distress syndrome.

Pediatr Res 1999; 45: 14-18

Wagner M, Amthauer H, Sonntag J, Drenk F, Eichstädt H W, Obladen M.

Endotracheal surfactant atomization: An alternative to bolus instillation?

Crit Care Med 2000; 28: 2540-2544

Wagner M H, Wiethoff S, Friedrich W, Mollenhauer I, Obladen M, Boenick U.

Ultrasonic surfactant nebulization with different exciting frequencies.

Biophys Chem 2000; 84: 35-43

Walti H, Couchard M, Relier JP.

Neonatal diagnosis of respiratory distress syndrome.

Eur Respir J 1989; 3 (suppl): 22s-26s.

Walti H, Relier JP, Huon C, Monset-Couchard M, Scemama M, De Gamarra E, Moriette G, Curstedt T, Robertson B.

Traitement de formes sévères de la maladie des membranes hyalines par une dose unique d'un surfactant exogène naturel d'origine porcine.

Arch Fr Pediatr 1990; 47: 329-334

Walti H, Boulé M, Moriette G, Relier JP.

Pulmonary functional outcome at one year of age in infants treated with natural porcine surfactant at birth.

Biol Neonate 1992; 61: 48-53

Walti H, Paris-Llado J, Bréart G, Couchard M on behalf of the French Collaborative Multicentre Study Group.

Porcine surfactant replacement therapy in newborns of 25-31 weeks' gestation: a randomised multicentre trial of prophylaxis versus rescue with multiple low doses.

Acta Paediatr 1995; 84: 913-921

Walti H, Polla BS, Bachelet M.

Modified natural porcine surfactant inhibits superoxide anions and proinflammatory mediators released by resting and stimulated human monocytes.

Pediatr Res 1997; 41: 114-119

Walti H, Paris-Llado J, Egberts J, Brand R, Bevilacqua G, Gardini F, Breart G.

Prophylactic administration of porcine-derived lung surfactant is a significant factor in reducing the odds for peri-intraventricular haemorrhage in premature infants.

Biol Neonate 2002; 81: 182-187

Walti H, Nicolas-Robin A, Assous MV, Polla BS, Bachelet M, Davis JM.

Effect of exogenous surfactant and recombinant human copper-zinc superoxide dismutase on oxygen-dependent antimicrobial defenses.

Biol Neonate 2002; 82: 96-102

Wang Y, Griffiths WJ, Curstedt T, Johansson J.

Porcine pulmonary surfactant preparations contain the antibacterial peptide prophenin and a C-terminal 18-residue fragment thereof.

FEBS Lett 1999; 460: 257-262

Wenzel U, Rüdiger M, Wagner M H, Wauer R.

Utility of deadspace and capnometry measurements in determination of surfactant efficacy in surfactant depleted lungs.

Crit Care Med 1999; 27: 946-952

Werner O, Björklund LJ.

Resuscitation strategy and surfactant therapy.

Biol Neonate 1997; 71 (suppl 1): 32-34

- Wiernik A, Curstedt T, Johansson A, Jarstrand C, Robertson B.  
Morphology and function of blood monocytes after incubation with lung surfactant.  
*Eur J Respir Dis* 1987; 71: 410-418
- Yu X-Q, Feet B, Moen A, Curstedt T, Saugstad OD.  
Nitric oxide contributes to surfactant-induced vasodilatation in surfactant-depleted newborn piglets.  
*Pediatr Res* 1997; 42:151-156
- Yu X-Q, Moen A, Feet BA, Saugstad OD.  
Oxygen delivery and consumption in surfactant-depleted newborn piglets.  
*Intensive Care Med* 1998; 24: 358-362
- Zaltash S, Palmblad M, Curstedt T, Johansson J, Persson B.  
Pulmonary surfactant protein B: a structural model and a functional analogue.  
*Biochim Biophys Acta* 2000; 1466: 179-186
- Zetterberg G, Curstedt T, Eklund A, Forslid J, Hed J.  
Increased mobilization of adhesion proteins (MAC-1) and altered metabolic response in human leucocytes exposed to surfactant in vitro.  
*Acta Pathol Microbiol Immunol Scand* 1992; 100: 695-700
- Zetterberg G, Lundahl J, Curstedt T, Eklund A.  
Surfactant prevents quartz induced down-regulation of complement receptor 1 in human granulocytes.  
*Inflammation* 1997; 21: 83-92
- Zetterberg G, Curstedt T, Lundahl J, Eklund A.  
Lysophosphatidylcholine abrogates the CR1 preserving effect of surfactant on quartz-exposed human granulocytes.  
*Inflammation* 1999; 23: 179-189
- Zhao DH, Sun B, Wu ZH, Lindwall R, Robertson B.  
Mitigation of endotoxin-induced acute lung injury in ventilated rabbits by surfactant and inhaled nitric oxide.  
*Intensive Care Med* 2000; 26: 229-238
- Zheng S, Zhang WY, Zhu LW, Lin K, Sun B.  
Surfactant and inhaled nitric oxide alleviate acute lung injury induced by intestinal ischemia and reperfusion in rats.  
*J Pediatr Surg* 2001; 36: 980-984
- Zhou BH, Sun B, Zhou ZH, Zhu LW, Fan SZ, Lindwall R.  
Comparison of effects of surfactant and inhaled nitric oxide in rabbits with surfactant-depleted respiratory failure.  
*Acta Pharmacol Sin* 1999; 20: 691-695

Zhou ZH, Zhu LW, Lin K, Sun B.  
Prevention of rabbit acute lung injury by early treatment of inhaled nitric oxide and surfactant during pressure support ventilation.  
Am J Respir Crit Care Med 2000; 161: 581-588

Zhu GF, Sun B, Niu SF, Cai YY, Lindwall R, Robertson B.  
Combined surfactant therapy and inhaled nitric oxide in rabbits with oleic acid induced acute respiratory distress syndrome.  
Am J Respir Crit Care Med 1998; 158: 437-443

## REVIEW ARTICLES

Adams EW, Counsell J, Hajnal JV, Allsop JM, Herlihy A, Edwards AD.  
Investigation of lung disease in preterm infants using magnetic resonance imaging.  
Biol Neonate 2000; 77 (suppl 1) 17-20

Amato M, Hüppi P, Markus D, Schneider H.  
Die hyaline Membranen Krankheit und die exogene Surfactant-Therapie.  
Pädiatr Prax 1990; 40: 555-565

Amato M.  
Exogene Surfactant-Therapie.  
Therapie Woche Schweiz 1992; 8: 64-68

Avery ME.  
Milestones in pediatric research.  
Biol Neonate 2001; 80 (suppl 1): 3-6

Bancalari E, del Moral E.  
Bronchopulmonary dysplasia and surfactant.  
Biol Neonate 2001; 80 (suppl 1): 7-13

Bevilacqua G.  
Attualità in terapia con surfattante esogeno nella sindrome respiratoria del neonato (RDS).  
Dev Physiopath Clin 1998; 85: 49-53

Bevilacqua G, Goelz R, Halliday HL.  
Guidelines on surfactant treatment.  
Prenat Neonat Med 2001; 6: 374-378

Bracci R.  
Free oxygen radicals and surfactant.  
Biol Neonate 1997; 71 (suppl 1): 23-27

Bręborowicz GH, Szymankiewicz M.  
Metabolizm i obrót surfaktantu w pęcherzyku płucnym.  
(Metabolism and surfactant turn-over in alveoli)  
Klin Perinat Ginek 1992; suppl II: 51-57

Calkovská A  
Pulmonary surfactant and the use of alternative ventilatory modes in meconium aspiration.  
Cs Pediatr 1997; 52: 56-60

Calvert S.

The role of high frequency oscillatory ventilation in very preterm infants.  
Biol Neonate 2002; 81 (suppl 1): 25-27

Collaborative European Multicenter Study Group.

The Curosurf<sup>®</sup> experience in Europe.

In: Lucey JF (ed): Hot Topics '88 in Neonatology. Ross Laboratories, Columbus, 1988;  
62-73

Corcoran D, Halliday HL.

Surfactant replacement for the prevention and treatment of respiratory distress syndrome.  
Postgrad Doctor 1992; 15: 315-321

Corcoran D, Halliday HL.

Surfactant replacement for the respiratory distress syndrome.  
Mat Child Health 1994; 19: 59-63

Cosmi EV, Di Renzo GC.

Prevention and treatment of fetal lung immaturity.  
Fetal Diagn Ther 1989; 4: 52-62

Cosmi EV.

Prenatal prevention of respiratory distress syndrome: new pharmacologic approaches.  
Early Hum Dev 1992; 29: 283-286

Cosmi EV.

Prenatal administration of surfactant.  
Prenat Neonat Med 1996; 1: 109-111

Cosmi EV, Szabo I, on behalf of the EURAIL Study Group.

New developments in intra-amniotic surfactant therapy.  
Prenat Neonat Med 2001; 6: 364-365

Curley AE, Halliday HL.

The present status of exogenous surfactant for the newborn.  
Early Hum Devel 2001; 61: 67-83

Curstedt T.

Lungsurfaktants struktur och funktion.  
Klinisk kemi, 1991; 1: 22-28

Curstedt T.

Hydrophobic proteins.  
Prog Respir Res 1994; 27: 8-14

Curstedt T.

Lipid-protein interactions in pulmonary surfactant.

J Jpn Soc Biol Interface 1996; 27: 1-4

Curstedt T.

Clinical importance of surfactant hydrophobic proteins.

Shanghai International Pediatric Symposium, 1998; 18-21

Curstedt T, Robertson B.

Samlokaliseraad surfaktantforskning.

Labyrinten 1999; 2

Curstedt T.

Future surfactant preparations.

Biol Neonate 2000; 78: 249-250

Curstedt T.

New surfactant preparations.

Acta Pharmacol Sin 2002; 23 (suppl): 82-83

Curstedt T.

Biochemistry and metabolism of surfactant.

Acta Pharmacol Sin 2002; 23 (suppl): 96-97

de Winter JP, Egberts J, de Kleine MJK, van Bel F, Wijnands JBG, Guit GL.

Preventie en behandeling van respiratoire distress syndroom bij vroeggeborenen door intratracheale toediening van surfactant.

Nederl Tijdschr Geneeskd 1992; 136: 2018-2024

de Winter JP, van Sonderen L, Egberts J, van Bel F.

Surfactantherapie bij het respiratoire distress syndroom; een overzicht.

Nederl Tijdschr Geneeskd 1992; 136: 2010-2012

de Winter JP, van Sonderen L, Egberts J, van Bel F.

Surfactanttherapie bij respiratoire distress-syndroom: een overzicht.

Tijdschr Vroedvr 1994; 1: 6-8

Diniz EMA, Lefort S;Vaz FAC.

Exogenous surfactant zherapeutics.

Ped Mod 2000; 36: 17-24

Diniz EMA, Costa MTZ.

Exogenous surfactant: other indications.

Ped Mod 2000; 36: 25-29

Diniz EMA, Ceccon MEJR.

Meconial aspiration syndrome.

Ped Mod 2000; 36: 42-44

Di Renzo GC, Anceschi MM, Cosmi EV.

Lung surfactant enhancement in utero.

Eur J Obstet Gynecol Reprod Biol 1989; 32: 1

Di Renzo GC, Anceschi MM, Guidetti R, Cosmi EV.

Requirements of perinatal prevention and treatment of neonatal RDS.

Eur Respir J 1989; 3 (suppl): 68s-72s

Egberts J.

Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation.

Biol Neonate 1992; 61 (suppl 1): 59-65

Enhorning G.

From bubbles to babies: The evolution of surfactant replacement therapy.

Biol Neonate 1997; 71 (suppl 1): 28-31

Fiori RM, Lopes JMA, Guinsburg R.

Terapia com surfactante exógeno. Manual de neonatologia da Sociedade Brasileira de Pediatria.

Tóp Esp Neonatol 2000; 1: 22-28

Floros J, Fan R.

Surfactant protein A and B genetic variants and respiratory distress syndrome: allele interactions.

Biol Neonate 2001; 80 (suppl 1): 22-25

Frostell CG.

Clinical aspects of nitric oxide and surfactant replacement.

Biol Neonate 1997; 71 (suppl 1): 39-43

Gadzinowski J.

Leczenie surfaktantem - pytania i odpowiedzi.

(Surfactant treatment - questions and answers.)

Klin Perinat Ginek 1992; suppl II: 168-171

Gadzinowski J, Szymankiewicz M, Bręborowicz GH.

Surfactant - new perspectives in treatment of RDS of the newborns.

Klin Perinat Ginek 1993; suppl III: 55-58

Gadzinowski J, Szymankiewicz M.

Leczenie surfaktantem noworodków z zespołem zaburzeń oddychania.

(Surfactant treatment in respiratory distress syndrome.)

Klin Perinat Ginek 1997; suppl XIX: 287-290

Grupo Respiratorio Neonatal de la Sociedad Española de Neonatología.  
Recomendaciones sobre ventiloterapia convencional neonatal.  
An Esp Pediatr 2001; 55: 244-250

Grupo de trabajo sobre Patología de la Sociedad Española de Neonatología.  
Recomendaciones sobre ventilación de alta frecuencia en el recién nacido.  
An Esp Pediatr 2002; 57: 238-243

Halihakoon C, Bell AH, Young, I, Halliday HL, McClure BG.  
EEG activity and antioxidant status after Exosurf administration.  
Pediatr Rev Commun 1995; 8, 212-226.

Halliday HL.  
Clinical experience with exogenous natural surfactant.  
Devel Pharmacol Therap 1989; 13: 173-181

Halliday HL.  
Hot Topics' 88 in Neonatology. Report of Ross Laboratory Special Conference.  
Pediatr Rev Comm 1990; 4: 173-181

Halliday HL.  
Treatment of respiratory distress syndrome with surfactant.  
Intens Therap Clin Monit 1990; 11: 75-79

Halliday HL.  
Management of the very low birthweight neonate.  
Curr Obstet Gynaecol 1992; 2: 207-211

Halliday HL.  
New hope for respiratory distress syndrome.  
Profess Care Mother Child 1992; 2: 136-138

Halliday HL.  
Surfactant treatment.  
Newborn News 1993; 55: 6-8

Halliday HL.  
Current views on the use of surfactant.  
Contemp Rev Obstet Gynaecol 1993; 5: 65-70

Halliday HL.  
Eight questions about surfactant.  
MIDIRS Midwif Dig 1993; 3: 456-458

Halliday HL.  
Surfactant.  
Abstracts of lectures for Neonatal Course for Senior Paediatricians, Royal Postgraduate  
Medical School, London, 1993; 41-45

Halliday HL.  
Surfactant Update.  
Abstracts of Lectures Neonatal Course for Senior Paediatricians. Royal Postgraduate Medical School, London, 1994; 67-69

Halliday HL.  
Overview of clinical trials comparing natural and synthetic surfactants.  
Biol Neonate 1995; 67 (suppl 1): 32-47

Halliday HL.  
Surfactant replacement therapy.  
Pediatr Pulmonol 1995; 11: 96-97

Halliday HL.  
Poractant - a porcine-derived lung surfactant.  
Br J Hosp Med 1995; 53: 47-48.

Halliday HL.  
Where are we now with the prenatal steroids and postnatal surfactant.  
Biol Neonate 1996; 69: 186-187

Halliday HL.  
Controversies: Synthetic or natural surfactant. The case for natural surfactant.  
J Perinat Med 1996; 24: 417-426

Halliday HL.  
Surfactant therapy in neonates.  
Paediatr Perinat Drug Ther 1997; 1: 30-40

Halliday HL.  
Viewpoint: Synthetic or natural surfactant.  
Acta Paediatr 1997; 86: 233-237

Halliday HL.  
Surfactant therapy: questions and answers.  
J Neonat Nurs 1997; 3: 28-36

Halliday HL.  
Clinical trials of surfactant replacement in Europe.  
Biol Neonate 1997; 71 (suppl 1): 8-12

Halliday HL.  
La terapia con surfattante nel neonato.  
Aggiorn Fisiopatol Terap Pediatr 1997; 6: 37-47

Halliday HL.  
Surfactant treatment.  
Hosp Manage Internat 1997; 203

Halliday HL.  
Which interventions for neonatal respiratory failure are effective?  
Croat Med J 1998; 39: 165-170

Halliday HL.  
The Bengt Robertson Lecture. Surfactant replacement: from the laboratory to routine clinical practice.  
Prenat Neonat Med 2000; 5: 204-208

Halliday HL, Speer CP.  
Laudatio: Bengt Robertson: a surfactant pioneer.  
Biol Neonate 2002; 82: 272-273

Hallman M.  
Editorial: Pulmonary surfactants – current status.  
Ann Med. 1990; 22: 293-295

Hallman M.  
Lung surfactant in respiratory distress syndrome.  
Acta Anaesthesiol Scand 1991; 35: 15-21

Hallman M, Bry K.  
Interactions of nitric oxide with the pulmonary surfactant.  
Semin Perinatol 1996; 20: 173-185

Hallman M.  
Molecular interactions between nitric oxide and lung surfactant.  
Biol Neonate 1997; 71 (suppl 1): 44-48

Hallman M.  
Cytokines, pulmonary surfactant and consequences of intrauterine infection.  
Biol Neonate 1999; 76 (suppl 1): 2-9

Hallman M.  
Alveolar surfactant and inflammatory mediators.  
Crit Care Med 2000; 14: 91-99

Hallman M, Glumoff V, Rämert M.  
Surfactant in respiratory distress syndrome and lung injury.  
J Comp Biochem Physiol 2001; 129: 287-294

Herting E.  
Sekundärer Surfactantmangel als Ursache von Atemstörungen in der Neonatalperiode.  
Sozialpädiatrie 1998; 20: 278-280

- Herting E, Robertson B.  
Surfactant treatment in neonatal group streptococcal pneumonia. From experimental studies to clinical application.  
Appl Cardiopulmon Pathophysiol 2000; 9: 241-243
- Hume R, Richard K, Kaptein E, Stanley EL, Visser TJ, Coughtrie MWH.  
Thyroid hormone metabolism and the developing human lung.  
Biol Neonate 2001; 80 (suppl 1) 18-21
- Jacobsen T, Verder H.  
Surfaktantbehandling til præmature nyfødte.  
Ugeskr Læger 1991; 153: 2166-2169
- Jacobsen T, Verder H, Skov L, Greisen G, Friis-Hansen B.  
Surfaktantbehandling af svært respiratorisk distress syndrom.  
Ugeskr Læger 1992; 154: 1642-1645
- Jobe AH.  
Hot topics in and new strategies for surfactant research.  
Biol Neonate 1998; 74 (suppl 1): 3-8
- Johansson J, Curstedt T, Robertson B.  
The proteins of the surfactant system.  
Eur Respir J 1994; 7: 372-391
- Johansson J, Curstedt T, Robertson B.  
Synthetic protein analogues in artificial surfactants.  
Acta Paediatr 1996; 85: 642-646
- Johansson J.  
Protein analogues in artificial surfactants.  
Biol Neonate 1997; 71 (suppl 1): 49-52
- Johansson J, Curstedt T.  
Molecular structures and interactions of pulmonary surfactant components.  
Eur J Biochem 1997; 244; 675-693
- Johansson J, Gustafsson M, Palmblad M, Zaltash S, Robertson B, Curstedt T.  
Synthetic surfactant protein analogues.  
Biol Neonate 1998; 74 (suppl 1): 9-14
- Johansson J, Gustafsson M, Palmblad M, Zaltash S, Robertson B, Curstedt T.  
Pulmonary surfactant: emerging protein analogues.  
Biodrugs 1999; 11: 71-77

Johansson J, Robertson B.

Nyupptäckta samband mellan lungsjukdom och surfaktantproteiner.  
Läkartidningen 1999;1191-119, 2002

Johansson J, Curstedt T, Robertson B.

Artificial surfactants based on analogues of SP-B and SP-C.  
Pediatr Pathol Molecul Med 2001; 20: 501-508

Jonson B.

Ventilation patterns, surfactant and lung injury.

Biol Neonate 1997; 71 (suppl 1): 13-17

Kobayashi T, Tashiro K, Cui X, Konzaki T, Xu Y, Kabata C, Yamamoto K.

Experimental models of acute respiratory distress syndrome: Clinical relevance and response to surfactant therapy.

Biol Neonate 2001; 80 (suppl 1): 26-28

Kuroki Y, Sano H.

Functional roles and structural analysis of lung collectings SP-A and SP-D.

Biol Neonate 1999; 76 (suppl 1): 19-21

Lam BCC.

Surfactant lavage for the management of severe meconium aspiration syndrome.

Biol Neonate 1999; 76 (suppl 1): 10-14

Lewis JF, Veldhuizen RAW.

Factors influencing efficacy of exogenous surfactant in acute lung injury.

Biol Neonate 1995; 67 (suppl 1): 48-60

Marraro G.

Emploi du surfactant dans la pathologie respiratoire du nouveau-né et du nourisson.

Cah Anesthesiol 1994; 42: 159-166

Marraro G, Casiraghi G, Marinari M, Valsecchi R, Riva A.

L'impiego del surfactante naturale nel trattamento della sindrome d'aspirazione massiva di liquido amniotico del neonato (The use of surfactant in meconium aspiration syndrome of newborns).

Neonatologica 1994; 4: 299-308

Marraro G.

Use of surfactant in adult respiratory distress syndrome.

J Anaesth Clin Pharmacol 1995; 11: 275-278

Marraro G, Casiraghi G, Riva A, Galbiati AM.

L'impiego del surfactante naturale suppletivo dell'adult respiratory distress syndrome (ARDS) del bambino (The use of natural surfactant in ARDS of child).

Riv Ital Pediatr 1995; 21: 284-289

Marraro G.

L'impiego del surfattante nel trattamento dell'ARDS e della bronchiolite grave in età pediatrica (The use of surfactant in the treatment of ARDS and severe bronchiolitis in pediatric age).

Minerva Anesthesiol 1997; 63: 509-513

Marraro G, Luchetti M, Galassini EM, Abbiati G.

Natural surfactant supplementation in ARDS in paediatric age.

Minerva Anesthesiol 1999; 65: 92-97

Marraro GA.

Surfactant use in severe bronchiolitis.

Biol Neonate 2002; 81 (suppl 1): 28

Merritt TA, Hallman M, Vaucher Y, Mc Feeley E, Tubman TR.

Impact of surfactant treatment on cost of neonatal intensive care: a cost-benefit analysis.

J Perinatol 1990; 10: 416-419

Merritt TA, Halliday HL.

On exogenous surfactant therapy.

Pediatr Pulmonol 1992; 14: 1-3

Milligan DW, Ainsworth SB.

Animal-derived or synthetic surfactant for the treatment of neonatal respiratory distress syndrome: A review.

Acta Paediatr 2001; 90 (suppl 436): 25-27

Moen A.

Circulatory effects of surfactant therapy.

Biol Neonate 1997; 71 (suppl 1): 18-22

Moriette G, Brunhes A, Jarreau PH.

High-frequency oscillatory ventilation in the management of respiratory distress syndrome.

Biol Neonate 2000; 77 (suppl 1): 14-16

Navas Serrano VM, Cuevas García MA, Vila Álvarez JA, Martínez Fernández V, Morcillo Sopena F, Valls i Soler A.

Profilaxis y tratamiento del síndrome de distrés respiratorio con diferentes surfactantes.

An Esp Pediatr 2002; 56: 40-44

Obladen M.

Future directions in surfactant therapy in neonates.

Appl Cardiopulm Pathophysiol 1995; 7: 87-88

Pérez-Gil J.

Molecular interactions in pulmonary surfactant films.

Biol Neonate 2002; 81 (suppl 1): 6-15

Pitkänen O.

Lung epithelial ion transport in neonatal lung disease.

Biol Neonate 2001; 80 (suppl 1): 14-17

Robertson B, Curstedt T, Berggren P.

Djurexperimentella och kliniska studier av surfactantsubstitut för kliniskt bruk.

Kvartalskrift Hjärta, Kärl, Lungor (Svenska Nationalföreningen mot Hjärt- och Lungsjukdomar) 1985; 4: 143-144

Robertson B.

Surfactant replacement therapy; recent progress and current problems.

J Jap Med Soc Biol Interface 1986; 17: 1-8

Robertson B.

Surfactant replacement in the management of the neonatal respiratory distress syndrome.

Eur J Respir Dis 1987; 71 (suppl 153): 242-248

Robertson B, Lachmann B.

Experimental evaluation of surfactants for replacement therapy.

Exp Lung Res 1988; 14: 279-310

Robertson B.

The evolution of neonatal respiratory distress syndrome into chronic lung disease.

Eur Respir J 1989; 2 (suppl 3): 33-37

Robertson B.

Neonatal respiratory distress syndrome and surfactant therapy: a brief review.

Eur Respir J 1989; 2 (suppl 3): 73-76

Robertson B.

Background to neonatal respiratory distress syndrome and treatment with exogenous surfactant.

Dev Pharmacol Ther 1989; 13: 159-163

Robertson B.

European multicenter trials of Curosurf<sup>®</sup> for treatment of neonatal respiratory distress syndrom.

Lung 1990; 168 (suppl): 860-863

Robertson B.

Curosurf<sup>®</sup> in Europe.

In: Lucey JF (ed): Hot Topics '90 in Neonatology. Ross Laboratories, Columbus, 1990; 274-282

Robertson B.

The dilemmas of surfactant replacement.  
J Perinat Med 1991; 19 (suppl 1): 183-188

Robertson B.

Surfactant inactivation and surfactant replacement in experimental models of ARDS.  
Acta Anaesthesiol Scand 1991; 35 (suppl 95): 22-28

Robertson B.

The origin of neonatal lung injury.  
Pediatr Pathol 1991; 2: iii-vi

Robertson B.

Corticosteroids and surfactant for prevention of neonatal RDS.  
Ann Med 1993; 25: 285-288

Robertson B.

The joy and benefits of surfactant replacement -- snap-shots from the evolution of a new principle for treatment of neonatal respiratory distress syndrome.  
Appl Cardiopulmonol Pathophysiol 1995; 5 (suppl 1): 119-129

Robertson B.

Synopsis of achievements. Background leading to the work recognized by the King Faisal International Prize for Medicine.  
The 1996 King Faisal International Prize, The King Faisal Foundation, 61-70, 1996

Robertson B.

New targets for surfactant replacement therapy; experimental and clinical aspects.  
Arch Dis Child 1996; 75: F1-F3

Robertson B.

Surfactant inactivation and surfactant therapy in acute respiratory distress syndrome (ARDS).  
Monaldi Archives for Chest Disease, 1998; 53: 64-69

Robertson B.

Widening indications for surfactant therapy; from RDS to ARDS.  
Shanghai International Pediatric Symposium, 1998; 14-17

Robertson B, Halliday HL.

Principles of surfactant replacement.  
Biochim Biophys Acta 1998; 1408: 346-361

Robertson B.

Counterbalancing surfactant inactivation.  
In: Cosmi EV (ed): New Technologies in Reproductive Medicine, Neonatology and Gynecology.  
Monduzzi, Bologna 1999; 235-240

Robertson B, Curstedt T, Johansson J.  
Prospects for a new synthetic surfactant.  
Acta Biomed Ateneo Parmense 2000; 71: 409-412

Robertson B, Johansson J, Curstedt T.  
Synthetic surfactants to treat neonatal lung disease.  
Molecular Medicine Today 2000; 6: 119-124

Saugstad OD, Gloppstad K.  
Surfaktantbehandling av premature barn med respiratorisk distress syndrome.  
Tidsskr Nor Lægefor 1990; 29: 3737-3741

Saugstad OD, Halliday HL, Robertson B, Speer CP.  
Replacement therapy with porcine natural surfactant – current status and future challenges.  
Biol Neonate 1993; 64: 269-278

Schürch S, Qanbar R, Bachofen H, Possmayer F.  
The surface-associated surfactant reservoir in the alveolar lining.  
Biol Neonate 1995; 67 (suppl 1): 61-76

Shinwell ES, Robertson B, Saugstad OD, Halliday HL, Speer CP.  
Update on surfactant therapy.  
Biol Neonate 1995; 67: 2-12

Sittlington N, Tubman TRJ, Halliday HL.  
Surfactant replacement therapy for severe neonatal respiratory distress syndrome: implications for nursing care.  
Midwifery 1991; 7: 20-24

Skov L, Bell A, Greisen G.  
Surfactant administration and the cerebral circulation.  
Biol Neonate 1992; 61 (suppl 1): 31-36

Słomko Z, Gadzinowski J.  
Rys historyczny badań nad surfaktantem.  
(Research on pulmonary surfactant - historical perspective.)  
Klin Perinat Ginek 1992; suppl II: 9-16

Soll RF.  
Surfactant therapy in the USA: Trials and current routines.  
Biol Neonate 1997; 71 (suppl 1): 1-7

Soll RF.  
Surfactant treatment of the very preterm infant.  
Biol Neonate 1998; 74 (suppl 1): 35-42

Song GW.

The application of pulmonary surfactant in children's respiratory disease.  
Chin J Pract Pediatr 1994; 5: 267-270

Song GW.

Pulmonary surfactant and its clinical applications.  
J Appl Clin Pediatr 2000; 15 (suppl 4): 235-236

Song GW.

Pulmonary surfactant: metabolism and clinical applications.  
J Appl Clin Pediatr 2002; 31 (suppl 17): 15-18

Speer CP.

Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome.  
Clinical Digest Series 1992; 13-14

Speer CP, Harms K, Herting E.

Möglichkeiten der Therapie des Atemnotsyndroms Frühgeborener mit natürlichem Surfactant. Krankenpfl J 1990; 28: 388-391

Speer CP, Halliday HL.

European experience with Curosurf<sup>®</sup>, Update 1991.

In: Lucey JF (ed): Hot Topics '91 in Neonatology, Ross Laboratories, Columbus, 1991; 314-317

Speer CP.

Das neonatale Atemnotsyndrom: Pathogenese, Klinik und Therapie.  
Atemw.-Lungenkrkh 1993; 19: 459-464

Speer CP, Halliday HL.

Surfactant therapy in the newborn.  
Curr Paediatr 1994; 4: 1-5

Speer CP, Robertson B, Halliday HL.

Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?

Acta Paediatr 2000; 89: 510-512

Speer CP.

Die Surfactant-Substitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener.

Monatsschr Kinderheilkd 2002; 150: 659-668

Speer CP.

Clinical experience with the natural porcine surfactant preparation Curosurf<sup>®</sup>.

Acta Pharmacol Sin 2002; 23 (suppl): 97-99

Spragg RG.

Surfactant therapy in acute respiratory distress syndrome.

Biol Neonate 1998; 74 (suppl 1): 15-20

Spragg, RG.

The future of surfactant therapy for patients with acute lung injury – new requirements and new surfactants.

Biol Neonate 2002; 81 (suppl 1): 20-24

Strayer DS.

Applications of anti-Curosurf® antibodies to understanding the biology of alveolar surfactant.

Biol Neonate 1992; 61 (suppl 1): 2-14

Sun B.

Use of surfactant in pulmonary disorders in full term infants.

Curr Opin Pediatr 1996; 8: 113-117

Sun B.

Surfactant and inhaled nitric oxide in acute lung injury.

Hong Kong J Paediatr 2000; 5: 121-124

Sweet DG, Halliday HL.

Surfactant therapy.

Curr Paediatr 1998; 8: 103-107

Sweet DG, Halliday HL.

Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Paediatr Drugs 1999; 1: 19-30

Szymankiewicz M, Gadzinowski J, Bręborowicz GH.

Surfactant treatment - prophylaxis or therapeutics.

Klin Perinat Ginek 1994; suppl VI: 267 - 272

Szymankiewicz M, Gadzinowski J.

Białka surfaktantu - ich rola i metabolizm.

(Surfactant proteins – role and metabolism.)

Postępy w Neonatologii 1994; 5: 35 - 42

Szymankiewicz M, Gadzinowski J, Burchardt-Kroll E.

Zastosowanie surfaktantu w leczeniu zespołu zaburzeń oddychania u noworodków z masą ciała poniżej 1500 g. (Surfactant usage in neonates < 1500g with respiratory distress syndrome.)

Klin Perinat Ginek 1997; suppl XXI: 39 - 46

Taeusch HW.

Treatment of acute (adult) respiratory distress syndrome.

Biol Neonate 2000; 77 (suppl 1): 2-8

- Thomson MA.  
Continuous positive airway pressure and surfactant; combined data from animal experiments and clinical trials.  
Biol Neonate 2002; 81 (suppl 1): 16-19
- Truffert P, Breart G, Goelz R, Saugstad OD, Halliday HL, Bevilacqua G.  
Treatment strategies in Europe for neonatal pulmonary morbidity using surfactant and postnatal corticosteroids.  
Prenat Neonat Med 2001; 6 (suppl 2): 8-14
- Tubman TRJ, Halliday HL.  
Respiratory distress syndrome.  
Spectrum 1990; 31: 17-20
- Tubman R, Halliday HL.  
Le syndrome de detresse respiratoire du nouveau-ne.  
Spect Internat 1991; 34: 1-5
- Tubman TRJ, Rankin SJ, Halliday HL, Johnston SS.  
Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity.  
Biol Neonate 1992; 61 (suppl 1): 54-58
- Umile A, Halliday HL, Robertson B, Speer CP, Saugstad OD.  
Review of surfactant treatment in the newborn.  
Med Progr 2002; 3: 1-6.
- Vaandrager AB, van Golde LMG.  
Lung surfactant proteins A and D in innate immune defense.  
Biol Neonate 2000; 77 (suppl 1) 9-13
- Valls i Soler A.  
Administración de surfactante exógeno  
Gaceta Méd Bilbao 1990; 87: 24-27
- Valls i Soler A.  
Tratamiento sustitutorio con surfactante exógeno.  
An Esp Pediatr 1994; 40: 325-331
- Valls i Soler A, Alvarez FJ, Gastiasoro E.  
Liquid ventilation: From experimental use to clinical application.  
Biol Neonate 2001; 80 (suppl 1): 29-33
- Valls i Soler A.  
Surfactantes naturales: sí, las diferencias realmente existen.  
An Esp Pediatr 2002; 57: 582-594

Van Golde LMG, Batenburg JJ, Robertson B.  
The pulmonary surfactant system: Biochemical aspects and functional significance.  
Physiol Rev 1988; 68: 374-455

Van Golde LMG, Batenburg JJ, Robertson B.  
The pulmonary surfactant system.  
NIPS 1994; 9: 13-20

Van Golde LMG.  
Potential role of surfactant proteins A and D in innate lung defense against pathogens.  
Biol Neonate 1995; 67 (suppl 1): 2-17

Van Sonderen L.  
De behandeling van ernstig IRDS door middel van surfactanttoediening.  
Tijdsch Verloskund 1991; 12: 468-471

Van Sonderen L, de Winter JP, Koppe JG, Benders MJNL, Egberts J.  
Klinische ervaringen met surfactanttherapie.  
Tijdschr Kindergeneeskd 1994; 62: 75-78

Van Sonderen L, Halsema EFW, Spiering EJH, Koppe JG.  
Genetic influences in respiratory distress syndrome: a twin study.  
Sem Perinatol 2002; 26 (suppl 6): 447-449

Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbessen F, Greisen G, Hobalth N, Holm V, Jacobsen T.  
Surfactantbehandling af nyfødte med respiratorisk distress syndrom primært behandlet med nasalt kontinuerligt positivt luftvejstryk.  
Ugeskr Læger 1992; 154:2136-2139

Walters DV.  
Lung lining liquid – the hidden depths.  
Biol Neonate 2002 ; 81 (suppl 1): 2-5

Walti H, Relier JP.  
Les surfactants exogènes.  
Méd Infant 1987; 94: 673-683

Walti H, Relier JP.  
Traitement de la maladie des membranes hyalines (MMH) par un surfactant naturel.  
In : Journées Parisiennes de Pédiatrie, Flammarion- Médecine Sciences, Paris 1988; 298-300.

Walti H.  
Les surfactants exogènes ; dix ans après Fujiwara.  
In : Relier JP (ed): Progrès en néonatalogie, Karger Paris, 1990; 10: 293-313

Walti H, Relier JP.

Effets des surfactants exogènes sur la mortalité et les principales complications de la maladie des membranes hyalines.

Pédiatrie 1990; 45: 657-663

Walti H.

Les surfactants exogènes: Une thérapie substitutive pleine de promesses.

Pediatr Prat 1991; 26: 4-6.

Walti H.

La thérapeutique substitutive par les surfactants exogènes: Une nouvelle solution à un vieux problème.

Réan Urg 1992; 1: 447-454

Walti H.

Utilisation des surfactants exogènes dans le traitement du syndrome de détresse respiratoire de l'adulte.

Réan Urg 1992; 1: 777-780.

Walti H, Bréart G, Relier JP.

Les surfactants exogènes d'origine naturelle: Quoi de neuf en 1992?

Arch Fr Pediatr 1992; 49: 231-232

Walti H.

Utilisation des surfactants exogènes naturels pour le traitement de la maladie des membranes hyalines en 1992.

Rev Internat Pédiatr 1993; 230: 21-26

Walti H.

Utilisation des surfactants exogènes pour la prévention et le traitement de la maladie des membranes hyalines en 1993.

Gynécol Internat 1993; 2: 255-263

Walti H.

Surfactant naturel ou artificiel? Les arguments en faveur des surfactants naturels.

Arch Pédiatr 1996; 3: 165-175

Walti H.

Utilisation préventive et thérapeutique des surfactants exogènes dans le syndrome de détresse respiratoire néonatal.

MT- Pédiatrie 1998; 1: 193-200

Walti H, Monset-Couchard M.

A risk-benefit assessment of (natural and synthetic) exogenous surfactants in the management of neonatal respiratory distress syndrome.

Drug Safety 1998; 18: 321-337

Walti H.

Bases de l'utilisation thérapeutique des surfactants exogènes dans les déficiences secondaires en surfactant.

MT- Pédiatrie 1999; 2: 15-22

Weaver TE, Beck DC.

Use of knockout mice to study surfactant protein structure and function.

Biol Neonate 1999; 76 (suppl 1): 15-18

Werner O. Björklund LJ.

Resuscitation strategy and surfactant therapy.

Biol Neonate 1997; 71 (suppl 1): 32-34

Zupan V, Lacaze-Masmonteil T.

Les surfactants exogènes.

Médecine/Sciences 1993; 9: 277-287

**BOOKS and SUPPLEMENTS**

Bevilacqua G, Cosmi EV, Robertson B.  
Prevention and treatment of respiratory distress syndrome.  
Eur J Respir Dis 1989; 2 (suppl 3)

Bevilacqua G, Parmigiani S, Robertson B.  
Surfactant in clinical practice.  
Harwood Academic Publishers, Chur, 1992

Bevilacqua G, Curstedt T, Halliday HL, Robertson D, Saugstad OD, Speer CP.  
Clinical management and experimental models of surfactant-related lung disease.  
Biol Neonate 2002; 81(suppl 1): 1-42

Cosmi EV, Di Renzo GC, Bevilacqua G, Anceschi MM.  
The surfactant system of the lung.  
Harwood Academic Publishers, London, 1990

Cosmi EV, Di Renzo GC, Anceschi MM.  
The surfactant system of the lung. Prevention and treatment of neonatal and adult  
respiratory distress syndrome.  
MacMillan Press, London, 1991

Curstedt T, Halliday HL, Robertson B, Saugstad OD, Speer CP, Svenningsen NW.  
New perspectives of surfactant research.  
Biol Neonate 1997; 7 (suppl 1): 1-70

Halliday HL, Robertson B, Speer CP, Walti H.  
10 years of research on porcine derived lung surfactant.  
Biol Neonate 1995; 67 (suppl 1): 1-92

Halliday HL, Robertson B, Saugstad OD, Speer CP, Curstedt T.  
Recent advances in surfactant research.  
Biol Neonate 1998; 74 (suppl 1); 1-58

Laing IA, Curstedt T, Halliday HL, Robertson B, Saugstad OD, Speer CP.  
Further advances in surfactant replacement.  
Biol Neonate 2001; 80 (suppl 1): 1-42

Papagaroufalos C, Curstedt T, Halliday HL, Robertson B, Saugstad OD, Speer CP.  
New challenges in surfactant research.  
Biol Neonate 2000; 77 (suppl 1): 1-30

Robertson B, Halliday HL, Speer CP, Büky B.  
Experimental and clinical aspects of surfactant replacement.  
Biol Neonate 1992; 61 (suppl 1): 1-66

Robertson B, van Golde LMG, Batenburg JJ.  
Pulmonary surfactant. From molecular biology to clinical practice.  
Elsevier, Amsterdam, 1992

Robertson B, Taeusch HW.  
Surfactant therapy for lung disease.  
Marcel Dekker, New York, 1995

Speer CP, Halliday HL, Robertson B.  
11<sup>th</sup> workshop on surfactant replacement.  
Biol Neonate 1996; 69: 213-224

Speer CP.  
Neonatologie.  
In: Speer CP, Gahr M (eds): Pädiatrie. Springer-Verlag Berlin, Heidelberg, New York 2001;  
153-239

Verder H, Ebbesen F, Curstedt T, Halliday HL, Robertson B, Saugstad OD, Speer CP.  
Update on neonatal respiratory disorders and surfactant.  
Biol Neonate 1999; 76 (suppl 1): 1-52

Vignali, Cosmi EV, Luerti M.  
Diagnosis and treatment of fetal lung immaturity.  
Masson, Milano-Paris, 1986

**BOOK CHAPTERS and EXTENDED ABSTRACTS**

Amato M, Hüppi P, Markus D.

Surfactant therapy and IgE levels in the neonatal period.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Macmillan Press, London, 1991; 156-158

Apostolidou I, Papagaroufalis C, Stamocosta E, Lafoyianni S, Kalpoyiannis N, Xanthou M. Association of intraventricular hemorrhage with perinatal anoxia and pneumothorax in premature neonates treated or not with surfactant.

In: Cosmi EV, di Renzo GC (eds): Proceedings of the 2<sup>nd</sup> World Congress of Perinatal Medicine, Monduzzi Editore, Bologna, 1993; 1107-1109

Apostolidou I, Papagaroufalis C, Touloumi J, Xanthou M, Kalpoyiannis N.

Antenatal maternal steroids reduce the risk of periventricular-intraventricular hemorrhage in very premature neonates treated with natural surfactants.

In: Roussos C (ed): Proceedings of the 8<sup>th</sup> European Congress of Intensive Care Medicine, Athens, 1995, Monduzzi Editore, Bologna, 1995; 87-91

Bambang Oetomo S, Robertson B, Okken A.

Transcutaneous PO<sub>2</sub> and PCO<sub>2</sub> before, during and after surfactant therapy in newborn infants with idiopathic respiratory distress syndrome.

In: Huch A, Huch R, Booth L (eds): Continuous transcutaneous monitoring. Plenum Press, New York, 1987; 121-123

Bambang Oetomo S, de Ley L, Schoots C, Lachmann B, Okken A.

Immunohistochemical study of the distribution of exogenous surfactant in the lungs of surfactant deficient rabbits using a monoclonal antibody.

In: Lachmann B (ed): Surfactant replacement therapy in neonatal and adult respiratory distress syndrome. Springer, Berlin/Heidelberg/New York, 1988; 298-300

Bergamo Andreis IA, Fugazzola C, Padovani EM.

Radiologic aspects of respiratory distress syndrome in newborns treated with mechanical ventilation and surfactant administration.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 155-162

Bevilacqua G, Cosmi EV, Parmigiani S, Volante E, Gaioni L, Gancia GP, Guerrini P, Robertson B.

Prevenzione e trattamento con surfattante suppletivo nella R.D.S. neonatale.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): Il Congresso Nazionale della Società Italiana di Medicina Perinatale, 1987; 305-310

Bevilacqua G, Volante E, Cosmi EV, Volta A, Vettoretti T, Robertson B.  
 Surfactant replacement in severe neonatal respiratory distress syndrome.  
 In: Cosmi EV, di Renzo GC (eds): XI European Congress of Perinatal Medicine, CIC Edizioni Internazionali, Rome, 1988; 85-88

Bevilacqua G, Monici Preti P, Parmigiani S, Volante E, Garani P, Guerrini P, Fossa S, Nahum L, Compagnoni G, Gaioni L, Foresti B, Marraro G, Benini F, Rubaltelli F, Buonocore G, De Filippo M, Chiaffoni GP, Padovani EM.  
 Studio multicentrico italiano sull'uso di un surfattante esogeno (CUROSURF®) nella terapia della RDS.  
 In: Luerti M, Bevilacqua G (eds): Attualità nella prevenzione e terapia della RDS del neonato, Editrice Centro Studi Sardini, Brescia, 1989; 65-77

Bevilacqua G.  
 Modificazioni delle funzioni respiratorie indotte dal surfattante suppletivo.  
 In: Pecorari D, Tosadori U, Gamper H (eds): Incontri di ostetricia e ginecologia 1990. CIC Edizioni Internazionali, Roma, 1990; 277-281

Bevilacqua G.  
 Curosurf® for therapy in neonatal RDS: an Italian randomized clinical trial.  
 In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Macmillan Press, London, 1991; 122-127

Bevilacqua G, Parmigiani S and Trial Participants.  
 Timing of surfactant therapy for neonatal respiratory distress syndrome.  
 In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 121-130

Bevilacqua G, Parmigiani S, Robertson B, Cosmi EV, Preti PM, Volante E, Halliday HL, Tubman R, Guerini P, Donzelli GP, Vecchi C, Magaldi R, Rinaldi G, Fossa S, Silvestri G, Turo P, Egberts J, de Winter P, Compagnoni G, Gaioni L, Foresti B, Marraro G, Taccone F, Trifiro G, Grano S, Tripoli V, Griffith P, Rubaltelli FF, Relier JP, Walti H, Bracci R, Bronocare G, Caltarossi L, Macagno F, Padovani E, Chiaffoni GP, Gardini F.  
 Timing of surfactant therapy for neonatal respiratory distress syndrome.  
 In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 121-127

Bevilacqua G, Parmigiani S, Borsi MC, Gugliotta M, Faienza C.  
 Neurodevelopmental outcome two years after natural surfactant treatment for neonatal respiratory distress syndrome (RDS).  
 In: Cosmi EV, di Renzo GC (eds): Proceedings of the 2<sup>nd</sup> World Congress of Perinatal Medicine. Monduzzi Editore, Bologna, 1993; 1205-1209

Bevilacqua G, Parmigiani S.  
 Prophylactic vs early treatment of neonatal respiratory distress syndrome with exogenous surfactant.  
 In: Voto LS, Margulies M, Cosmi EV (eds): 4<sup>th</sup> World Congress of Perinatal Medicine. Monduzzi Editore, Bologna, 1999; 275-280

Bevilacqua G, Parmigiani S.

Surfactant effectiveness in clinical practice. Observational study.

In: Carrera JM, Cabero L, Baraibar R (eds): The perinatal medicine of the new millennium. Monduzzi Editore, Bologna, 2001; 751-756

Bracci R, Buoncore G, Taccone F, Berni S, Trifiró G, Gioia D.

Oxygen toxicity and surfactant replacement therapy in the newborn.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 199-206

Collaborative European Multicenter Study Group.

The European multicenter trial of surfactant replacement in neonatal respiratory distress syndrome.

In: Lachmann B (ed): Surfactant replacement therapy in neonatal and adult respiratory distress syndrome. Springer, Berlin/Heidelberg/New York 1988; 123-126

Cosmi EV, Robertson B.

Morphologic and functional aspects of neonatal lung adaption.

In: Cosmi EV (ed): Obstetric anesthesia and perinatology. New York, Appleton - Century-Crofts, 1981; 16: 625-675

Cosmi EV, Anceschi MM, Petrelli A, Collini P, Di Renzo GC.

Prenatal prevention of RDS.

In: Wauer RR (ed): Hyaline membrane disease: surfactant and its pharmacological influence. Proceedings of the international workshop on "Diagnosis and Prevention of Neonatal RDS", Wauer RR (ed) VEB Verlag Volk und Gesundheit, Berlin 1987; 37-44

Cosmi EV, Barbati A, Anceschi MM, Di Renzo GC.

Assessment of fetal lung maturity and prenatal prevention of respiratory distress syndrome.

In: Maeda K (ed): The fetus as a patient. Elsevier, Amsterdam, 1987; 259- 266

Cosmi EV, Di Renzo GC.

RDS: Requirements of perinatal diagnosis, prevention and treatment.

In: Lachmann B (ed): Surfactant replacement therapy. Springer Verlag, Berlin/Heidelberg/New York 1988; 49-57

Cosmi EV, La Torre R, Di Iorio R, Anceschi MM.

A novel treatment of fetal lung immaturity. A preliminary report.

In: Cosmi EV (ed): Proceedings of the symposium "The Place for New Technologies in Gynecology, Obstetrics and Perinatology", Monduzzi Editore, Rome, 1995; 41-44

Cosmi EV, Anceschi MM, Di Renzo GC.

Surfactant production enhancement in utero.

In: Di Renzo GC, Hawkins DF (eds): Perinatal medicine: Problems and controversies. Raven Press, New York 1996; 129-136

Cosmi EV, Anceschi MM, Piazzè Garnica J, Marinoni E.  
Prevention of fetal and neonatal lung immaturity.  
In: Kurjak A (ed): Textbook of perinatal medicine. Parthenon Publishing Group, Lancaster 1998; 2:1382-1392

Cosmi EV.  
In utero treatment of fetal lung immaturity.  
In: Cabero L, Carrera MJ (eds): Proceedings of the 5<sup>th</sup> World Congress on Perinatal Medicine, Monduzzi Editore, Bologna, 2001; 541-547

Cosmi EV, Breart G, Halliday HL, Saugstad OD, Szabo I, Visser GHA.  
Antenatal and postnatal management of fetal lung immaturity in Europe.  
Report of EURAIL (Europe Against Immature Lung), EC-Concerted Action, Contract No. BMH-4-CT98-3658. The Parthenon Publishing Group, Lancaster, 2001

Curstedt T, Jörnvall H, Berggren P, Robertson B.  
Artificial surfactant based on different hydrophobic low-molecular weight proteins.  
In: Lachmann B (ed): Surfactant replacement therapy in neonatal and adult respiratory distress syndrome, Springer, Berlin/Heidelberg/New York 1988; 332-337

Curstedt T, Robertson B, Johansson J, Jörnvall H.  
Structure of hydrophobic low-molecular weight (3.7 and 8.7 kDa) proteins used for reconstitution of artificial surfactants.  
In: Cosmi EV, di Renzo GC (eds): XI European Congress of Perinatal Medicine. CIC Edizioni Internazionali, Rome, 1988; 147-150

Curstedt T, Johansson J, Robertson B, Persson P, Löwenadler B, Jörnvall H.  
Structure and function of hydrophobic surfactant-associated proteins.  
In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 55-60

Diniz EMA.  
Hyaline membrane disease.  
In: Rozov T, Carvalho CRR (eds): Doenças pulmonares em pediatria. Harper & Row São Paulo, 1987; 35-48

Diniz EMA, Olivi GGB.  
Meconium aspiration syndrome  
In: Marcondes E (ed): Pediatria básica. Sarvier São Paulo, 1991; 363-366

Diniz EMA.  
Hyaline membrane disease.  
In: Rozov T (ed): Doenças respiratórias em pediatria. Atheneu São Paulo, 1999; 90 - 102

Diniz EMA, Vieira RA, Grassi MS, Ceccon MEJ, Krebs VLJ, Feferbaum R, Vaz FAC.  
Exogenous porcine surfactant therapy for the high-risk neonate with severe pneumonia.  
In: Cosmi EV, Di Iorio R, Marinoni E, Anceschi MM (eds): The woman and child: Before, during and after pregnancy. Monduzzi Editore, Bologna, 2001; 445-449

Egberts J, Curstedt T, Robertson B.  
Inhibition of porcine surfactant by serum proteins of neonates and adults.  
In: Cosmi EV, di Renzo GC (eds): XI European Congress of Perinatal Medicine Vol. II, CIC Edizioni Internazionali, Rome, 1989; 359-361

Egberts J.  
Prophylactic surfactant application in preterm infants.  
In: Caramia GM (ed): Bambino: Progetto salute. Le nuove frontiere della neonatologia europea, Ancona, 1990; 163-170

Egberts J, de Winter JP, van Bel F.  
Surfactant prophylaxis in the delivery room.  
In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 113-120

Egberts J, Brand R.  
Randomized trials with surfactant and the meta-analysis.  
In: Cosmi EV, di Renzo GC (eds): Current progress in perinatal medicine. The Parthenon Publishing Group, Carnforth, 1994; 51-56

Fiori RM, Fiori HH.  
Surfactante: O estado da arte.  
In: Alves Filho N, Trindade Filho O (eds): Clínica de perinatologia. Editora Medsi, Rio de Janeiro, 2001; 429-441

Foresti B, Marraro G.  
Preliminary results in the use of a natural surfactant (Curosurf®) in four infants with severe RDS.  
In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Macmillan Press, London, 1991; 131-138

Fujiwara T, Robertson B.  
Pharmacology of exogenous surfactant.  
In: Robertson B, van Golde LMG, Batenburg JJ (eds): Pulmonary surfactant. From molecular biology to clinical practice. Elsevier, Amsterdam, 1992; 561-592

Gadzinowski J.  
Leczenie surfaktantem egzogennym.  
(Treatment with exogenous surfactant.)  
In: Słomko Z (ed): Medycyna perinatalna. Warszawa, 1994; 80-89

Green FHY, Gehr P, Lee MM, Schürch S.

The role of surfactant in disease associated with particle exposure.

In: Gehr P, Heyder J (eds): Particle-lung interaction.

Marcel Dekker, New York, 2000; 533-576

Halahakoon CH, Halliday HL.

Other acute lung disorders.

In: Yu VYH (ed): Pulmonary problems in the perinatal period. Balliere Tindall, London, 1995; 87-114

Halliday HL, McClure BG, Reid MMcC, Meban C.

Surfactant replacement studies in Belfast.

In: Clinch J, Matthews T (eds): Perinatal medicine. MTP Press, Lancaster, 1985; 293-297

Halliday HL, Tubman TRJ.

Further experience with Curosurf® in Europe.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung.

Macmillan Press, London, 1991; 112-121

Halliday HL.

Surfactant replacement.

In: Klaus MH, Fanaroff AA (eds): Neonatal and perinatal medicine. 1991 Yearbook, Yearbook Medical Publishers, London, 1991; 13-21

Halliday HL.

Other acute lung disorders.

In: Sinclair JC, Bracken MB (eds): Effective care of the newborn infant. Oxford University Press, Oxford, 1992; 359-384

Halliday HL.

Follow-up data from babies treated with surfactant.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 149-156

Halliday HL.

Surfactant therapy.

Background paper for the report of a joint working part of the British Association of Perinatal Medicine and the Research Unit of the Royal College of Physicians, Publications Department, Royal College of Physicians, London, 1992

Halliday HL.

Pulmonary surfactants.

In: Dollery C (ed): Therapeutic drugs. (suppl 1), Churchill Livingstone, Edinburgh, 1992; 172-178

Halliday HL.

Pulmonary disorders and apnoea.

In: Campbell AGM, McIntosh N (eds): Forfar and Arneil's Textbook of Paediatrics. Churchill Livingstone, Edinburgh, 1992; 148-221

Halliday HL.

Prevention of respiratory distress syndrome.

In: Caramia BM (ed): Bambino: Progetto salute. Prevenzione e terapia pediatrica in ambito europeo. Ancona, 1992; 45-47

Halliday HL.

Follow-up data from babies treated with surfactant.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1993; 147-154

Halliday HL, Robertson B.

Surfactant replacement.

In: Hanson MA, Spencer JAS, Rodeck CH, Walters D (eds): Fetus and neonate, physiology and clinical applications. Breathing, Cambridge University Press, Cambridge, 1994; 265-302

Halliday HL, Speer CP.

Strategies for surfactant therapy in established neonatal respiratory distress syndrome.

In: Robertson B, Taeusch HW (eds): Surfactant therapy for lung disease. Marcel Dekker, New York, 1995; 443-459

Halliday HL.

Prophylactic surfactant. The case against.

In: Cockburn F (ed): Advances in perinatal medicine. Parthenon Publishing Group, London, 1997; 360-370

Halliday HL.

The Newborn : Pulmonary disorders and apnea.

In: Campbell AGM, McIntosh N (eds): Forfar and Arneil's Textbook of Paediatrics. Churchill Livingstone, New York, 1998; 175-198

Halliday HL.

Guidelines for the management of respiratory distress syndrome.

In : Cosmi EV (ed): Labour and delivery. Parthenon Publishing, Lancaster, 1998; 242-246

Halliday HL.

Prevention and management of respiratory distress syndrome.

In: Levitt G, Harvey D, Cooke R (eds): Practical perinatal care: The baby under 1000 g. Butterworth Heinemann, Oxford, 1999; 33-51

Halliday HL.

Aggiornamento sull'impiego del surfattante nel neonato prematuro: revisione degli studi clinici.

In: Marraro G (ed): L'uso del surfattante naturale nella patologia respiratoria acuta. Mediserve, Milano 2002; suppl.: 12-19

Hallman M, Abraham JL, Pitkänen O, Arjomaa P.

Diagnosis of surfactant defects in newborn, children and adults in the era of surfactant therapy.

In: Lachmann B (ed): Surfactant replacement therapy in neonatal and adult respiratory distress syndrome. Springer-Verlag, Berlin/Heidelberg/New York, 1988; 58-67

Hallman M.

Treatment of established respiratory distress syndrome with surfactant.

In: Ekelund L, Jonson R, Malm L (eds): Surfactant and the respiratory tract. Elsevier, Amsterdam 1989; 187-195

Hallman M.

Antenatal diagnosis of lung maturity.

In: Robertson B, van Golde LMG, Batenburg JJ (eds): Pulmonary surfactant. From molecular biology to clinical practice. Elsevier, Amsterdam 1992; 425-458

Hallman M, Merritt TA, Bry K.

Biochemical prediction of response to surfactant therapy.

In: Robertson B, Taeusch HW (eds): Surfactant therapy for lung disease. Marcel Dekker, New York 1995; 325-348

Harms K, Müller U, Herting E, Speer CP, Curstedt T, Robertson B.

Früh- und Spätbehandlung des schweren Atemnotsyndroms (RDS) Frühgeborener mit einer einmaligen Dosis eines natürlichen porcinen Surfactant.

In: Stockhausen (ed): Pädiatrische Intensivmedizin X, Georg Thieme-Verlag, Stuttgart, 1989; 40-42

Herting E, Harms K, Speer CP, Curstedt T, Robertson B.

Surfactant replacement in severe RDS: effects of perinatal acidosis on therapeutic response.

In: Cosmi EV, Di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Prevention and treatment of neonatal and adult respiratory distress syndrome. MacMillan Press, London, 1991; 151-155

Herting E, Speer CP, Harms K, Robertson B, Curstedt T.

Treatment of severe neonatal respiratory distress syndrome with single- or multiple-dose treatment with a porcine natural surfactant: logistic regression analysis of parameters influencing survival.

In: Koppe JG, Eskes AB, van Geijn HP (eds): Care, concern and cure in perinatal medicine, Parthenon, Carnforth, 1992; 589-595

Herting E, Harms K, Speer CP.

Ansätze zur Optimierung der Surfactanttherapie des schweren Atemnotsyndroms (RDS) Frühgeborener: Indikation, Dosis und Applikationstechnik.

In: Wauer R (ed): Surfactanttherapie des neonatalen Atemnotsyndrom. Georg Thieme-Verlag, Stuttgart 1993; 37-46

Herting E, Jorch G.

Surfactanttherapie des neonatalen Atemnotsyndroms: Dosis und Applikationstechnik.

In: Wauer R (ed): Surfactanttherapie. Grundlagen, Diagnostik, Therapie. Georg Thieme Verlag, Stuttgart 1997:65-74

Herting E.

Neue Indikationen zur Surfactanttherapie - Surfactanttherapie bei neonataler Pneumonie und beim Mekoniumaspirationssyndrom.

In: Wauer R (ed): Surfactanttherapie. Grundlagen, Diagnostik, Therapie. Georg Thieme Verlag, Stuttgart 1997:123-132

Herting E, Jorch G.

Surfactant therapy for neonatal RDS: Dose and administration technique.

In: Wauer R (ed): Surfactant therapy. Basic principles, diagnosis. Georg Thieme Verlag, Stuttgart-New York, 1998: 65-73

Herting E.

Surfactant therapy for neonatal pneumonia and for meconium aspiration syndrome.

In: Wauer R (ed): Surfactant therapy. Basic principles, diagnosis. Georg Thieme Verlag, Stuttgart-New York, 1998; 124-132

Johansson J, Curstedt T, Persson P, Robertson B, Löwenadler B, Jörnvall H.

Hydrophobic surfactant proteins SP-B and SP-C: Special analytical problems.

In: Jörnvall H, Höög JO, Gustavsson AM (eds): Methods in protein sequence analysis. Birkhäuser Verlag, Basel, 1991; 197-204

Koppe JG, Smolders-de Haas H.

RDS and the use of corticosteroids.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Macmillan Press, London, 1991; 91-95

Koppe JG.

Steroids or surfactant replacement or both?

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 223-227

Lacaze-Masmonteil T.

Les surfactants exogènes en néonatalogie.

Conférences d'actualisation 1995 de la société française d'anesthésie et de réanimation. Masson, Paris, 1995; 387-402

Lacaze-Masmonteil T.

Exogenous surfactant therapy in neonatology.

In: Chapman & Hall (eds): Current practice in critical illness. London, 1997, pp 117-136.

Lacaze-Masmonteil T.

Les surfactants artificiels avec analogues peptidiques.

In: Caulin C, Chevret S, Pons G (eds): Médicaments en réanimation néonatale.

Springer Verlag Berlin/Heidelberg/New York 1999; 185-196.

Lacaze-Masmonteil T.

Le surfactant pulmonaire. Structure, fonctions, métabolisme de régulation

In: Dehan M, Micheli JL (eds): Le poumon du nouveau-né. Collection Progrès en Pédiatrie.

Initiative Santé Liaison, Paris 2000; 25-38

Lacaze-Masmonteil T.

Surfactants exogènes.

In: Gold F (ed): Soins intensifs et réanimation du nouveau-né. Masson, Paris 2002; 291-299

López Heredia J, Hernández Ortega E, Román Echebarria L, Valls i Soler A.

Tratamiento sustitutivo von surfactante exógeno (Curosurf®).

In: Cabero i Roura L, Cabero I Roura A, Martínez de la Riva A (eds): Ostetrica y

ginecologia 25 años, Autonomous University of Barcelona, Barcelona, 1993; 363-368

Malm L.

Surfactant and the Eustachian tube.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood

Academic Publishers, Chur, 1992; 181-186

Marraro G.

Respiratory emergencies and supplementary surfactant in the treatment of severe RDS in leukaemic adolescents.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung.

Macmillan Press, London, 1991; 198-206

Marraro G, Foresti B, Casiraghi G, Riva A.

Surfactant treatment of respiratory failure in children.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood

Academic Publishers, Chur, 1992; 173-180

McCord B, Halliday HL, McClure BG, Reid MMCC.

Changes in pulmonary and cerebral blood flow after surfactant treatment for severe respiratory distress syndrome.

In: Lachmann B (ed): Surfactant replacement therapy in neonatal and adult respiratory distress syndrome. Springer-Verlag Berlin/Heidelberg/New York, 1989; 195-200

Merritt TA, Wilson MJ, Turner YT, Hallman M.

Outcomes of surfactant treated infants: analysis of developmental outcome and economic impact of surfactant therapy for the prevention and treatment of respiratory distress syndrome.

In: Robertson B, Taeusch HW (eds): Surfactant therapy for lung disease. Marcel Dekker, New York, 1995; 601-620

Mosca F, Farina C, Colnaghi MR, Marini A.

Pulmonary function in mechanically ventilated surfactant-treated preterm infants.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Macmillan Press, London, 1991; 159-167

Nilsson R, Berggren P, Curstedt T, Grossmann G, Renheim G, Robertson B.

Surfactant treatment and ventilation by high frequency oscillation in premature newborn rabbits: effect on survival, lung aeration, and bronchiolar epithelial lesions.

In: Green GM (ed): The Year Book of Pulmonary Disease. Chicago, 1986; 338-340

Obladen M, Maier R, Kattner E, Segerer H.

Compliance of the preterm lung before and after surfactant replacement.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 27-36

Papagaroufalis C, Stamocosta E, Klavdianou M, Papazissis G, Xanthou M.

Early versus late treatment of neonatal respiratory distress syndrome with multiple doses of surfactant.

In: Cosmi EV, di Renzo GC (eds): Proceedings of the 2<sup>nd</sup> World Congress of Perinatal Medicine, Monduzzi Editore, Bologna, 1993; 1133-1136

Papagaroufalis C.

Surfactant.

In: C.Costallos (ed): Neonatology (in Greek). Litsas Publications, Athens, 1996; 460-479

Papagaroufalis C.

Respiratory distress syndrome.

In: C.Costallos (ed): Neonatology (in Greek). Litsas Publications, Athens, 1996; 480-491

Papagaroufalis C.

Randomized trial comparing two surfactant regimens for the late treatment of neonatal respiratory distress syndrome.

In: P.Behrakis (ed): Proceedings of the 2<sup>nd</sup> Mediterranean Congress on Thoracic Diseases, Athens, 1998. Monduzzi Editore, Bologna, 1998; 71-74

Parmigiani S, Bevilacqua G, Volante E, Gancia GP, Silvestri G.

Pulmonary mechanics after surfactant replacement for neonatal respiratory distress syndrome.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 211-216

Parmigiani S, Gambini L, Volta A, Bevilacqua G.

The case of Dulcinea: use of exogenous surfactant in viral pneumonia.

In: Cosmi EV, di Renzo GC (eds): Proceedings of the 2<sup>nd</sup> World Congress of Perinatal Medicine. Monduzzi Editore, Bologna, 1993; 1181-1184

Parmigiani S, Monici Preti P, Bevilacqua G.

Pulmonary mechanics two years after surfactant administration for neonatal respiratory distress syndrome (RDS).

In: Cosmi EV, di Renzo GC (eds): Proceedings of the 2<sup>nd</sup> World Congress of Perinatal Medicine. Monduzzi Editore, Bologna, 1993; 1191-1195

Parmigiani S, Bevilacqua G.

Profilassi della sindrome respiratoria del neonato in sala parto verso trattamento precoce con surfattante esogeno suino.

In: Cosmi EV (ed): Atti del VI congresso nazionale della Società Italiana di Medicina Perinatale. Monduzzi Editore, Bologna, 1996; 131-136

Pettenazzo A, Alberti A, Gamba PG, Benevento M, de Marchi A, Ventura P, Baritussio A. Alveolar clearance of Curosurf<sup>®</sup> in developing and mature lungs.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 83-86

Pollak A, Hayde M, Salzer HR, Trittenwein G.

Der Einsatz von Surfactant in der Neonatologie.

In: F. Kummer, N. Konietzko, T.C. Medici (eds): Pharmakotherapie bronchopulmonaler Erkrankungen. Springer Verlag, Berlin/Heidelberg/New York 2000: 309-324

Rigaut JP, Robertson B.

Le poumon comme objet semi-fractal.

In: Cherbit G (ed): Fractals - le concept de dimension non entière et ses applications. Masson, Paris, 1987; 250-258, 277-281

Robertson B.

Overview of surfactant replacement.

In: Clinch J, Matthews T (eds): Perinatal medicine. MTP Press, Lanchester, 1985; 285-292

Robertson B.

Surfactant replacement - items of consensus and controversy.

In: Cosmi EV, di Renzo GC (eds): Selected topics in perinatal medicine. CIC Edizioni Internazionali, Rome, 1986; 199-210

Robertson B.

Surfactant replacement: theory and practice.

In: Walters DV, Strang LB, Guebelle F (eds): Physiology of the fetal and neonatal lung. MTP Press, Lanchester, 1986; 241-254

Robertson B, Noack G, Bevilacqua G, Berggren P, Cosmi EV, Curstedt T, Grossmann G. Surfactant replacement in severe neonatal respiratory distress syndrome.

In: Vignali M, Cosmi EV, Luerti M (eds): Diagnosis and treatment of fetal lung immaturity. Masson, Milano, 1986; 193-197

Robertson B.

Surfactant replacement in neonatal RDS; Experimental and clinical trials.

In: Cosmi EV (ed) La respirazione perinatale. La clinica ostetrica e ginecologica. Piccin Med Press, Padova 1987; 783-797

Robertson B.

Pathology of neonatal surfactant deficiency.

In: Rosenberg H, Bernstein J (eds): Respiratory and alimentary tract diseases. Perspect Pediatr Pathol, Karger, Basel, 1987; 11: 6-46

Robertson B.

New approaches to the prophylaxis and treatment of the neonatal respiratory distress syndrome.

In: Wauer RR (ed): Respiratory distress syndrome of premature infants - Significance of surfactant and its pharmacological influence. VEB Verlag Volk und Gesundheit, Berlin, 1987; 116-126

Robertson B.

Surfactant and lung injury.

In: Jobe AH, Taeusch HW (eds): Surfactant treatment of lung diseases. Ross Laboratories, Columbus, 1988; 62-69

Robertson B.

International multicenter trial of surfactant replacement in neonatal respiratory distress syndrome.

In: di Renzo GC, Cosmi EV, Hawkins DF (eds): Advances in perinatal medicine. Harwood Academic Publishers, Chur, 1988; 105-113

Robertson B.

Experimental pathology of neonatal and adult respiratory distress syndrome: Effects of surfactant replacement.

In: Ekelund L, Jonson B, Malm L (eds): Surfactant and the respiratory tract. Elsevier, Amsterdam 1989; 155-163

Robertson B.

Surfactant deficiency and lung injury.

In: Shapiro DL, Notter RH (eds): Surfactant replacement therapy. Alan R. Liss Inc, New York, 1989; 127-144

Robertson B.

New perspectives in the treatment of pulmonary immaturity; surfactant replacement.

In: Caramia GM (ed): Bambino: Progetto salute. Le nuove frontiere della neonatologia europea. Ancona, 1990; 171-174

Robertson B.

Experiences with Curosurf® in Europe.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Macmillan Press, London, 1991; 107-111

Robertson B.

The dilemmas of surfactant replacement.

In: Thoulon JM, Putet G (eds). Proceedings of XII European Congress of Perinatal Medicine.

J Perinat Med 1991; 19 (suppl 1) 183-188

Robertson B.

Experiences with Curosurf® in Europe

In: Cosmi EV, Di Renzo GC, Anceschi MM (eds): The surfactant system of the lung: Prevention and treatment of neonatal and adult respiratory distress syndrome. Stockton Press, Basingstoke, 1991; 107-111

Robertson B.

Animal models of neonatal surfactant dysfunction.

In: Robertson B, van Golde LMG, Batenburg JJ (eds): Pulmonary surfactant. From molecular biology to clinical practice. Elsevier, Amsterdam, 1992; 459-484

Robertson B.

Surfactant therapy in infants and children; basic concepts and clinical experience.

In: Artigas A (ed): 6<sup>th</sup> European Congress on Intensive Care Medicine, Barcelona, 1992; 67-69

Robertson B, Kobayashi T, Suzuki Y, Grossmann G, Ganzuka M, Li WZ, Nitta K, Curstedt T.

Inhibition of neonatal surfactant function by a monoclonal antibody to the surfactant-associated hydrophobic protein B, SP-B.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 73-78

Robertson B, Noack G.

Pathogenesis and early diagnosis of bronchopulmonary dysplasia.

In: Koppe JG, Eskes TKAB, van Geijn HP, Wiesenhaan PE, Ruys JH (eds): Care, concern and cure in perinatal medicine. Parthenon, Carnforth, 1993; 523-529

Robertson B.

Surfactant deficiency and surfactant inactivation in experimental neonatal respiratory distress syndrome.

In: Müller B, von Wichert P (eds): Lung surfactant: Basic research in the pathogenesis of lung disorders. Progress in Respiration Research, Karger, Basel, 1994; 27: 232-239

Robertson B.

Differences between available surfactants

In: Briaschi A, Chiaranda M, Gattinoni L, Pesenti A, Raimondi F (eds): Simposio Mostra Anestesia Rianimazione e Terapia Intensiva, Milano, Springer-Verlag, 1994; 35-37

Robertson B.

Surfactant replacement and neonatal lung pathology.

In: Askin F, Langston C (eds). *Perspect Pediatr Pathol*, Karger, Basel, 1995; 18: 5-31

Robertson B.

Experimental models for evaluation of exogenous surfactants.

In: Robertson B, Taeusch HW (eds): *Surfactant therapy for lung disease*. Marcel Dekker, New York, 1995; 239-267

Robertson B, Taeusch HW.

Postscript: Perspectives for the future.

In: Robertson B, Taeusch HW (eds): *Surfactant therapy for lung disease*. Marcel Dekker, New York, 1995; 621-629

Robertson B, Schürch S.

Assessment of surfactant function.

In: Uhlig S, Taylor AE (eds): *Methods in pulmonary research*. Birkhäuser Verlag, Basel, 1998; 349-386

Robertson B.

New surfactants; new objectives.

In: Cosmi EV (ed): *Women's health in the 2000 from reproduction to menopause*. Monduzzi Editore, Bologna 1999; 201-208

Robertson B.

Il surfattante naturale e le sue indicazione cliniche.

In: Marraro G (ed): *L'Uso del surfattante naturale nella patologia respiratoria acuta*. *Interactive Medicine (Suppl Settembre 2002)*, Mediserve, Milano 2002; 5-11

Saugstad OD, Tubman TRJ, Gloppstad K, Øyasæter S, Halliday HL, Curstedt T, Robertson B.

Washing out of hypoxanthine after treatment with natural surfactant (Curosurf®).

In: Bevilacqua G, Parmigiani S, Robertson B (eds): *Surfactant in clinical practice*. Harwood Academic Publishers, Chur, 1992; 207-210

Schürch S, Bachofen H.

Biophysical aspects in the design of a therapeutic surfactant.

In: Robertson B, Taeusch HT (eds): *Surfactant therapy for lung disease*. Marcel Dekker, New York, 1995; 3-32

Schürch S, Bachofen H.

Alveolar lining layer: Functions, composition, structures.

In: Hlastala MP, Robertson HT (eds): Complexities in structure and function of the lung. Marcel Dekker, New York, 1998; 35-73.

Silvestri G, Tuo P, Pongiglione G, Puccio V, Fossa S.

Cardiocirculatory function in premature infants treated with surfactant.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 141-146

Sittlington N, Tubman TRJ, Halliday HL.

Surfactant replacement therapy for severe neonatal respiratory distress syndrome.

Implications for nursing care.

In: McCormick F, Renfrew MJ (eds): The midwifery research database. Miriad 1996; 308: 135-136

Speer CP.

Therapie des schweren Atemnotsyndroms Frühgeborener mit natürlichem Surfactant.

In: Rath W, Kuhn W. (eds): Pränatale Erkrankungen des Kindes. Diagnostik, Prophylaxe und therapeutische Konsequenzen, Editiones Roche, Basel, 1991; 101-112

Speer CP, Götze B, Curstedt T.

The effect of a porcine surfactant (Curosurf®) on the phagocytosis-associated functions of human neutrophils.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Macmillan Press, London, 1991; 142-150

Speer CP, Compagnone D, Herting E, Curstedt T, Robertson B.

Clinical response to surfactant replacement.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 129-135

Speer CP.

Das Frühgeborene, pulmonale Erkrankungen des Neugeborenen, konnatale und neonatale Infektionen.

In: von Harnack GA, Heimann G (eds): Kinderheilkunde. Springer-Verlag, Berlin/Heidelberg/ New York 1994; 60-93

Speer CP.

Atemnotsyndrom (RDS).

In: Gahr M (ed): Pädiatrie. de Gruyter, Berlin/New York 1994; 55-59

Speer CP, Reuss D, Harms K, Herting E, Gefeller O.

Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome.

In: Fanaroff AA (ed): Yearbook of neonatal and perinatal medicine. Chicago, 1994; 278-280

Speer CP.

Neonatales Atemnotsyndrom.

In: Reinhardt D (ed): Therapie der Krankheiten des Kindesalters. Springer-Verlag, Berlin/Heidelberg/New York 1997; 11-15

Speer CP.

Das Frühgeborene; Atemnotsyndrom Frühgeborener.

In: von Harnack GA, Koletzko B (eds): Kinderheilkunde. Springer-Verlag, Berlin/Heidelberg/New York 1997; 69-78

Speer CP.

Atemnotsyndrom.

In: Martius G, Rath W (eds): Geburtshilfe und Perinatalogie. Georg Thieme-Verlag, Stuttgart, 1998; 548-549.

Speer CP.

Das Frühgeborene; das Atemnotsyndrom Frühgeborener.

In: von Harnack GA, Koletzko B (eds): Kinderheilkunde. Springer-Verlag, Berlin/Heidelberg/New York 2000; 69-78

Speer CP.

Das Atemnotsyndrom Frühgeborener.

In: Speer CP, Gahr M (eds): Pädiatrie. Springer-Verlag, Berlin/Heidelberg/New York 2001; 179-183

Speer CP.

Lungenerkrankungen Früh- und Neugeborener; das Atemnotsyndrom Frühgeborener.

In: Lentze MJ, Schaub J, Schulte FJ, Spranger J (eds): Pädiatrie. Springer-Verlag, Berlin/Heidelberg/New York 2001; 409-423

Speer CP.

Das Atemnotsyndrom Frühgeborener.

In: Buchardi H, Larsen R, Schuster HP, Suter PM (eds): Intensivmedizin. Springer-Verlag, Berlin/Heidelberg/New York 2001; 1309-1312

Spragg RG, Richman P, Gilliard N, Merritt TA, Robertson B, Curstedt T.

The use of exogenous surfactant to treat patients with acute high-permeability lung edema.

In: Schlag G, Redl H (eds): Proceedings of Second Vienna Shock Forum. Alan R. Liss, New York, 1989; 791-796

Stamacosta E, Papagaroufalis C, Polalis G, Xanthou M.

Retinopathy of prematurity in very low birth weight infants treated with surfactant.

In: Cosmi EV, di Renzo GC (eds): Proceedings of the 2<sup>nd</sup> World Congress of Perinatal Medicine, Monduzzi Editore, Bologna, 1993; 977-980

Strayer DS.

Surfactant proteins and their immunogenicity: implications for the pathogenesis and treatment of respiratory distress syndrome.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1992; 61-72

Svenningsen NW, Hellström-Westas L, Rosén I.

Cerebral function and oxygenation in babies receiving surfactant.

In: Bevilacqua G, Parmigiani S, Robertson B (eds): Surfactant in clinical practice. Harwood Academic Publishers, Chur, 1993; 137-140

Szymankiewicz M.

Rola białek surfaktantu w patogenezie zespołu zaburzeń oddychania noworodków. (The role of proteins in pathogenesis of neonatal respiratory distress syndrome.)

In: Szymankiewicz M (ed): Seminaria z medycyny perinatalnej – Surfaktant. OWN, Poznań, 1998, I, 23-40

Szymankiewicz M, Gadzinowski J.

Stosowanie surfaktantu w zapobieganiu i leczeniu niewydolności oddechowej u noworodków. (Surfactant usage in respiratory insufficiency of the newborns.)

In: Słomko Z, Bręborowicz GH, Gadzinowski J (eds): Leki w medycynie perinatalnej. OWN, Poznań, 1999, 245-256

Troester T, Roll C, Neudorf U, Hentrich F, Hanssler L.

Incidence and outcome of persistent ductus arteriosus in premature babies treated with surfactant for severe RDS.

In: Cosmi EV, di Renzo GC, Anceschi MM (eds): The surfactant system of the lung. Macmillan Press, London, 1991; 139-141

Valls i Soler A, Alvarez FJ, Alfonso LF, Gastiasoro E, López Heredia J.

Multiple small doses of exogenous surfactant in experimental failure induced by lung lavage in rats.

In: Lucey JF (ed): Hot Topics '92 in Neonatology, Ross Laboratories, Columbus, 1992; 62-67

Valls i Soler A.

Displasia broncopulmonar. Estrategias de prevención.

In: de Miguel JR, Gómez-Ullate J (eds): Proceedings XIV Spanish Congress of Perinatal Medicine, Santander, 1993; 123-139

Vandenbussche G, Johansson J, Clercx A, Curstedt T, Ruyschaert JM.

Structure and orientation of hydrophobic surfactant-associated proteins in a lipid environment.

In: Jollès P, Jörnvall H (eds): Interface between chemistry and biochemistry. Birkhäuser, Basel, 1995; 27-47

Volante E, Parmigiani S, Bevilacqua G, Cosmi EV.

Affidabilità del monitoraggio transcutaneo dei neonati trattati con surfattante suppletivo.

In: Giron GP, Vincenti E, Chiaranda M (eds): Monitoraggio neurologico e cardio-respiratorio del paziente critico. Editrice La Garangola, Padova, 1988; 219-223

Walti H, Couchard M, Relier JP.

Exogenous surfactant in the management of hyaline membrane disease.

In: Bourbon JR (ed): Pulmonary surfactants: Biochemical, functional, regulatory and clinical concepts. CRC Press, Boston, 1991; 385-429

Walti H .

Comparaison des modes d'administration préventifs et curatifs d'un surfactant naturel modifié d'origine porcine (Curosurf®) dans une population de nouveau nés de moins de 31 semaines d'âge gestationnel.

In: Relier, JP (ed) : Progrès en néonatalogie. Karger, Paris, 1991; 12: 359-369

Walti H, Paris-Llado J, Bréart G.

Prévention de la maladie des membranes hyalines par les surfactants exogènes.

In: Relier JP (ed) : Progrès en neonatologie. Karger, Paris, 1994; 14:117-127

Walti H.

Le Curosurf®: Un surfactant naturel d'origine porcine.

In: Treisser A, Puech F (eds): Rapport 24es journées nationales de la Société Française de Médecine Périnatale (Vittel), Arnette-Blackwell, Paris, 1994; 129-137

Walti H.

Prévention des complications de la prématurité par les surfactants exogènes.

In: Treisser A, Blanc B (eds): Rapport des 26es journées nationales de la Société Française de Médecine Périnatale (Brest), Arnette-Blackwell, Paris, 1996; 47-56

Walti H.

Surfactants exogènes et détresses respiratoires du nouveau-né.

In: Devictor D, Hubert P, Moriette G (eds): Ventilation artificielle chez le nouveau né et l'enfant. Arnette Blackwell, Paris, 1997; 175-196

Walti H.

Indications des surfactants exogènes en dehors de la maladie des membranes hyalines.

In: Dehan M, Micheli J (eds): Le poumon du nouveau-né. Doin Editeurs, Paris 2000; 325-327

Walti H

Le poumon du prématuré.

In: Dehan M, Micheli J (eds): Le poumon du nouveau-né. Doin Editeurs, Paris 2000;134-151

Weintraub Z, Iancu TC, Eytan GD.

Artificial surfactant replacement therapy in the neonatal respiratory distress syndrome.

In: Stern L, Xanthou M, Friis-Hansen B (eds): Physiologic foundations of perinatal care. Praeger Publishers, New York, 1985; 254-261

Wilson DC, Scrimgeour CM, Halliday HL, Reid M, McClure G, Rennie MJ.

Inadequate nutrition in tiny babies at risk of bronchopulmonary dysplasia: Studies using doubly labelled water.

In: Koppe JG, Eskes TKAB, van Geijn HP, Wiesenkoan PF, Rujs JH (eds): Care, concern and care in perinatal medicine. Parthenon Publishing, Camforth, UK, 1993; 399-403

**ABSTRACTS**

Ahuja A, Spragg RG, Smith RM.

Modulation of respiratory burst oxidase activity in human neutrophils by surfactant.

Am J Resp Crit Care Med 1995; 151 (suppl 4): 310

Ainsworth SB, Atkinson E, Cooke RJ, Fenton AC, Milligan DWA.

Has switching from ALEC to Curosurf<sup>®</sup> in a level III neonatal unit increased the incidence of chronic lung disease?

Biol Neonate 2001; 80 (suppl 1): 34-35

Aiton NR, Alexander J, Fox GR, Milner AD.

Early physiological changes following administration of natural surfactant.

Biol Neonate 1997; 71 (suppl 1): 57-58

Almaas R, Moen A, Gortner L, Saugstad OD.

Effect of meconium and antioxidants on lipid peroxidation in three different commercial surfactant preparations.

Biol Neonate 1998; 74 (suppl 1): 47-48

Almaas R, Robertson B, Saugstad O D, Moen A.

Iron abolishes inhibitory effects of meconium on surfactant.

Pediatr Res 1999; 45: 41A, 1999

Almaas R, Robertson B, Saugstad OD, Moen A.

Inhibitory effect of meconium on surfactant is prevented by iron.

Biol Neonate 1999; 76 (suppl 1): 42

Almlén A, Curstedt T, Robertson B, Johansson J.

Resistance to inhibition of a synthetic pulmonary surfactant.

Biol Neonate 2002; 81 (suppl 1): 29

Alvarez FJ, Gómez MA, López de Heredia J, Gastiasoro E, Arnaiz A, Alfonso L, Valls i Soler A.

Effect of pulmonary surfactant on total liquid ventilation in lavaged rats.

Eur J Med Res 2000; 5: 22

Alvarez FJ, Valls i Soler A, Rey-Santano MC, Gastiasoro E, Arnaiz A, Gómez MA, Larrabe JL, Loureiro B, Casla JA.

Natural surfactant decreases in vitro evaporation of PFC-SF mixtures.

Pediatr Res 2001; 50: 278

Amato M, Hüppi P, Markus D.

Die Hoch-Risiko-Schwangerschaft und die Möglichkeit der neonatalen exogenen Surfactant-

therapie.

Arch Gynecol Obstet 1991; 249: 111

- Amato M, Doyle C, Burri P, Frantz I, Nielsen H.  
Exogenous surfactant doesn't alter endogenous surfactant protein mRNA expression in developing lung.  
*Pediatr Res* 1995; 37: 32
- Amato M, Schürch S, Grunder R, Bachofen H, Burri P.  
Effect of bilirubin on surface tension properties of natural and artificial surfactant.  
*Pediatr Res* 1995; 37:193
- Amato M, Schürch S, Grunder R, Bachofen H, Burri PH.  
Bilirubin interference with surface tension properties of natural and artificial surfactant.  
*Biol Neonate* 1995; 67 (suppl 1): 86-87
- Amato M, Doyle C, Burri PH, Frantz I, Nielsen H.  
Endogenous protein mRNA expression after exogenous surfactant exposition.  
*Biol Neonate* 1996; 69: 216
- Amato M, Scherrer R, Schürch S, Bachofen H, Burri PH.  
Effect of immunoglobulin G on surface tension properties of lipid extract surfactant.  
*Biol Neonate* 1997; 71 (suppl 1): 62-63
- Amato M, Schürch S, Sherrer R, Burri PH, Bachofen H.  
Influence of immunoglobulin G and calcium on surface tension properties of natural and artificial surfactant.  
*Biol Neonate* 1998; 74: 44
- Amato M, Scherrer R, Schürch S, Bachofen H, Burri PH.  
The role of calcium on surfactant activity.  
*Pediatr Res* 1999; 45: 294
- Amato M, Palmblad M, Linderholm B, Lundberg E, Tashiro K, Schürch S, Valls i Soler A, Robertson B.  
Partial liquid ventilation and surfactant-perfluorocarbon interaction.  
*Biol Neonate* 2000; 77 (suppl 1): 24-25
- Andréasson B, Juvonen P, Rudnicki J, Arborelius M, Wiklund K-E, Robertson B, Curstedt T.  
A device for nebulizing surfactant during CPAP treatment in neonates.  
*Pediatr Res* 1995; 37: 325A
- Apostolidou I, Papagaroufalis C, Xanthou M, Kalpoyiannis N.  
Impact of natural surfactants on intraventricular hemorrhage-associated factors.  
4<sup>th</sup> European Workshop on Neonatology, Corfu, 1993  
*Biol Neonate* 1993; 64: 175

- Babnik J, Bregant L, Kornhauser-Cerar L.  
Decreased mortality in infants after introduction of surfactant replacement therapy: 8-year  
observative study.  
Biol Neonate 1996; 69: 223
- Bahlmann H, Sun B, Curstedt T, Robertson B.  
Lung compliance and gas exchange in lung-lavaged rats treated with aerosolized  
surfactant.  
Biol Neonate 1996; 69: 216
- Bahlmann H, Sun B, Curstedt T, Robertson B.  
Surfactant recovery and vascular-to-alveolar leakage of albumin in lung-lavaged rats  
treated with aerosolized surfactant: Correlations with physiological parameters.  
Biol Neonate 1997; 71 (suppl 1): 62
- Ball RJ, Primhak R, Chetcuti PAJ.  
Clinical aspects of familial surfactant protein B deficiency.  
Biol Neonate 1995; 67 (suppl 1): 81
- Bambang Oetomo S, deLey L, Schoots C, Robertson B, Okken A.  
Immunohistochemical study of the distribution of exogenous surfactant in the lungs of  
surfactant deficient rabbits using a monoclonal antibody.  
Pediatr Res 1987; 22: 230
- Baur F, Goetze-Speer B, Neu S, Speer CP.  
Curosurf<sup>®</sup> down-regulates TNF- $\alpha$ -mRNA in monocytes.  
Pediatr Res 1996; 40: 518
- Beeretz I, BambangOetomo S, Herting E.  
Dynamische Compliance und Oxygenierungsindex als Verlaufsparameter beim  
Atemnotsyndrom Frühgeborener.  
Kinderärztl Prax 2002; 73: 32-33
- Berggren P, Eklind J, Linderholm B, Robertson B.  
Bildanalys av bubblor för mätning av surfaktantaktivitet.  
Svenska Läkaresällskapets Riksstämman, Hygiea 1991; 100: 286
- Berggren P, Corcoran D, Curstedt T, Robertson B.  
Exosurf versus Curosurf<sup>®</sup>: comparison of surface properties, resistance to inhibition, and  
physiological effects in preterm rabbits.  
European Society for Pediatric Research Annual Meeting, Uppsala, 1992; 105
- Berggren P, Linderholm B.  
Evaluation of surfactant function by assessment of microbubble stability.  
Biol Neonate 1996; 69: 214

- Berggren P, Linderholm B, Lundberg E.  
Assessment of surfactant activity and lung maturity by microbubble measurements.  
*Biol Neonate* 1997; 71 (suppl 1): 64
- Berggren P, Linderholm B, Ebbesen F, Verder H, Eschen C, Robertson B.  
Evaluation of lung maturity in newborn babies by microbubble stability test.  
*Biol Neonate* 1999; 73 (suppl 1): 44
- Bernhard W, Clark G, Rau GA, Poets CF, Postle AD, Hohlfeld J, Freihorst J.  
Investigation of the molecular design of human surfactant composition using deuterated choline in vivo.  
*Biol Neonate* 2002; 81 (suppl 1): 29
- Bevilacqua G, Cosmi EV, Robertson B, Volante E.  
Natural surfactant therapy in newborns with severe respiratory distress syndrome.  
*Biol Neonate* 1985; 48: 366
- Bevilacqua G, Cosmi EV, Volante E, Parmigiani S, Gaioni L, Guerrini P, Chirico G, Robertson B.  
Studio clinico controllato sul trattamento della sindrome respiratoria del neonato (R.D.S.) con surfattante suppletivo.  
*Nova Acta Med Virgil* 1987; 2: 8-9
- Bevilacqua G, Bini F, Parmigiani S, Soliani U, Gavazzoli L, Cosmi EV.  
Rilievi radiologici in neonati pre-termine con grave RDS. trattati con surfattante suppletivo.  
*Nova Acta Med Virgil* 1987; 2: 7
- Bevilacqua G, Parmigiani S, Volante E in the ambit of Collaborative European Multicenter Study Group.  
Factors influencing the clinical response to surfactant replacement therapy.  
Floating Congress on the River Rhine "60 Years of Surfactant Research", 1989
- Bevilacqua G.  
Exogenous surfactant in the neonate: suggestions for the use in the developing countries.  
*J Perinat* 2002; 10: 158
- Björklund LJ, Vilstrup CT, Larsson A, Werner O.  
Pressure-volume relations and surfactant.  
*Pediatr Res* 1992; 31: 301
- Björklund LJ, Vilstrup CT, Larsson A, Werner O.  
Pressure-volume relations and surfactant.  
*J Perinat Med* 1992; 20: 239
- Björklund LJ, Lindroth M, Svenningsen NW.  
Changing trend in respiratory support of ELBW infants in a level III NICU.  
*Pediatr Res* 1994; 34: 265

Björklund LJ, Curstedt T, Ingimarsson J, John J, Robertson B, Werner O, Vilstrup CT.  
Manual ventilation with a few large breaths at birth may compromise the effect of  
surfactant rescue treatment on lung mechanics in immature lambs.  
Appl Cardiopulm Physiol 1995; 5 (suppl 3): 9

Björklund LJ, Curstedt T, Ingimarsson J, Larsson A, Robertson B, Svenningsen NW,  
Werner O.  
Lung injury caused by neonatal resuscitation of immature lambs – relation to volume of  
lung inflations.  
Pediatr Res 1996; 39: 326

Björklund LJ, Werner O.  
Should we do lung recruitment maneuvers when giving surfactant?  
Pediatr Res 2001; 50: 6-7

Bohlin K, Blennow M, Jonsson B, Sarman I, Dahlström A, Robertson B.  
Surfaktant behandling i kombination med CPAP minskar behovet av respiratorvård hos  
barn med RDS.  
Svenska Läkaresällskapets Riksstämman, Hygiea 1998; 107: 316

Bos AF, Bambang Oetomo S, de Ley L, Robertson B, Okken A.  
Immune response after heterologous surfactant treatment of newborns with respiratory  
distress syndrome (RDS).  
Pediatr Res 1990; 28: 293

Bourbon JR, Chailley-Heu B, Gautier B.  
Curosurf<sup>®</sup> stimulates phosphatidylcholine reuptake and biosynthesis by isolated fetal lung  
type II cells.  
Biol Neonate 1995; 67 (suppl 1): 88

Büky B, András K, Nobilis A, Jancsó G.  
Preliminary results with surfactant in bronchopulmonary dysplasia.  
Gyermekgyógy 1999; 1: 15-17

Calkovská A, Sun B, Curstedt T, Robertson B  
Combined effects of high-frequency oscillatory ventilation and surfactant therapy in  
experimental meconium aspiration syndrome.  
Biol Neonate 1995; 67 (suppl 1): 78

Calkovská A, Sun B, Curstedt T, Robertson B  
Meconium aspiration syndrome treated with high-frequency oscillatory ventilation and  
exogenous surfactant.  
Eur Respir J 1995; 8 (suppl 19): 360

Calkovská A, Some M, Linderholm B, Curstedt T, Robertson B  
Effect of surfactant therapy in near-term newborn rabbits after airway instillation of  
albumin.  
Biol Neonate 2001; 80 (suppl 1): 39

Calkovská A, Some M, Linderholm B, Johansson J, Curstedt T, Robertson B  
Biophysical and physiological properties of Curosurf<sup>®</sup> enriched with polymyxin B.  
Biol Neonate 2002; 81 (suppl 1): 30

Casiraghi G, Rataggi M, Marraro G  
Surfactant supplementary treatment in children ARDS.  
J Perinat Med 1992; 20: 313

Chao W, Spragg RG, Smith RM.  
Alteration of human neutrophil respiratory burst oxidase assembly by porcine surfactant.  
Am J Resp Crit Care Med 1995; 151 (suppl 4): 602

Choukroun ML, Llanas B, Cavert MH, Galperine RI, Guenard H, Demarquez JL.  
Transient pulmonary function changes in ventilated preterm neonates with respiratory  
distress syndrome (RDS) treated with natural porcine surfactant: predictive factors.  
Biol Neonate 1995; 67 (suppl 1): 89

Collaborative European Multicenter Study Group.  
Short-term clinical response and follow-up in 164 babies treated with porcine surfactant  
(Curosurf<sup>®</sup>) for severe neonatal respiratory distress syndrome.  
Pediatr Res 1989; 26: 512

Collaborative European Multicenter Study Group.  
Surfactant-Substitutionsbehandlung bei 164 Frühgeborenen mit schwerem  
Atemnotsyndrom (RDS).  
Monatsschr Kinderheilkd 1989; 137: 484

Collaborative European Multicenter Study Group.  
Factors influencing the clinical response to surfactant replacement therapy.  
Floating Congress on the River Rhine "60 Years of Surfactant Research" 1989

Collaborative European Multicenter Study Group.  
Factors influencing the clinical response to surfactant replacement therapy.  
Pulmoselectief 1990; 1: 13-14

Corcoran D, Halliday HL.  
Respiratory distress syndrome.  
J Ir Coll Phys Surg 1991; 20: 261

Corcoran JD, Berggren P, Halliday HL, Robertson B.  
Curosurf<sup>®</sup> versus Exosurf: comparison of surface properties, resistance to inhibition and  
physiological effects in preterm rabbits.  
Ir J Med Sci 1993; 162: 423-424

Corcoran JD, Halliday HL.  
Prediction of chronic lung disease (CLD).  
Arch Dis Child 1995; 72: F80

Corcoran JD, Halliday HL on behalf of the European Collaborative Multicentre Study Group.

Prediction of mortality and chronic lung disease from variables recorded after surfactant replacement therapy.

Pediatr Res 1997; 41; 294

Corvol H, Lanotte P, Quentin R, Cantagrel S, Laugier J.

Effects of two different surfactant preparations on bacterial growth in vitro.

Biol Neonate 1998; 74 (suppl 1): 49

Cosmi EV, Szabo I.

In utero treatment of fetal lung immaturity: surfactant and corticosteroids

J Perinat Med 2001; 29 (suppl 1): 174

Cosmi EV.

In utero treatment of fetal lung immaturity.

J Perinat Med 2001; 29 (suppl 1): 175

Costeloe KL and the EPICure Study Steering Group.

The use of surfactant replacement in babies born at the limit of viability.

Biol Neonate 1997; 71 (suppl 1): 54

Curstedt T, Nilsson G, Robertson B, Johansson J.

Hydrophobic proteins and their analogues in pulmonary surfactant.

Biol Neonate 1996; 69: 184-185

De Jongh FHC, Schipper JA, Bos H, Prins A, van Sonderen L.

Frequency dependency of surfactant and its implication on alveolar stability.

Biol Neonate 1995, 67 (suppl 1): 87

De Jongh FHC, Schipper JA, van Sonderen L, Koppe JG.

Effect of surfactant therapy on lung function of preterm neonates.

Prenat Neonat Med 1996; 1 (suppl 1): 232

De Winter JP, van Bel F, Wijnands H, van de Bor M, Robertson B, Egberts J.

Veranderingen in hersen- en aortadoorbloeding tijdens en na profylactische surfactant-behandeling in preterme pasgeborenen.

In: Vreede WB, Hess J (eds): XII Congres Ned Ver v Kindergeneeskunde, Veldhoven, 1990; 55-56

De Winter JP, Egberts J, van Bel F, Bakker GCH.  
Prophylactic versus rescue treatment: duration of assisted ventilation (IPPV) and extra oxygen after surfactant.  
Pediatr Res 1991; 29 (suppl): 314

De Winter JP, van Bel F, Egberts J.  
Profylaxe van hyaline membranenziekte met surfactant.  
In: Vroeggeboorte, obstetrische en neonatologische aspecten, Postacademisch Onderwijs Geneeskunde, Amsterdam, 1991; 84

Dellagrammaticas HD, Christodoulou C, Iacovidou N, Kapetanakis J, Kourakis G.  
Comparison of patient-triggered ventilation versus conventional ventilation in outborn neonates with respiratory distress syndrome: A randomized controlled study.  
Biol Neonate 2000; 77 (suppl 1): 23

Dessens AB, Smolders-de Haas H, Koppe JG.  
Twenty-year follow-up of subjects treated antenatally with corticosteroids.  
Biol Neonate 1999; 76 (suppl 1): 47

Dinger J, Töpfer A, Schaller P, Schwarze R, Gmyrek D.  
Effect of surfactant on functional residual capacity and lung compliance in infants with respiratory distress syndrome.  
Biol Neonate 1997; 71 (suppl 1): 57

Diniz EMA, Fiori RM.  
Curosurf<sup>®</sup> therapy in severe meconium aspiration.  
Biol Neonate 1995; 67 (suppl): 86

Diniz EMA, Vieira RA, Ceccon MEJ, Krebs VLJ, Grassi MS, Feferbaum R, Vaz FAC.  
Exogenous porcine surfactant therapy for the high-risk neonate with severe pneumonia.  
Prenat Neonat Med 2001; 6: 42.

Diniz EMA.  
Other indications of exogenous surfactant.  
In: Marcondes E (ed): Pediatria Básica. São Paulo: Sarvier, 2002; 421-422

Dushe T, Hammer H, Rüdiger M, Schmalisch G, Wauer RR:  
Einfluss zweier natürlicher Surfactantpräparationen auf Gasaustausch und Outcome von Frühgeborenen.  
Kinderärztl Prax 2002; 73: 19

Egberts J, de Winter JP, Sedin G, Broberger U, de Kleine MJK, van Bel F, Robertson B, Curstedt T.  
Comparison of prophylaxis and rescue treatment with Curosurf<sup>®</sup> of babies less than 30 weeks gestation.  
In: Lucey JF (ed): Hot Topics '92 in Neonatology, Ross Laboratories, Columbus, 1992; 112

Egberts J, Walti H, Bevilacqua G.

A difference in effect between surfactant prophylaxis and rescue therapy on the rate of bronchopulmonary dysplasia.

Biol Neonate 1995; 67 (suppl 1): 85

Eschen C, Verder H, Albertsen P.

Laryngeal mask used as a guideway for brief access to the intra-tracheal space in premature infants.

Acta Paediatr 1992; 384

Fellman V, Kukkonen K, Virtanen M, Järvenpää AL, Pokela ML, Raivio KO.

Increased risk of infection after treatment with Curosurf®?

Biol Neonate 1997; 71 (suppl 1): 56

Fiori HH, Henn R, Baldisserotto M, Bicca IGO, Fiori RM.

Evaluation of surfactant function at birth determined by the stable microbubble test in term and near term infants with respiratory distress.

Biol Neonate 2002; 81 (suppl 1): 30-31

Fiori HH; Varela I, Fiori RM.

Stable microbubble test and click test on gastric aspirates of preterm infants not ventilated at birth to predict respiratory distress syndrome.

Biol Neonate 2000; 77 (suppl 1): 26

Fiori RM, Diniz EMA.

Curosurf® therapy in severe meconium aspiration syndrome.

Biol Neonate 1995; 67: 86.

Fiori RM, Fiori HH, Varella I.

Teste das microbolhas estáveis (TME) e teste do clique (TC) para o diagnóstico precoce da síndrome de desconforto respiratório do recém-nascido.

J Pediatr, 2000; 76: 40

Floros J, Fan R, Matthews A, Koppe J, van Sonderen L, Gewolb I, Nilesen H.

The transmission disequilibrium test reveals linkage between the SP-A locus and respiratory distress syndrome; SP-A alleles are susceptibility or protective factors for respiratory distress syndrome.

Biol Neonate 2000; 77 (suppl 1): 21

Gadzinowski J, Szymankiewicz M, Twarowska I, Halliday HL.

Importance of gas exchange after surfactant administration in neonates with respiratory distress syndrome.

J Perinat Med 1992; 20 (suppl 1): 311

Galassini EM, Padovani EM, Rataggi M, Luchetti M, Marraro G.  
Independent lung ventilation and exogenous surfactant in congenital diaphragmatic hernia.  
Intensive Care Med 1998; 24: E14.

Galperine RI, Pedespan L, Cavert MH, Sarlangue J, Choukroun ML, Demarquez JL.  
Adult respiratory distress syndrome in a child : combined treatment with high-frequency oscillation, porcine surfactant, and inhaled nitric oxide.  
Biol Neonate 1995; 67 (suppl 1): 85-86

Gan XZ, Jarstrand C, Herting E, Robertson B.  
Surfactant-borne antibody against encapsulated bacteria causing pneumonia in neonates and older children.  
Biol Neonate 1997; 71 (suppl 1): 67

Gan XZ, Song GW, Wang F, Ma GS, Sun LP, Li H.  
Polymer-surfactant treatment for acute lung injury induced by lung-lavage in ventilated adult rats.  
Acta Pharmacol Sin 2002; 23 (suppl): 167

Gavino R, Brodsky N, Bhandari V.  
SURF-N-SAVE: Surfactant instillation and nasal ventilation: A randomized, controlled trial of synchronized nasal ventilation versus conventional ventilation in neonates with respiratory distress syndrome.  
Biol Neonate 2002; 81 (suppl 1): 31

Glover R, Stenson B, Wilkie R, Laing I, Parry G, Tarnow-Mordi WO.  
Rapid improvement in respiratory compliance after porcine surfactant.  
Pediatr Res 1992; 32: 635

Greisen G.  
Surfactant and brain damage: which and how?  
Biol Neonate 1996; 69: 221-222

Groneck P, Goetze-Speer B, Speer CP.  
Mikrovasculäre permeability of the lung following surfactant treatment in preterm infants with respiratory distress syndrome.  
Biol Neonate 1996; 69:221

Groneck P, Goetze-Speer B, Speer CP.  
Mikrovaskuläre Permeabilität der Lunge nach Surfactantsubstitution bei Frühgeborenen mit Atemnotsyndrom.  
Z Geburtsh Neonatol 1997; 201: 200

Groneck P, Goetze-Speer, Speer CP.  
Pulmonary inflammation in newborn infants with severe meconium aspiration syndrome.  
Biol Neonate 1997; 71(suppl 1): 59

Groneck P, Temur A, Goetze-Speer B, Speer CP.

Systemic and pulmonary inflammation related to severity of respiratory distress syndrome.  
Biol Neonate 1998; 74 (suppl 1): 48

Gross T, Berman A, Regev O, Zmora E.  
Supramolecular structural changes in lung surfactant after exposure to meconium.  
Biol Neonate 2002; 81 (suppl 1): 32

Gustafsson L, Curstedt T, Johansson J, Robertson B.  
Factors influencing spreading of Curosurf<sup>®</sup> at an air-liquid interface.  
Biol Neonate 2002; 81 (suppl 1): 32-33

Halahakoon C, Bell AH, Young I, Halliday HL, McClure BG.  
Antioxidant status and EEG activity after Exosurf administration.  
Biol Neonate 1995; 67 (suppl 1): 91

Halahakoon C, Bell AH, Young I, Halliday HL.  
Is hyperoxia after surfactant treatment associated with utilisation of antioxidants? Results  
of a randomised comparative trial.  
Biol Neonate 1997; 71 (suppl 1): 58

Halley GC, Stenson BJ, Laing IA, McIntosh N.  
Acute blood pressure response to surfactant administration.  
Arch Dis Child 1995; 73: F197.

Halley GC, Stenson BJ, Laing IA, McIntosh N.  
Physiological changes around surfactant administration: a randomised comparison of  
Exosurf and Curosurf<sup>®</sup>.  
Biol Neonate 1995; 67 (suppl 1): 90

Halley GC, Stenson BJ, Laing IA, McIntosh N.  
Physiological changes around surfactant administration.  
Pediatr Res 1996; 39: 213

Halliday HL, McCord B, McClure BG, Reid M.  
Natural surfactant therapy for severe respiratory distress syndrome reduces the incidence  
of intraventricular haemorrhage.  
Ir J Med Sci 1988; 157: 56

Halliday HL, McClure BG, Reid MMcC, Robertson B and Collaborative European Study  
Group.  
Improved outcome following natural surfactant treatment in severe respiratory distress  
syndrome.  
Abstracts of British Paediatric Association Annual Scientific Meeting, York, 1988; 51

Halliday HL, McClure BG, Reid MMcC, Robertson B (on behalf of the Collaborative European Multicentre Study Group).

Improved outcome following natural surfactant treatment in severe respiratory distress syndrome.

Arch Dis Child 1988; 63: 691

Halliday HL, Tubman TRJ.

Cost of surfactant replacement therapy for severe respiratory distress syndrome.

Scientific abstracts of the Irish American Paediatric Society, Atlanta, 1989; 9: 7

Halliday HL.

Akutwirkungen der Surfactantinstillation bei Frühgeborenen mit schwerem Atemnotsyndrom.

Päd Referate 1989; 6: 17

Halliday HL.

Vyznam surfaktantu pro dychani novorozencu po porodu.

X. Neonatologicke Dny Ceske Budejovice 1989; 4: 7

Halliday HL.

Economic evaluation of surfactant therapy.

Published abstracts of a Satellite Symposium on the value of surfactant therapy, Eur Soc Pediatr Res, Zürich, 1991; 22-23

Halliday HL, Tubman TRJ, Rankin SJA, Johnston SS.

Surfactant therapy with Curosurf<sup>®</sup> lowers the incidence of retinopathy of prematurity.

Scientific abstracts of the Irish American Paediatric Society, Pittsburgh, 1991; 38

Halliday HL, Tarnow-Mordi WO.

Surfactant replacement therapy - time for thought.

Arch Dis Child 1993; 68: 619

Halliday HL.

The European OSECT study.

Biol Neonate 1994; 66: 164-165

Halliday HL, Patterson CC.

Randomised trial of methods of extubation in acute and chronic respiratory distress.

Arch Dis Child 1994; 70: F157

Halliday HL.

Clinical comparisons of natural and synthetic surfactant.

Intensive Care Med 1996; 22 (suppl 2): 183

Halliday HL.

Prophylactic surfactant for preterm infants: the case against.

Prenat Neonat Med 1996; 1 (suppl 1): 18

Halliday HL.

Commentary on: High frequency oscillatory ventilation improved pulmonary and clinical outcomes in neonates with respiratory distress syndrome.

Evidence-Based Med 1997; 3: 83

Halliday HL.

Surfactant therapy.

Promoting Health 1998; 2: 33

Halliday HL, Soll R F.

Timing of surfactant treatment.

Arch Dis Child 1998; 78: F157

Halliday HL.

New applications of exogenous surfactant.

Neonatal Rassegna Fisiopatol Clin Terapia Pediatr Neonatol: 2001; 10-11

Halliday HL, Heckel ML.

Steroids for preterm infants? Jury is still out.

Pulm Rev 2001; 6: 34

Hallman M, Paananen R, Glumoff V, Lahti M, Löfgren J, Marttila R, Rämetsä M.

Surfactant proteins SP-A and SP-D are expressed in the upper airway and may protect against infections.

Biol Neonate 2001; 80 (suppl 1): 36-37

Hallman M, Löfgren J, Lahti M, Marttila R, Haataja R, Rämetsä M, Renko M.

Allelic association of surfactant proteins SP-A and SP-D with severe respiratory syncytial virus bronchiolitis.

Biol Neonate 2002; 81 (suppl 1): 33

Halsema EFW, Spiering EJJ, van Sonderen L, Bleker OP, Koppe JG.

IRDS en erfelijke factoren.

Tijdsch Kindergeneesk 1997; suppl 1: 30

Halsema EFW, Spiering EJJ, van Sonderen L, Bleker OP, Koppe JG.

Genetic influences in respiratory distress syndrome.

Biol Neonate 1998; 74 (suppl 1): 52

Hamilton P, Littleton P, Carter ND.

Correlation between brain natriuretic peptide and atrial natriuretic peptide levels in neonatal plasma.

Pediatr Res 1992; 32: 624

Harms K, Herting E, Speer CP.

Inzidenz von neonatalen Infektionen bei Frühgeborenen mit schwerem Atemnotsyndrom (RDS) nach Behandlung mit einem natürlichen Surfactant.

Monatschr Kinderheilkd 1991; 139: 514

Harms K, Speer CP, Gefeller O, Goeneck P, Soditt V, Hanssler L, Roll C, Herting E, Laufkötter E, Boenisch H, Robertson B.

Randomisierte Pilotstudie: Vergleich zweier Therapieregime mit natürlichen Surfactantpräparationen.

Monatsschr Kinderheilkd 1993; 141 (suppl 1):6

Hastings RH, Summers-Torres D, Ditmer LS, Burton DW, Cheung TC, Spragg RG, Brown EM, Deftos LJ.

Pulmonary alveolar epithelial cells express a functional PTHrP-calcium-surfactant regulatory loop.

J Bone Mineral Res 1995; 10: 382

Haumont D, Rössle C, Clercx A, Biver A, Richelle M, Carpentier YA.

Influence of LCT emulsions on surfactant (S) composition, ventilatory needs and plasma lipids in premature infants treated with porcine (Porc) S for respiratory distress syndrome.

Clin Nutr 1991; 10: 5

Haumont D, Rössle C, Biver A, Clercx A, Spehl M, Richelle M, Carpentier YA.

Modifications of surfactant phospholipid pattern (SPLP) in premature infants with respiratory distress syndrome (RDS) receiving porcine surfactant replacement therapy.

Pediatr Res 1991; 29 (suppl 4): 319

Haumont D, Waroquier L, Van Herreweghe I.

Outcome of very low birth weight infants treated with early surfactant and early dexamethasone.

Biol Neonate 1998; 74 (suppl 1): 53-54

Hermon M, Wassermann E, Pfeiler C, Redl H, Srohmaier W.

Therapeutic efficacy of bronchoalveolar lavage with diluted surfactant is reduced by preceding ventilation in a rabbit aspiration model.

Biol Neonate 2002; 81 (suppl 1): 33

Herting E, Harms K, Speer CP, Curstedt T, Robertson B.

Surfactant-Substitution beim schweren Atemnotsyndrom Frühgeborener <1000 g.

Monatsschr Kinderheilkd 1989; 137: 484

Herting E, Harms K, Mahn G, Speer CP.

Activity of elastase and alpha-1-proteinase inhibitor in bronchial secretions of premature infants suffering from severe respiratory distress syndrome (RDS) treated with a natural porcine surfactant (Curosurf®).

Pediatr Res 1990; 28: 281

Herting E, Mahn G, Speer CP.

Freie Elastase und (1-Proteinaseinhibitoraktivität im Bronchialsekret von Frühgeborenen mit schwerem Atmenotsyndrom (RDS) nach Substitutionstherapie mit natürlichem porcinen Surfactant (Curosurf®).

Monatschr Kinderheilkd 1990; 138: 523

Herting E, Harms K, Speer CP, Curstedt T, Robertson B, Kok J, Koppe J, Halliday HL, McClure G, Reid M, Tubman TRJ, Laufkoetter E, Hanssler L, Compagnone D, Groneck P, Relier JP, Walti H.

Incidence of neonatal infections in very low birthweight infants with severe RDS treated with a natural porcine surfactant.

Biol Neonate 1991; 59: 382-383

Herting E, Speer CP, Harms K, Compagnone D, Kok J, Koppe J, van Sonderen L, Halliday H, McClure G, Reid M, Tubman R, Laufkötter E, Köhler W, Boenisch H, Albrecht K, Hanssler L, Haim M, Oetomo SB, Okken A, Natzschka L, Groneck P, Kachel W, Relier JP, Walti H, Herin P, Noack G, Curstedt T, Robertson B.

Effects of acidosis on surfactant response and 28 day outcome in infants with severe respiratory distress syndrome (RDS) following surfactant replacement therapy.

Klin Pädiatrie 1991; 203: 57

Herting E, Harms K, Speer CP, Compagnone D, Curstedt T, Robertson B and members of the Collaborative European Multicenter Study Group.

Influence of clinical factors on mortality and morbidity in infants with severe respiratory distress syndrome following surfactant replacement therapy.

Pediatr Res 1991; 30: 656

Herting E, Weigel W, Compagnone D, Harms K, Speer CP.

Radiologischer Befund und Komplikationsrate bei Frühgeborenen mit schwerem Atemnotsyndrom (RDS) nach Einfach- bzw. Mehrfachbehandlung mit einem natürlichen Surfactant (Curosurf®).

Zentralbl Radiol 1991; 144: 636

Herting E, Gefeller O, Harms K, Speer CP.

Hirnblutungen bei Frühgeborenen mit schwerem Atemnotsyndrom (RDS) nach Surfactanttherapie: Verlauf und Risikofaktoren.

Monatschr Kinderheilkd 1992; 140: 505

Herting E, Speer CP, Harms K, Curstedt T, Robertson B, Halliday HL.

Treatment of severe neonatal respiratory distress syndrome with a single or multiple doses of a porcine natural surfactant. Logistic regression analysis of parameters influencing survival.

J Perinat Med 1992; 20 (suppl 1): 240

Herting E, Jarstrand C, Rasool O, Curstedt T, Sun B, Robertson B.

Experimentelle neonatale B-Streptokokkenpneumonie: Einfluss von Surfactant auf das Bakterienwachstum.

Perinat Med 1993; 5:90

Herting E, Jarstrand C, Håkansson S, Curstedt T, Robertson B.  
Einfluss einer Kombinationsbehandlung von Surfactant mit einem Streptokokken-Antiserum auf den oxidativen Metabolismus neutrophiler Granulozyten.  
Monatschr Kinderheilkd 1994; 142: 116

Herting E, Speer CP, Jarstrand C, Curstedt T, Sun B, Robertson B.  
Einfluss von Surfactant auf Entzündungsgeschehen und Elastasefreisetzung bei experimenteller neonataler B-Streptokokkenpneumonie.  
Monatschr Kinderheilkd 1994; 142: 41

Herting E, Jarstrand C, Curstedt T, Sun B, Calkovska A, Robertson B.  
Neonatal experimental group B streptococcal pneumonia : effects of gestational age, infectious dose and surfactant treatment on bacterial proliferation and inflammatory response.  
Appl Cardiopulm Pathophysiol 1995; 5 (suppl 3): 58-59

Herting E, Jarstrand C, Curstedt T, Sun B, Robertson B.  
Surfactant improves lung function and mitigates bacterial growth in immature rabbits with experimental neonatal group B streptococcal pneumonia.  
Biol Neonate 1995; 67 (suppl 1): 79

Herting E, Sun B, Harms K, Schiffmann H, Curstedt T, Robertson B.  
Surfactant-Behandlung bei Mekoniumaspiration: Widerspruch tierexperimenteller und klinischer Ergebnisse.  
Z Geburtsh Neonatol 1995; 199: 210

Herting E, Möller O, Rauprich P, Harms K, Robertson B.  
Einfluß von Surfactant auf das in vitro Wachstum von B-Streptokokken.  
Monatsschr Kinderheilkd 1996; 144 (suppl 1): 49

Herting E, Strayer D, Sun B, Robertson B.  
Influence of a monoclonal anti-SP-A antibody (R-5) on bacterial growth in term rabbits with experimental neonatal group B streptococcal (GBS) pneumonia.  
Biol Neonate 1996; 96: 217

Herting E, Gan XZ, Rauprich P, Jarstrand C, Robertson B.  
Surfactant as a "carrier" for immunoglobulin treatment in experimental neonatal pneumonia.  
Eur J Pediatr 1997; 156: 162

Herting E, Gan XZ, Rauprich P, Jarstrand C, Robertson B:  
Surfactant als Trägersubstanz für eine intratracheale Immunglobulinbehandlung bei experimenteller neonataler B-Streptokokkenpneumonie.  
Z Geburtsh Neonatol 1997; 201: 207

Herting E, Harms K, Gefeller O, Pralle L, Robertson B.  
Surfactant treatment of respiratory failure in neonatal group B streptococcal infections.  
First results of a European retrospective trial.  
Biol Neonate 1997; 71 (suppl 1): 67

Herting E, Harms K, Gefeller O, Pralle L, Robertson B.  
Surfactant-Behandlung neonataler B-Streptokokkeninfektionen mit respiratorischer  
Insuffizienz.  
Monatsschr Kinderheilkd 1997; 145 (suppl 1): 106

Herting E, Harms K, Gefeller O, van Sonderen L, Robertson B on behalf of the  
Collaborative European Multicenter Study Group.  
Surfactant improves oxygenation but allows only slow reduction in inspiratory pressure in  
neonates with ARDS-like disease due to group B-streptococcal infection.  
Biol Neonate 1998; 74 (suppl 1): 46-47

Herting E, Harms K, Gefeller O, van Sonderen L, Robertson B and members of the  
Collaborative European Multicentre Study Group:  
Surfactant treatment of neonates with respiratory failure due to group B-streptococcal  
infections: A European multicentre study.  
Intensive Care Med 1998; 24 (suppl 1): 167

Herting E, Rauprich P, Walter G, Robertson B.  
Influence of porcine modified surfactant on in vitro growth of bacteria causing pneumonia  
or sepsis in the neonatal period.  
Biol Neonate 1998; 74 (suppl 1): 49

Herting E, Gan XZ, Rauprich P, Jarstrand C, Robertson B.  
Combined treatment with surfactant and specific immunoglobulin in experimental neonatal  
group B streptococcal pneumonia.  
Biol Neonate 1999; 76 (suppl 1): 49-50

Herting E, Gefeller O, Land M, Harms K, van Sonderen L, Robertson B und Mitglieder der  
European Collaborative Multicentre Study Group.  
Vergleichende Untersuchung der Komplikationsrate von Früh- und Neugeborenen mit  
B-Streptokokkenpneumonie bzw. schwerem Atemnotsyndrom.  
Monatsschr Kinderheilkd 1999; 147 (suppl 2): 92

Herting E, Gefeller O, Land M, van Sonderen L, Harms K, Robertson B und Mitglieder der  
Collaborative European Multicenter Study Group.  
Surfactantbehandlung Neugeborener mit Atemnotsyndrom (RDS) und B-Streptokokken  
(GBS) Infektion.  
Z Geburtsh Neonatol 1999; 203 (suppl 1): 9

Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B.  
Resistenz neuer synthetischer Surfactant Präparate gegenüber einer Inhibition durch  
Mekonium.  
Z Geburtsh Neonatol 2000; 204 (suppl 1): 16

Herting E, Gefeller O, Harms K, Robertson B.

Mortalität bei beatmeten Früh- und Neugeborenen mit B-Streptokokkensepsis nach Surfactantbehandlung.

Z Geburtsh Neonatol 2001; 205 (suppl 1): 2

Herting E, Gefeller O, Land M, van Sonderen L, Harms K, Robertson B and members of the Collaborative European Multicenter Study Group.

Factors determining response to surfactant treatment in neonates with severe respiratory failure and group B streptococcal infection.

Biol Neonate 2001; 80 (suppl 1): 38

Herting E, Wang Y, Agerberth B, Johansson J.

Addition of the antimicrobial peptide prophenin (62-79) does not interfere with the biophysical activity of Curosurf®.

Biol Neonate 2002; 81 (suppl 1): 34

Herting E, Wang Y, Agerberth B, Johansson J.

Einfluss des antimikrobiellen Peptids Prophenin (62-79) auf die biophysikalische Aktivität von Surfactant.

Kinderärztl Prax 2002; 73: 19

Hohlfeld JM, Erpenbeck VJ, Braun A, Krug N.

Effect of porcine and bovine surfactant preparations on proliferation and LPS-induced TNF- $\alpha$  release of peripheral blood mononuclear cells.

Biol Neonate 2002; 81 (suppl 1): 34

Hornakova A, Curstedt T, Robertson B, Saugstad OD.

Variation in intratissue pO<sub>2</sub> in relation to surfactant replacement in surfactant depleted newborn pigs.

Pediatr Res 1994; 36: 19

Ingimarsson J, Björklund LJ, Curstedt T, John J, Robertson B, Werner O, Vilstrup CT. Neonatal resuscitation with a few large breaths compromises the effect of subsequent surfactant replacement in immature lambs.

Acta Anaesthesiol Scand 1995; 39 (suppl 105): 153

Ingimarsson J, Björklund LJ, Curstedt T, Larsson A, Robertson B, Svenningsen NW, Werner O.

Preceding surfactant treatment does not protect against lung volutrauma at birth.

Pediatr Res 1997; 41: 255

Ingimarsson J, Björklund LJ, Curstedt T, Gudmundsson S, Larsson A, Robertson B, Svenningsen NW, Werner O.

Lung trauma from five moderately large manual inflations immediately after surfactant instillation in newborn immature lambs.

Pediatr Res 1998; 43: 286

- Ingimarsson J, Björklund LJ, Larsson A, Svenningsen NW, Werner O.  
Static pressure-volume (P-V) loops of the respiratory system in surfactant-treated immature lambs in vivo - effect of positive end-expiratory pressure (PEEP).  
*Pediatr Res* 1998; 43: 286
- Ingimarsson J, Björklund LJ, Larsson A, Werner O.  
Static pressure-volume loops of the respiratory system in surfactant-treated immature lambs-effect of PEEP.  
*Intensive Care Med* 1998; 24 (suppl 1): 174
- Ingimarsson J, Björklund LJ, Curstedt T, Robertson B, Werner O.  
Large lung inflations immediately before rescue surfactant do not affect the lung mechanical response in immature lambs with established respiratory distress syndrome.  
*Biol Neonate* 1999; 76 (suppl 1): 45
- Ingimarsson J, Björklund LJ, Jonson B, Larsson A, Palmer J, Robertson B, Werner O.  
A radio-isotope technique for visualisation of exogenous surfactant spreading in immature lamb lungs at birth.  
*Biol Neonate* 2000; 77 (suppl 1): 24
- Ingimarsson J, Björklund LJ, Curstedt T, Jonson B, Larsson A, Robertson B, Werner O.  
Uneven distribution of exogenous surfactant after hyperinflation of the lungs at birth in immature lambs.  
*Pediatr Res* 2001; 49: 383
- Ingimarsson J, Björklund LJ, Hernandez Andrade E, Dyhr T, Jonson B, Larsson A, Werner O.  
Surfactant distribution and lung mechanics in immature lambs treated either immediately at birth or after ten minutes of mechanical ventilation.  
*Biol Neonate* 2002; 81(suppl 1): 35
- Iniguez JL, Tordet C, Walti H.  
Chemiluminescence (CL) and TNF secretion of alveolar macrophages (AM) in human premature infants: Influence of natural porcine surfactant (Curosurf®).  
*Pediatr Res* 1993; 33: 382
- Johansson J, Gustafsson M, Nilsson G, Curstedt T, Robertson B, Jörnvall H:.  
Structure and function of SP-B, SP-C and synthetic peptide analogs.  
*Appl Cardiopulm Pathophysiol* 1995; 5 (suppl 3): 67
- Johansson J, Nilsson G, Strömberg R, Robertson B, Jörnvall H, Curstedt T.  
Secondary structure and biophysical activity of synthetic SP-C analogs.  
*Biol Neonate* 1995; 67 (suppl 1):87-88
- Johansson J.  
Transmembrane and amphipathic peptides in surfactant preparations.  
*Biol Neonate* 1996; 69: 214

- Johnsson H, Heldin P, Sedin G, Laurent TC.  
Hyaluronan Production in vitro by fetal lung fibroblasts and epithelial cells exposed to surfactants.  
Biol Neonate 1997; 71 (suppl 1): 65
- Klavdianou M, Papagaroufalis C, Charitou A, Stamocosta E, Stefanidis C, Alevizou B, Kitsou E, Xanthou M.  
Atrial natriuretic factor plasma levels in neonates treated with multiple doses of surfactant.  
Pediatr Res 1992; 32: 617
- Kobayashi T, Curstedt T, Grossmann G, Robertson B.  
Inhibition of replaced surfactant and aggravation of lung mechanics in ventilated premature rabbits.  
J Jpn Med Soc Biol Interface 1987; 19: 140-141
- Kobayashi T, Ganzuka M, Nitta K, Robertson B, Grossmann G, Suzuki Y.  
Selective blocking of surfactant-associated hydrophobic polypeptide SP-B in near-term newborn rabbits.  
Floating Congress on the River Rhine "60 Years of Surfactant Research", 1989
- Koehne P, Wagner M, Willam C, Sonntag J, Bühner C, Obladen M:  
Soluble ICAM-1 and L-selectin plasma levels and response to surfactant.  
Pediatr Res 2001; 49: 292
- Koolen A, de Winter JP, van Sonderen L, van de Bor M, de Kleine M.  
Ervaringen met Curosurf<sup>®</sup> ter behandeling van RDS.  
14e Congres Kindergeneeskunde 1992; 114
- Kramer BW, Willet K, Sly PD, Newnham J, Moss T, Ikegami M, Jobe AH.  
Intra-amniotic endotoxin rapidly induces proinflammatory response in fetal sheep lungs and induces lung maturation.  
Biol Neonate 2001; 80 (suppl 1): 37
- Kramer BW, Ikegami M, Speer CP, Jobe AH.  
Epithelial cells of large airways in fetal lungs are injured by chorioamnionitis.  
Biol Neonate 2002; 81 (suppl 1): 35
- Lacaze-Masmonteil T, Claris O, Walti H.  
Prospective longitudinal study of 1154 babies with RDS treated with natural porcine surfactant (NPS).  
Pediatr Res 1997; 41: 213
- Lefort S, Diniz EMA, Vaz FAC.  
Gasometrical evolution between two dosage regime involving preterm neonates with respiratory distress syndrome (RDS).  
Prenat Neonat Med 2000; 5 (suppl 2): 85

Lefort S, Diniz EMA, Vaz FAC.

Clinical evolution of two different dosage regime involving preterm neonates at risk for respiratory distress syndrome (RDS) during the first month of life.

Prenat Neonat Med 2000; 5 (suppl 2):85

Ley D, Björklund LJ, Hellström-Westas L, Lindroth M, Polberger S, Svenningsen NW.

Outcome of severe respiratory insufficiency in near term infants who failed on conventional treatment.

Pediatr Res 1999; 45: 310

Ley D, Björklund L, Hellström-Westas L, Lindroth M, Polberger S, Svenningsen NW.

Severe respiratory insufficiency in near term infants – what's the use of ECMO?

Pediatr Res 1999; 45: 889

Lista G, Castoldi F, Azzali A, Marangione P, Pogliani L, Compagnoni G.

Surfactant lavage for lung debris in newborns with respiratory distress syndrome.

Pediatr Res 2001; 49: 2192

Li C, Xiao J, Minoo P.

WNT5A controls proximo-distal lung morphogenesis.

Biol Neonate 2001; 80 (suppl 1): 37-38

Littleton P, Carter N, Hamilton PA.

Atrial natriuretic peptide and brain natriuretic peptide concentrations in surfactant treatment.

Early Hum Dev 1992; 31: 77

Lopes JMA, Carvalho M, Cacho AR, Moreira EL, Cabral JO, Figueiredo EAN.

Surfactant in very sick low birth weight infants.

Biol Neonate 1995; 67 (suppl 1): 81-82

Loredo JS, Spragg RG.

Effects of cigarette smoke and tar on porcine surfactant.

Am J Resp Crit Care Med 1998; 157: 445

Luc F, Aubas P, Cambonie G, Walti H.

Intérêt du FLM-Test dans l'évaluation de la maturation pulmonaire du nouveau-né .

Arch Pédiatr 1996; 3: 623

Luchetti M, Valsecchi R, Casiraghi G, Marraro G.

Porcine-derived surfactant supplementation in the treatment of severe bronchiolitis.

Minerva Anesthesiol 1997; 63: 50

Luchetti M, Casiraghi G, Marraro G.

100 vs 200 mg/kg of exogenous surfactant in the treatment of neonatal respiratory distress syndrome.

Intensive Care Med 1998; 24: E 24.

Luchetti M, Casiraghi G, Valsecchi R, Cereda G, Galassini EM, Marraro G.  
Porcine-derived surfactant treatment of severe bronchiolitis.  
*Intensive Care Med* 1998; 24: E06.

Lyra PR, Diniz EMA, Vaz FAC, Zheng C, Angelo SDI, Lin Z, Floros J, Hoffmann JW, de Mello DE.  
Analysis of SP-B and SP-C gene mutation/polymorphisms in paraffin embedded lung tissue and blood from infants with severe respiratory insufficiency.  
*Pediatr Res* 2002; 39 (suppl 4): 352

Lyra PR, Diniz EMA, Vaz FAC, Zheng C, Angelo SDI, Lin Z, Floros J, Hoffmann JW, de Mello DE.  
Analysis of SP-B and SP-C gene mutation/polymorphisms in paraffin embedded lung tissue and blood from infants with severe respiratory insufficiency.  
*Pediatr Res* 2002; 51 (suppl 4): 347

Malm U, Andersson A-C, Björklund LJ, Lindroth M.  
Outcome of surfactant-treated infants in a level III neonatal unit 1995 vs. 1998.  
*Biol Neonate* 2000; 77 (suppl 1): 23

Marraro G, Casiraghi G, Monici-Prete PP, Vignati D.  
Supplementary surfactant in ARDS infants.  
*Pediatr Res* 1993, 33: 37

Marraro G.  
Surfactant replacement in lung pathology of children and adults.  
*Hot Topics in Neonatology, Washington, USA, 1994*; 346

Marraro G, Diomede L, Casiraghi G, Salmona M.  
Human lung surfactant evaluation using bronchoalveolar lavage before and after natural surfactant supplementation.  
*Pediatr Res* 1994; 35: 343

Marraro G, Casiraghi G, Galbiati A.  
A study of pressure regulated volume control (PRVC) ventilation in natural surfactant treated infants with RDS.  
*Pediatr Res* 1995; 37: 223

Marraro G, Marinari M, Valsecchi R, Riva A, Casiraghi G, Soldi R.  
Somministrazione selettiva di surfactante nella patologia polmonare a prevalenza monolaterale in età pediatrica (Selective surfactant administration in monolateral lung pathology in pediatric age).  
*Minerva Anestesiol* 1995; 62: 376

Marraro G, Casiraghi G.  
Six years of natural surfactant supplementation in lung pathologies of infants and children.  
*Biol Neonate* 1996; 69: 223

- Marraro R, Galassini EM, Padovani EM.  
Independent lung ventilation and exogenous surfactant in congenital diaphragmatic hernia complicated by unilateral lung pathology.  
Biol Neonate 1998, 74 (suppl 1): 47
- Marraro G, Luchetti M, Casiraghi G, Valsecchi R, Cereda G, Galassini E.  
Porcine derived surfactant treatment of severe bronchiolitis.  
Biol Neonate 1998; 74 (suppl 1): 46
- Marraro G.  
Surfactant use in severe bronchiolitis.  
Biol Neonate 2002; 81 (suppl 1): 28.
- McKnight J, O'Connor M, Halliday HL, McClure BG, Tubman TRJ.  
A five-year follow-up of Curosurf<sup>®</sup>-treated children.  
Biol Neonate 1995; 67 (suppl 1): 81
- McKnight J, O'Connor M, Halliday HL, McClure BG, Tubman TRJ.  
Curosurf<sup>®</sup>-treated infants - a five year follow-up.  
Prenat Neonat Med 1996; 1 (suppl 1): 15
- Merth IT, de Winter JP, Quanjer PH.  
Increase of static respiratory system compliance in ventilated newborns after surfactant administration.  
Am Rev Resp Dis 1992; 145 (suppl 4): 338
- Mildenberger E, Vogel M, Stevens P, Dirksen U, Kössel H, Richter C, Hoehn T, Versmold H.  
Atemnotsyndrom reifgeborener Brüder aufgrund congenitaler Alveolarproteinose.  
Monatsschr Kinderheilkd 1999; 147: 135
- Minoo P, Ballard P, Derynck R.  
TGF-beta-induced repression of surfactant protein B gene is mediated by SMAD3.  
Biol Neonate 2001; 80 (suppl 1): 37
- Möller O, Rauprich P, Walter G, Harms K, Herting E.  
Einfluss von Surfactant auf das in vitro Wachstum von B-Streptokokken, E. coli und S.aureus.  
Klin Pädiatr 2000; 212: 71
- Möller O, Schiffmann JH, Herting E.  
Einfluss von Surfactant auf den Gasaustausch von Kindern mit acute respiratory distress syndrom (ARDS) infolge einer Pneumonie.  
Monatsschr Kinderheilkd 2001; 149 (suppl 2): 139

Möller O, Walter G, Herting E.

Einfluss von Surfactant auf die Chemotaxis von polymorphkernigen Leukozyten.

Kinder Jugendmed 2002; 2: 5

Moen A, Rootwelt T, Curstedt T, Robertson B, Saugstad OD.

Acute blood pressure effects of surfactant replacement in newborn piglets.

Pediatr Res 1994; 36: 29

Moen A, Rootwelt T, Curstedt T, Robertson B, Hall C, Saugstad OD.

Hemodynamics and regional blood flow after porcine surfactant replacement in surfactant depleted newborn piglets.

Pediatr Res 1995; 38: 445

Moen A, Rootwelt T, Curstedt T, Robertson B, Hall C, Saugstad OD.

Hemodynamics and regional blood flow after porcine surfactant replacement in hypovolemic or hypoxemic newborn piglets.

Biol Neonate 1995; 67 (suppl 1): 79-80

Moen A, Yu XQ, Rootwelt T, Saugstad OD.

Systemic and pulmonary hemodynamics after instillation of porcine surfactant in surfactant-depleted newborn piglets.

Biol Neonate 1996; 69: 217-218

Moen A, Linderholm B, Lundberg E, Almaas R, Robertson B.

Effect of FeCl<sub>3</sub> on meconium inhibition of Curosurf<sup>®</sup> in preterm rabbits.

Biol Neonate 2000; 77 (suppl 1): 26-27

Moriette G, Walti H, Salanave B, Chognot D et al.

Prospective randomized multicenter comparison of high-frequency oscillatory ventilation (HFOV) and conventional ventilation (CV) in preterm infants <30 weeks gestational age (GA) with RDS.

Pediatr Res 1999; 45: 212

Mortensson W, Berggren P, Curstedt T, Grossmann G, Herin P, Nilsson R, Noack G, Robertson B.

Inverkan av surfaktantbehandling av IRDS-barn på lungförändringarna - en radiologisk undersökning.

Svenska Läkaresällskapets Riksstämma, Hygiea 1986; 95: 204

Moya F, Thomas V, Valls i Soler A, Maturana A, Serrano P.

Tracheal fluid (TF) saturated phosphatidylcholine (Sat. OC) and surfactant protein A (SP-A) in newborns with congenital diaphragmatic hernia (CDH).

Pediatr Res 1997; 41: 166

- Müller U, Speer CP, Harms K, Schröter W, Curstedt T, Robertson B.  
Einmalige Behandlung des schweren Atemnotsyndroms Frühgeborener mit natürlichem porcinem Surfactant.  
In: Pachler JM (ed): 37. Jahrestagung der Nordwestdeutsche Gesellschaft für Kinderheilkunde, 1988. Alete Wissenschaftlicher Dienst, München, 1988; 56
- Neu S, Bauer F, Goetze-Speer B, Speer CP.  
Curosurf® und Alveofact: Vergleich anti-inflammatorischer Eigenschaften von Surfactant-Präparationen unterschiedlichen Ursprungs.  
Z Geburtsh Neonatol 1997; 201: 207
- Noack G, Curstedt T, Robertson B.  
Surfactant replacement therapy in severe neonatal respiratory distress syndrome - an international randomized clinical trial.  
Svenska Läkaresällskapetets Riksstämman, Hygiea 1987; 96: 269
- Palmblad M, Johansson J, Robertson B, Curstedt T.  
Biophysical activity of artificial surfactant based on an SP-C analogue.  
Biol Neonate 1998; 74 (suppl 1): 43-44
- Palmblad M, Robertson B, Curstedt T, Zaltash S, Johansson J.  
An artificial surfactant preparation.  
Biol Neonate 1999; 76 (suppl 1): 43
- Papagaroufalis C, Apostolidou I, Touloumi G, Xanthou M.  
Antenatal betamethasone enhances the response to surfactant administration in preterm neonates.  
Biol Neonate 1995; 67 (suppl 1): 83-84
- Papagaroufalis C, Megreli C, Xanthou M.  
Effects of vitamin A supplementation in very low birth weight (VLBW) neonates treated with surfactant.  
Biol Neonate 1996; 69: 222.
- Papagaroufalis C, Magiakou MA, Koumenidou M, Xanthou M, Dakou-Voutetakis C.  
Evidence of adrenocortical suppression in very-low-birth-weight (VLBW) neonates receiving budesonide inhaler for prevention of bronchopulmonary dysplasia (BPD).  
Biol Neonate 1997; 71(suppl 1): 55-56
- Papagaroufalis C, Koumenidou M, Xanthou M.  
High-dose (HD) versus low-dose (LD) Curosurf® for the late treatment of respiratory distress syndrome (RDS).  
Biol Neonate 1998; 74 (suppl 1): 53
- Papagaroufalis C, Koumenidou M, Magiakou MA, Xanthou M, Dakou-Voutetakis C.  
Early adrenal insufficiency in very low birth weight (VLBW) neonates who develop bronchopulmonary dysplasia (BPD).  
Pediatr Res 1998; 44: 438

- Papagaroufalis C, Megreli C, Xanthou M.  
Low vitamin A plasma levels (VAPL) during airway infection in mechanically ventilated very low birth weight (VLBW) infants.  
*Pediatr Res* 1998; 44: 437
- Pauchard JY, Burguet A, Fromentin C, Menget A.  
Possible influence of surfactant therapy on severe bronchopulmonary dysplasia (SBPD).  
*Biol Neonate* 1995; 67 (suppl 1): 83
- Pfeiler C, Trupka A, Strohmaier W.  
Lavage treatment influences surface tension (ST) values.  
*Am J Respir Crit Care Med* 1999; 159: A827
- Pinot F, Walti H, Haagsman HP, Polla BS, Bachelet M.  
Inhibition of cyclic AMP accumulation by a modified natural porcine surfactant (Curosurf®) in human monocytes.  
*Biol Neonate* 1998; 74 (suppl 1): 55
- Pinot F, Bachelet M, Polla BS, Walti H.  
Modified natural porcine surfactant modulates tobacco smoke-induced stress response in human monocytes.  
*Biol Neonate* 1998; 74 (suppl 1): 55-56
- Ramanathan R, Su FH, Kwong KY, Nowicki M, Jones C, Minoo P.  
Curcumin inhibits proinflammatory cytokines in preterm neonatal lung cells.  
*Biol Neonate* 2001; 80 (suppl 1): 34
- Ramanathan R.  
Curosurf® versus Survanta in the treatment of neonatal respiratory distress syndrome in preterm infants: results from a randomized, multicenter masked comparison trial.  
*Acta Pharmacol Sin* 2002; 23 (suppl): 85-87
- Ramanathan R.  
Prophylactic and rescue surfactant use in the treatment of neonatal respiratory distress syndrome. *Acta Pharmacol Sin* 2002; 23 (suppl): 99-100
- Ramanathan R, Naing S, Kwong K, Literat A, Jones C, Minoo P.  
Transforming growth factor beta in the lungs of preterm infants.  
*Biol Neonate* 2002; 81 (suppl 1): 36
- Ramanathan R, Rasmussen MR, Gerstmann D, Finer N, Sekar K and The North American Study Group.  
A randomized multicenter masked comparison trial of Curosurf® and Survanta® in the treatment of established neonatal respiratory distress syndrome in preterm infants.  
*Biol Neonate* 2002; 81 (suppl 1): 36

- Rämet M, Haataja R, Marttila R, Floros J, Hallman M.  
Allelic association of surfactant protein A genes with respiratory distress syndrome in Finland.  
*Biol Neonate* 2000; 77 (suppl 1): 21
- Rankin SJA, Tubman TRJ, Halliday HL, Johnston SS.  
Surfactant and ROP incidence.  
*Ophthalmology* 1991; 98: 1148-1149
- Rauprich P, Möller O, Walter G, Herting E, Robertson B.  
Influence of modified porcine surfactant on in vitro growth and phagocytic killing of group B streptococci.  
*Biol Neonate* 1997; 71 (suppl 1): 63
- Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B, Herting E.  
Resistance of new recombinant surfactant preparations to inhibition by meconium.  
*Biol Neonate* 1999; 76 (suppl 1): 42-43
- Rey-Santano MC, Alvarez FJ, Gastiasoro E, Arnaiz A, Gómez MA, Larrabe JLL, Loureiro B, Casla JA, Valls i Soler A.  
Combined effect of perfluorocarbons (PFC) and natural surfactant (SF) on evaporative rate.  
*Eur J Med Res* 2001; 6: 121-122
- Richman PS, Spragg RG, Merritt TA, Robertson B, Curstedt T.  
Administration of porcine-lung surfactant to humans with ARDS: initial experience.  
*Am Rev Respir Dis* 1987; 35: 5
- Richman P, Spragg R, Asser S, Merritt T, Notter R, Robertson B.  
Comparison of the safety of three surfactant preparations for human use.  
*Pediatr Res* 1987; 21: 464
- Robertson B, Grossmann G, Ikegami M, Jobe A, Pettenazzo A, Seidner S.  
Leakage of albumin and iron dextran in the immature rabbit lung.  
*Pediatr Pathol* 1988; 8: 349
- Robertson B.  
Postnatal prevention and treatment of surfactant deficiency.  
*Eur J Obstet Gynecol Reprod Biol* 1989; 32: 11-12
- Robertson B.  
European multicenter trials of Curosurf® for treatment of neonatal respiratory distress syndrome (RDS).  
*Eur Respir J* 1989; 2: 763

Robertson B.

Surfactant replacement in animal models of neonatal respiratory distress syndrome (RDS).  
Floating Congress on the River Rhine "60 Years of Surfactant Research", 1989

Robertson B, Berggren P, Song G-W, Sun B, Suzuki Y.

Experimentellt neonatalt respiratoriskt distress syndrom framkallat med monoklonal antikropp mot surfaktant-associerat hydrofobt protein (SP-B).  
Svenska Läkaresällskapets Riksstämman, Hygiea 1990; 99: 269

Robertson B.

Surfactant replacement therapy for respiratory failure in infancy and childhood; new strategies and problems.

20<sup>th</sup> World Congress of Pediatrics, Rio de Janeiro, 1992; 319

Robertson, B.

New strategies for surfactant therapy in neonatal lung disease.

Appl Cardiopulm Pathophysiol 1995; 5 (suppl 3): 101-102

Robertson B, Grossmann G, Kobayashi T, Suzuki Y, Tashiro K, Matsumoto Y, Waseda Y, Akino T.

Lung permeability in experimental neonatal respiratory failure induced by lysophosphatidylcholine.

Biol Neonate 1995; 67 (suppl 1): 77

Robertson B.

Biophysical aspects of the surfactant system in relation to neonatal lung function.

Biol Neonate 1996; 69: 180-181.

Robertson B.

Nya indikationer för surfaktantbehandling.

Contenta Serono 1996; 4: 98

Robertson, B.

Experimental evaluation of new targets for surfactant therapy.

The neonate of extremely-low birthweight:update 98.

Dev Pathophysiol Clin, 1998; (suppl 8):1

Robertson B, Lundberg E.

Ultrastructure of Curosurf<sup>®</sup> instilled into the airways of immature newborn rabbits.

Biol Neonate 1998; 74 (suppl 1): 44-45

Robertson B, Taeusch HW, Lu KW, Goerke J, Clements JA.

Polyethylene glycol prevents formation of hyaline membranes in rats with experimental meconium aspiration syndrome treated with surfactant.

Biol Neonate 1999; 76 (suppl 1): 41-42

Robertson B, Linderholm BM, Lundberg E, Tashiro K, Valls i Soler A.  
Surfactant therapy and partial liquid ventilation with FC75 in preterm newborn rabbits;  
preliminary observations.  
Eur J Med Res 2000; 5: 28

Robertson B.  
New avenues in surfactant research.  
Z Geburtsh Neonatol 2001; 205: 77-78

Roll C, Brunier E, Hanssler L  
Radiologische Befunde nach Surfactant-Behandlung.  
Monatsschr Kinderheilkd 1992; 140: 537

Roll C., Knief J, Horsch S, Hanssler L.  
Effect of surfactant administration on cerebral hemodynamics and oxygenation in very-low-  
birth-weight infants.  
Biol Neonate 1999; 76 (suppl 1): 46-47

Rüdiger M, Friedrich W, Wauer RR  
Einfluss der liquid Ventilation auf die Oberflächenspannung von Curosurf®.  
Perinat Med 1997; 9: 112

Rüdiger M, Rüstow B, Proquitté H, Wauer RR.  
Umwandlung grosser in kleine Surfactantaggregate unter liquid Ventilation.  
Z Geburtshilfe Neonatol 1997; 201: 233

Rüdiger M, Köpke U, Proquitté H, Rüstow B, Grauel EL, Wauer RR.  
Mischung von Curosurf® in PFC unter Flüssigkeitsbeatmung.  
Monatsschr Kinderheilkd 1998; 146: 152

Rüdiger M, Hoeffe J, Proquitté H, Wauer RR, Rüstow B.  
Perfluorocarbons and the pulmonary surfactant system.  
Eur J Med Res 1999; 4:199-200

Rüdiger M, Köpke U, Rauprich P, Walter G, Proquitté H, Wauer R, Herting E.  
Einfluß von PFC auf das Wachstum von B-Streptokokken.  
Z Geburtsh Neonatol 1999; 203 (suppl 1): 6

Rüdiger M, Jarstrand C, Some M, Calkovska A, Robertson B, Herting E.  
Die Flüssigkeitsbeatmung mit PF 5080 führt im Kaninchen nicht zur Exazerbation einer B-  
Streptokokken pneumoniae.  
Monatsschr Kinderheilkd 2001; 149 (suppl 2): 139

Rüdiger M, Some M, Jarstrand C, Calkovska A, Linderholm B, Robertson B, Herting E.  
Partial liquid ventilation does not stimulate bacterial growth and improves alveolar  
expansion in newborn rabbits with group B-streptococcal pneumoniae.  
Biol Neonate 2002; 81 (suppl 1): 36

- Rüdiger M, Jarstrand C, Some M, Calkovska A, Robertson B, Herting E.  
Das bakterielle Wachstum ist im Kaninchen mit kongenitaler B-Streptokokken Pneumonie unter Flüssigkeitsbeatmung reduziert.  
Kinderärztl Prax 2002; 73: 9
- Saliba E, Laugier J.  
Cerebral hemodynamic effects and electroencephalogram activity during treatment with modified natural surfactant.  
Biol Neonate 1995; 67 (suppl 1): 91
- Saugstad OD, Gloppestad K, Tubman TRJ, Halliday HL, Øyasæter S, Curstedt T, Robertson B.  
Washing out of hypoxanthine (Hx) in preterm babies with RDS treated with natural surfactant (Curosurf®).  
Pediatr Res 1989; 26: 511
- Saugstad OD, Røise O, Gloppestad K, Curstedt T, Robertson B, Aasen AO.  
Activation of the plasma kallikrein-kinin system in RDS is not influenced by treatment with natural surfactant.  
Pediatr Res 1990; 28: 301
- Saugstad OD, Buø L, Johansen HT, Aasen AO.  
Activation of the kallikrein-kinin system in RDS.  
Pediatr Res 1991; 30: 657
- Schiffmann JH, Herting E, Harms K, Speer CP.  
Radiologische Veränderungen bei Frühgeborenen mit schwerem Atemnotsyndrom nach Surfactanttherapie.  
Monatschr Kinderheilkd 1992; 140: 537
- Schiffmann JH, Harms K, Herting E.  
Surfactant treatment in infants with acute respiratory failure triggered by atypical pneumonia. Biol Neonate 1997; 71 (suppl 1): 68
- Schipper JA, van Sonderen L, de Jongh FHC, Koppe JG.  
Influence of exogenous surfactant therapy on lung function.  
Biol Neonate 1995; 67 (suppl 1): 89
- Schipper JA, van Sonderen L, de Jongh FHC, Koppe JG.  
Influence of exogenous surfactant therapy on lung function in preterm newborns with RDS.  
Appl Cardiopulm Pathophysiol 1995; 5 (suppl 3): 104-105
- Schmidt B, Cao L, Mackensen-Haen S, Kendziorra H, Klinikel K, Speer CP.  
Chorioamnionitis and inflammation of the fetal lung.  
Biol Neonate 2000; 77 (suppl 1): 22-23

- Schollin J, Liljedahl M, Berggren E, Winbladh B, Robertson B, Curstedt T.  
Nebulized surfactant for treatment of respiratory distress syndrom: a pilot study in preterm babies.  
Biol Neonate 1998; 74 (suppl 1): 51
- Schröder A, Speer CP.  
Superoxiddismutase und Katalase im Bronchialsekret Frühgeborener mit Atemnotsyndrom.  
Monatschr Kinderheilkd 1994; 142: 508
- Schürch S, Bachofen H, Qanbar R, Possmayer F.  
Incorporation of surface-associated surfactant material into the surface active film.  
Appl Cardiopulm Pathophysiol 1995; 5 (suppl 3): 106-107
- Schürch S, Lee MM, Putz G.  
Calcium reduces surfactant inhibition by serum protein.  
Biol Neonate 1996; 69: 215
- Schürch S, Palmer D, Amato M.  
Effect of cholesterol on the surface activity of lipid extract surfactant.  
Biol Neonate 1997; 71 (suppl 1): 66
- Schürch S, Amato M, Valls i Soler A.  
Surface properties of surfactant-perfluorocarbon combinations studied in a modified captive bubble system.  
Biol Neonate 1999; 76 (suppl 1): 49
- Schürch S, Valls i Soler A.  
Surface properties of surfactant-perfluorocarbon combinations studied in a modified captive bubble system.  
Eur J Med Res 2000; 5: 6
- Schürch S, Amato M, Valls i Soler A, Green FHY.  
Surface properties of surfactant-perfluorocarbon fluid combinations related to partial and total liquid ventilation.  
Biol Neonate 2000; 77 (suppl 1): 25
- Schürch S, Koetzler R, Amato M, Green FHY.  
Reversal of airway closure with surfactant-perfluorocarbon combinations.  
Biol Neonate 2001; 80 (suppl 1): 40
- Schürch S, Amato M, Valls i Soler A, Green FHY.  
Surface properties of surfactant-perfluorocarbon fluid combinations related to partial and total liquid ventilation.  
Eur J Med Res 2001; 6: 121
- Schürch S, Amato M, Robertson B.  
Surface activity and structure of spread films in relation to surfactant concentration.  
Biol Neonate 2002; 81 (suppl 1): 37

Sevecova D, Calkovska A, Drgova A, Javorka K  
HFJV and lung lavage with exogenous surfactant in experimental meconium aspiration syndrome.

Anästhesiol Intensivmed 2002; 43 : 534

Segerer H, Vogel M, Obladen M, Curstedt T, Robertson B.  
Pulmonary lipid deposits after surfactant substitution for neonatal respiratory distress syndrome (RDS).

Pediatr Res 1989; 26: 511

Segerer H, Stevens P, Schadow B, Maier R, Kattner E, Robertson B, Obladen M.  
Surfactant response depends on maturity and disorder of the lung.

Klin Pädiatr 1991; 203: 57

Segerer H, van Gelder W, Curstedt T, Obladen M, Lachmann B.  
Response to surfactant treatment in surfactant-depleted rabbits is related to administration technique.

Biol Neonate 1992; 62: 2-3

Segerer H, van't Veen A, Gommers D, Lachmann B, Obladen M.  
Multiple small dose of exogenous surfactant in surfactant-deficient rats: how often should the standard dose be subdivided?

Biol Neonate 1992; 62: 177

Segerer H, Scheid A, Wagner M, Obladen M.  
Tracheal surfactant infusion during 5 min is less effective than bolus instillation in rabbits.

Pediatr Res 1994; 36: 37

Segerer H, van't Veen A, van Gelder W, Obladen M, Lachmann B.  
Effects of multiple small doses (MSD) of exogenous surfactant (s) vs one bolus (b) in surfactant-deficient rabbits.

Pediatr Res 1994; 35: 277

Segerer H, Wagner M, Scheid A, Lachmann B, Obladen M.  
Pulmonale Verteilung von exogenem Surfactant (Surf) nach verschiedenen Instillationsmethoden im Tiermodell des Atemnotsyndroms.

Monatsschr Kinderheilkd 1994; 142: 41

Shinwell ES, Kuint J, Dolfen T.  
Comparison of morbidity and mortality with three different surfactant preparations in RDS.

Biol Neonate 1996; 69: 219

- Shinwell ES, Kofman M, Zmora E, Golan A, Landau D, Karplus M.  
Nasal continuous positive airway pressure versus nasal synchronized intermittent mandatory ventilation during weaning from mechanical ventilation in preterm infants with respiratory distress syndrome.  
Biol Neonate 1998; 74 (suppl 1): 51-52
- Sindelar R, Dammann V, Jonzon A, Schaller P, Schulze A, Sedin G.  
Effect of a porcine surfactant (Curosurf®) on slowly adapting pulmonary stretch receptors during spontaneous breathing and intermittent positive pressure ventilation in surfactant-depleted cats.  
Biol Neonate 1997; 71 (suppl 1): 60-61
- Sindelar R, Jonzon A, Sedin G.  
The activity of slowly adapting pulmonary stretch receptors reflects the changes in lung mechanics in small segments of the lung in a model of surfactant depletion, before and after instillation of surfactant.  
Biol Neonate 2002; 81 (suppl 1): 37
- Smith RM, Pappert D, Spragg RG.  
KL<sub>4</sub>-surfactant improves gas exchange of pigs with acute lung injury.  
Am J Resp Crit Care Med 1995; 151 (suppl 4): 310
- Some M, Linderholm B, Johansson J, Curstedt T, Robertson B.  
Effects of an artificial surfactant containing a new surfactant protein C analogue evaluated in preterm newborn rabbits.  
Biol Neonate 2002; 81(suppl 1): 38
- Song GW, Gan XZ, Song H.  
Six clinical reports of the surfactant replacement therapy for neonatal respiratory distress syndrome.  
J Neonatol 1995; 10 (suppl 1): 5
- Song GW, Gan XZ, Zhang Y.  
The improvement of oxygenation by pulmonary surfactant in severe neonatal pneumonia.  
Chin J Pediatr 1995; 33 (suppl 6): 336
- Speer CP, Harms K, Herting E, Schröter W, Curstedt T, Robertson B.  
Early versus late surfactant replacement therapy in severe respiratory distress syndrome.  
Eur Respir J 1989; 2: 763
- Speer CP, Robertson B.  
Surfactant-Substitution - kausale Therapie des Atemnotsyndroms Frühgeborener - Schlußwort.  
Dtsch Arztebl 1989; 86, 22: 1684

Speer CP, Curstedt T, Robertson B, Herin P, Noack G, Kok J, Koppe J, Van Sonderen L, Halliday H, McClure G, Reid M, Tubman R, Laufkötter E, Köhler W, Boenisch H, Albrecht K, Hanssler L, Haim M, Oetomo SB, Okken A, Compagnone D, Harms K, Herting E, Natzschka J, Groneck P, Kachel W, Relier JP, Walti H.

Internationale randomisierte klinische Studie zur Surfactant-Therapie des schweren Atemnotsyndroms (RDS) Frühgeborener: Surfactant-Einzeldosis versus Dreifachtherapie. Monatsschr Kinderheilkd 1990; 138: 488

Speer CP, Curstedt T, Robertson B, Herin P, Noack G, Kok J, Koppe J, van Sonderen L, Halliday HL, McClure G, Reid M, Tubman R, Laufkötter E, Kohler W, Boenisch H, Albrecht K, Hanssler L, Haim M, Oetomo SB, Okken A, Compagnone D, Harms K, Herting E, Altfield PC, Groneck P, Kachel W, Relier JP, Walti H.

Randomized European multicenter trial of surfactant replacement in neonatal respiratory distress syndrome (RDS) - single versus multiple doses of Curosurf®. Pediatr Res 1990; 28: 281

Speer CP, Götze B, Curstedt T, Robertson B.

Phagocytic functions and TNF secretion of human monocytes exposed to natural porcine surfactant (Curosurf®).

Pediatr Res 1990 ; 28: 281

Speer CP.

Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: Single versus multiple doses of Curosurf®.

Pediatr Dig 1992; 6: 9-10

Speer CP, Herting E, Harms K, Rosinski D, Gefeller O.

Neutrophil elastase in tracheal aspirates of infants with severe respiratory distress syndrome (RDS).

Pediatr Res 1992; 32: 623

Speer CP, Groneck P.

Inflammatory mediators in bronchoalveolar secretions of infants with respiratory distress syndrome.

Appl Cardiopulm Pathophysiol 1995; 5: 115

Speer CP, Goetze-Speer B, Bauer FM.

Anti-inflammatory properties of a natural porcine surfactant preparation (Curosurf®) compared with a bovine surfactant (Alveofact).

Biol Neonate 1997; 71 (suppl 1): 60

Speer CP, Schmidt B, Cao L, Klingel K, Mackensen-Haen S, Lang F.

Association between inflammation and expression of human serine threonine kinase (h-sgk) in fetal and neonatal lung tissue.

Biol Neonate 2001; 80 (suppl 1): 35

Spragg RG, Smith RM, Harris K.

Synthetic surfactant containing phospholipids and rSP-C improves gas exchange in a porcine lavage model of acute lung injury.

Am J Resp Crit Care Med 1998; 157: 561

Stenson BJ, Kelly KP, Drummond GB.

Effects of partial liquid ventilation (PLV), porcine surfactant and artificial surfactant on lung mechanics and gas exchange in surfactant depleted lung-injured rabbits.

Early Hum Dev 1999; 56: 246-247

Sterniste W, Voithl P, Peithner S, Sacher M.

Do we need exogenous surfactant prophylaxis in premature babies in a perinatal care?

Biol Neonate 1995; 67 (suppl 1): 82

Stichtenoth G, Rauprich P, Walter G, Herting E.

Auswirkungen von Mekonium auf die Oberflächenspannung unterschiedlicher Surfactant-Präparationen.

Z Geburtsh Neonatol 1998; 202 (suppl 1): 234

Stichtenoth G, Herting E, Rauprich P, Walter G, Johansson J, Robertson B.

Inhibition of surfactant preparations used for treatment of neonatal acute respiratory distress syndrome (ARDS) caused by meconium aspiration: surface tension vs. area compression.

Biol Neonate 2000; 77 (suppl 1): 25-26

Stichtenoth G, Curstedt T, Robertson B, Herting E.

Increasing the resistance of Curosurf® to meconium inactivation by adding lipids, phospholipids or dextran.

Biol Neonate 2001; 80 (suppl 1): 39

Stichtenoth G, Robertson B.

An artefact interfering with measurements of dynamic surface tension with a pulsating bubble surfactometer.

Biol Neonate 2001; 80 (suppl 1): 36

Stichtenoth G, Walter G, Johansson J, Robertson B, Herting E.

Dextran erhöht die Resistenz von Surfactant gegen eine Inaktivierung durch Mekonium.

Z Geburtsh Neonatol 2001; 205 (suppl 1): 3

Strayer DS, Chander A, Pinder R.

Antibody against SP-A receptor increases surfactant secretion by cultured alveolar type II cells: Insights into the regulation of surfactant secretion, and its inhibition by SP-A.

Biol Neonate 1995; 67 (suppl 1): 88-89

Strayer DS, Pinder RS, Thomas AP.

SP-A inhibits type-II cell activation by secretagogues by inhibiting intracellular calcium-related signaling.

Biol Neonate 1996; 69: 215

- Strayer DS, Korutla L.  
Regulation of surfactant protein expression in type II cells by SP-A.  
Biol Neonate 1997; 71 (suppl 1): 66
- Strayer DS, White MK, Fenn GB, Hoek J.  
Signals that cause surfactant secretion.  
Biol Neonate 1998; 74 (suppl 1): 43
- Strohmaier W, Kneidinger , Redl H, Müller B, Schlag G.  
Natural surfactant phospholipids are required to decrease in vitro adherence of human PMNL by pulmonary SP-A.  
Am Rev Respir Dis 1992; 4: 145
- Strohmaier W.  
Rational concepts for the application of exogenous surfactant.  
SHOCK 1995; 3 (suppl): 8
- Strohmaier W, Redl H, Schlag G.  
Surfactant function in a long-term lung injury model.  
Biol Neonate 1995; 67 (suppl 1): 77-78
- Strohmaier W, Schlag G, Redl H.  
Changes of surfactant in vitro function in a long term lung injury model.  
SHOCK 1995; 3 (suppl): 11
- Strohmaier W, Pfeiler C, Trupka A, Schöchli H, Kröpfl A, Redl H.  
New concepts in the treatment of ALI/ARDS with exogenous surfactant.  
SHOCK 1999; 12 (suppl): 8
- Strohmaier W, Trupka A, Redl H.  
Bronchopulmonary lavage with diluted surfactant is a therapeutic option in progressive respiratory failure.  
Biol Neonate 1999; 76 (suppl 1): 41
- Stucin Gantar I, Babnik J.  
Surfactant inhibitors in amniotic fluid from gastric aspirates in premature infants with respiratory distress syndrome.  
Biol Neonate 1999; 76 (suppl 1): 43-44
- Su G, Spragg RG.  
Effect of endogenous nitric oxide production on CTP: phosphocholine cytidyltransferase activity in rat alveolar type II cells.  
Am J Respir Crit Care Med 2000; 161: 659
- Sun B, Robertson B, Curstedt T, Grossmann G.  
Surfactant inhibited by meconium aspiration.  
Floating Congress on the River Rhine, "60 Years of Surfactant Research", 1989

- Sun B, Herting E, Curstedt T, Robertson B.  
Surfactant improves lung function in ventilated rats with meconium aspiration.  
*Pediatr Res* 1993; 33: 347
- Sun B, Calkovska A, Curstedt T, Robertson B.  
SP-A added to Curosurf<sup>®</sup> increases resistance to inactivation by fibrinogen and other surfactant inhibitors.  
*Biol Neonate* 1995; 67 (suppl 1) : 78
- Sweet DG, Schock BC, Ennis M, Halliday HL, Warner JA.  
Oxidative stress and upregulation of matrix metalloproteinase-9 and its inhibitor in neonatal bronchoalveolar lavage fluid.  
*Biol Neonate* 1999; 76 (suppl 1): 47-48
- Sweet DG, Huggett MT, Moss TJ, Nitsos I, Warner JA, Halliday HL, Newnham JP, Ikegami M, Jobe AH.  
Increased lung collagenase levels in a sheep model of chorioamnionitis - implications for the pathogenesis of neonatal chronic lung disease.  
*Pediatr Res* 2002; 51: 474
- Taeusch HW, Lu K.  
Beneficial effects of adding dextran to Curosurf<sup>®</sup> in a rat model of meconium aspiration.  
*Biol Neonate* 2002; 81 (suppl 1): 39
- Tannuri U, Diniz EMA, Santos MM, Maksoud FJG, Tannuri ACA, Rodrigues CJ, Rodrigues JRAJ.  
Prenatal intraamniotic administration of surfactant substance improves lung compliance and morphometric parameters in an animal model of congenital diaphragmatic hernia (CDH).  
*Pediatr Res* 1996; 39 (suppl 4): 352
- Tannuri U, Diniz EMA, Santos MM, Maksoud FJG, Tannuri ACA, Rodrigues CJ, Rodrigues JRAJ.  
Intraamniotic infused surfactant is aspirated by the fetus and improves lung biochemical parameters in animal model of congenital diaphragmatic hernia (CDH).  
*Pediatr Res* 1998; 43: 299
- Tarnow-Mordi W, Tucker J, McCabe C, Parry G, Malek M, Hey E, Normand C, Mugford M, Halliday HL on behalf of the MRC Project for the Economic Evaluation of Surfactant.  
Issues in cost function specification for neonatal care: an interdisciplinary perspective.  
*J Publ Health Med* 1997; 19: 479-480.
- Tashiro K, Yamada, K, Konzaki T, Kobayashi T, Robertson B.  
Surfactant replacement therapy for experimental meconium aspiration syndrome in rats: effects of lung lavage and administered doses.  
*J Anaesthesiol* 2001; 15 (suppl): 3

- Thome U, Goetze-Speer B, Speer CP, Pohlandt F.  
Entzündungsmediatoren im Trachealsekret von Frühgeborenen mit konventioneller Beatmung (CMV) oder Hochfrequenzoszillation (HFO).  
Z Geburtsh Neonatol 1997; 201: 220
- Thornton CM, Halliday HL, O'Hara D.  
Does exogenous surfactant alter pulmonary histology in idiopathic respiratory distress syndrome?  
J Pathol 1993; 172: 53
- Tølløfsrud PA, Medbø S, Solas AB, Robertson B, Drevon CA, Saugstad OD.  
Surfactant function after meconium aspiration in newborn piglets: Effects of blocking the free fatty acids with bovine serum albumin.  
Biol Neonate 2000; 77 (suppl 1): 27
- Trupka A, Strohmaier W, Thurnher M, Khakpour Z, Schweiberer L, Redl H, Schlag G.  
Bronchoalveolar lavage with low-dose-surfactant in a porcine model of severe pulmonary contusion (PC).  
SHOCK 1997; 8 (suppl): 63 – 64.
- Tubman TRJ, Halliday HL.  
Surfactant replacement in severe respiratory distress syndrome: follow-up at one year.  
Ir J Med Sci 1989; 158: 283
- Tubman TRJ, Halliday HL.  
The effect of surfactant replacement therapy on dynamic lung compliance in neonatal respiratory distress syndrome.  
Intensive Care Med 1990; 16: 859, 222
- Tubman TRJ, Halliday HL, Normand C.  
Economic impact of surfactant replacement for severe neonatal respiratory distress syndrome.  
Ir J Med Sci 1990; 159: 258
- Tubman TRJ, Rankin SJ, Halliday HL, Johnston SS.  
Impact of surfactant replacement therapy on the incidence of retinopathy of prematurity.  
Pediatr Res 1991; 30: 657
- Valls i Soler A, Lizarraga M, López Heredia J, Román L, Hernáez E, Gastiasoro L.  
Effectiveness of clinical use or porcine surfactant in severe RDS. A case control study.  
J Perinat Med 1992; 20 (suppl 1): 309
- Valls i Soler A, Wolfson MR, Shaffer TE.  
Enhanced pulmonary distribution (PD) of exogenous surfactant (SF) with the use of liquid ventilation (LV) in experimental RDS.  
Biol Neonat 1992; 62: 179

Valls i Soler A, Wolfson MR, Kachner N, Foust F, Shaffer TH.  
Comparison of natural surfactant and brief liquid ventilation rescue treatment in very immature lambs.  
*Pediatr Res* 1993; 33 (suppl 2): 347

Valls i Soler A and Members of the Spanish Surfactant Collaborative Group.  
A simplified surfactant dosing procedure.  
*Biol Neonate* 1993; 64: 174

Valls i Soler A, Arnaiz A, Alvarez FJ, Gastiasoro E, Baoquan Q, Díaz Pardo JA, Tovar JA, Alfonso JF.  
Biochemical lung immaturity in experimental congenital diaphragmatic hernia.  
*Pediatr Res* 1994; 36: 41

Valls i Soler A, Hernández E, Quintana JM, Román L, López Heredia J, Gastiasoro E.  
Immediate oxygenation response to exogenous surfactant (SF) predicts survival of preterm neonates with RDS.  
*Pediatr Res* 1994; 35 (suppl 4): 357

Valls i Soler A, López Heredia J, Fernández B, Gastiasoro E and Members of Spanish Collaborative Group.  
A simplified surfactant (SF) dosing procedure. The "Side-hole" pilot study.  
*Pediatr Res* 1994; 35 (suppl 4): 357

Valls i Soler A, Wolfson MR, Kachner N, Foust F, Shaffer TH.  
Natural surfactant (SF) vs brief liquid ventilation rescue treatment in very immature lambs.  
*Pediatr Res* 1994; 35, 2: 279

Valls i Soler A, Alvarez FJ, Gómez MA, López de Heredia J, Gastiasoro E, Arnaiz A, Fernández B, Alfonso LF.  
Is surfactant (SF) needed in perfluorocarbon filled lungs?  
*Pediatr Res* 1995; 37: 354

Valls i Soler A, Alvarez A, Gómez MA, López de Heredia J, Gastiasoro E, Arnaiz A, Fernández B, Alfonso LF.  
Is surfactant (SF) needed in perfluorocarbon (PFC) filled lungs?  
*Biol Neonate* 1995; 67 (suppl 1) : 80

Valls i Soler A, Alvarez FJ, Gómez MA, López de Heredia J, Gastiasoro E, Arnaiz A, Fernández B, Alfonso LF.  
Surfactant in tidal liquid ventilation (TLV) with perfluorocarbons (PFC).  
*Biol Neonate* 1995; 67 (suppl 1): 314

Valls i Soler A, Fernández B, Alvarez A, Gastiasoro E, Arnaiz A.  
Evaluation of a simplified surfactant (SF) dosing procedure in rats with respiratory failure: the side-tube method.  
*Biol Neonate* 1995; 67 (suppl 1): 80

Valls i Soler A, Fernández-Ruanova B, López de Heredia J, Román L and the Spanish Collaborative Group.

A prospective trial of a side-tube surfactant (SF) dosing.

Pediatr Res 1996; 40: 554

Valls i Soler A, Fernández-Ruanova B, López-de-Heredia J, Román L and the Spanish Collaborative Group.

A side-tube surfactant (SF) dosing procedure. A prospective clinical trial.

Pediatr Res 1997; 41: 271

Valls i Soler A, Fernández-Ruanova B, López de Heredia J, Román L and the Spanish Collaborative Group.

The 'side-tube' Curosurf<sup>®</sup> clinical trial.

Biol Neonate 1997; 71 (suppl 1): 53-54

Valls i Soler A, Fernández-Ruanova B, López de Heredia J, Román L, Rodríguez-Soriano J and the Spanish Collaborative Study Group.

Early prediction of intraventricular hemorrhage in surfactant treated very low birth weight infants with RDS.

Pediatr Res 1998; 44: 447

Valls i Soler A, Fernández-Ruanova B, Robertson B on behalf of the Collaborative Surfactant Study Group.

Treatment of congenital diaphragmatic hernia with surfactant: a multicenter retrospective study.

Biol Neonate 1998; 74 (suppl 1): 54

Valls i Soler A, Fernández-Ruanova B, Robertson B and the Collaborative Surfactant Study Group.

Surfactant (SF) treatment on congenital diaphragmatic hernia (CDH). A retrospective study. Pediatr Res 1999; 45: 324

Valls I Soler A, López-de Heredia J, Román L, Fernández-Ruanova B, and the Spanish Collaborative Study Group.

Comparative effects of two different prophylactic indomethacin infusion regimens in Curosurf<sup>®</sup>-treated infants with respiratory distress syndrome.

Biol Neonate 1999; 76 (suppl 1): 48-49

Valls i Soler A, Páramo S on behalf of the Spanish Surfactant Collaborative Study Group.

Prenatal steroids do not modify surfactant needs after prophylaxis in infants 28-30 wks.

Pediatr Res 2001; 50: 305

Valls i Soler A, Rey Santano MC, Alvarez FJ, Gastiasoro E, Arnáiz A, Gómez MA, Larrabe JL, Loureiro B, Casla JA.

Combined effects perfluorocarbons (Pfc) and natural surfactant (SF) on evaporative rate. *Pediatr Res* 2001; 49: 416

van Bel, de Winter JP, Wijnands HBG, van de Bor M, Robertson B, Egbert J.

Cerebral- (CBFV) and aortic blood flow velocity (AoBF) in preterm infants during and after surfactant (SF) treatment.

*Pediatr Res* 1990; 28: 279

Van Helden HMP, Kuijpers WC, Langerwerf E, Langen R, Bruijnzeel PLB.

Efficacy of Curosurf<sup>®</sup> in a rat model of ARDS.

*Biol Neonate* 1997; 71 (suppl 1): 63-64

Van Kaam AHLC, De Jaegere A, Haitzma J, van Aalderen WMC, Kok JH, Lachmann B.

Pressure controlled ventilation using the open lung concept compared to high frequency oscillatory ventilation and conventional pressure controlled ventilation: effects on gas exchange and lung injury in surfactant deficient newborn piglets.

*Biol Neonate* 2001; 80 (suppl 1): 39

Van Kaam AHLC, De Jaegere A, Haitzma JJ, van Aalderen WMC, Kok JH, Lachmann B.

Surfactant therapy during open lung concept ventilation: Effects on gas exchange, lung mechanics and surfactant conversion in surfactant deficient newborn piglets.

*Biol Neonate* 2002; 81 (suppl 1): 39

van Landeghem K, van Sonderen L, Schipper JA, Koppe JG.

Prognostic values of neonatal blood count in newborns with the respiratory distress syndrome (RDS): results of a retrospective study.

*Biol Neonate* 1996; 69: 220

van Landeghem K, Schipper JA, van Sonderen L, Koppe JG.

Prognostic values of neonatal blood count in newborns with the respiratory distress syndrome (RDS). Results of a retrospective study.

*Prenat Neonat Med* 1996; 1 (suppl 1): 238

van Sonderen L.

Voorbeeld van verdere intensivering van de neonatale zorg. Het toedienen van surfactant in de longen bij vroeggeborenen met ernstige hyaliene membranen ziekte.

*Nieuwsbulletin V.O.C.* 1986; 4: 9

Verder H.

Forebyggelse af RDS. Glucocorticosteroidprofylakse, L/S-ratio. Surfactantbehandling. Status i dag.

*Dansk Pædiatrisk Selskabs Årbog* 1985; 86

Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbesen F, Greisen G, Hobolth N, Holm V, Jacobsen T, Johansen KH, Kamper J, Lange A, Mølgaard C, Nathan E, Nielsen F, Pedersen-Bjergaard L, Peitersen B, Robertson B, Skov L, Svenningsen N, Tegllund L.

Treatment of RDS with nasal-CPAP and Curosurf®. Danish-Swedish randomized multicenter study.

Acta Paediatr 1992; 384

Verder H, Albertsen P, Ebbesen F, Geisen G, Robertson B for the Danish-Swedish Multicenter Study Group.

Surfactant and nasal-CPAP before 30 weeks of gestation.

Pediatr Res 1997; 42: 175

Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B on behalf of the Danish-Swedish Multicenter Study Group.

Surfactant (Curosurf®) and nasal continuous positive airway pressure in babies born before 30 weeks of gestation.

Biol Neonate 1997; 71 ( suppl 1): 53

Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B, Agertoft L, Grytter C, Djernes B, Nathan E, Pryds O, Hertel J, Peitersen B, Pedersen-Bjergaard L, Berg A, Vrang C, Christensen MF, Johansen K, Eschen C, Kroner J, Reinholdt J, Bertelsen A.

Behandling af præmature født før 30 uger med tidlig nasal-CPAP, tidlig surfactant og respirator.

Dansk Pædiatrisk selskabs Årbog 1997; 98

Vezzol D, Marraro G, Luchetti M, Galassini EM.

Bronchopulmonary lavage with Curosurf® in acute respiratory distress syndrome.

Biol Neonate 2002; 81 (suppl 1): 39

Volante E, Bevilacqua G, Parmigiani S, Chirico G, Gaioni L, Guerrini P.

Risultati del trattamento della RDS neonatale con surfattante suppletivo. Ricerca multicentrica.

Riv Ital Ped 1988; 14: 153

Wagner MH, Koch H, Schmitz L, Scheid A, Segerer H.

Drop of blood pressure after surfactant bolus instillation: haemodynamic measurements.

Appl Cardiopulm Pathophysiol 1995; 5 (suppl 3): 129

Wagner MH, Segerer H, Scheid A, Lekka A, Obladen M.

Platelet-activating factor (PAF) and blood pressure (BP) drop after surfactant instillation.

Biol Neonate 1996; 69: 217

Wagner MH, Wiethoff S, Mollenhauer I, Boenick U, Obladen M.

Ultrasonic nebulization of surfactant by means of different exciting frequencies.

Biol Neonate 1997; 71 (suppl 1): 61

Wagner MH, Sonntag J, Strauß E, Obladen M.  
Surfactant responders and non-responders differ in complement activation.  
Biol Neonate 1998; 74 (suppl 1): 52-53

Wagner M H, Amthauer H, Sonntag J, Drenk F, Eichstädt H, Obladen M.  
Surfactant aerosol - an alternative?  
Biol Neonate 2001; 80 (suppl 1): 40

Wagner MH, Koehne P, Willam C, Sonntag J, Bühner C, Obladen M.  
Different levels of intercellular cell adhesion molecule-1 and L-selectin in surfactant responders and nonresponders.  
Biol Neonate 2002; 81 (suppl 1): 40

Walther FJ, Hernández-Juviel JM, Gordon LM, Waring AJ.  
Dimeric SP-B<sub>1-25</sub> in a mixture of lung lavage lipids mimics lung function improvement with natural surfactant in lavaged rats.  
Biol Neonate 2002; 81 (suppl 1): 41

Walti H, Egberts J, Bevilacqua G.  
Meta analysis of three controlled studies: Prophylaxis versus rescue trials of RDS.  
In: Lucey JF (ed): Hot Topics' 92 in Neonatology, Ross Laboratories Columbus, 1992; 482.

Walti H, Paris J, Couchard M, Bréart G, Relier on behalf of the French Collaborative Multicentre Study Group.  
Prophylaxis vs rescue therapy of RDS with multiple low doses of Curosurf<sup>®</sup>.  
In: Lucey JF (ed): Hot Topics '92 in Neonatology, Ross Laboratories Columbus, 1992; 484

Walti H, Paris J, Bréart G, Relier JP on behalf of the French Collaborative Multicentre Study Group.  
Porcine surfactant replacement therapy in neonates of less than 31 week's gestation: A randomized trial of prophylaxis versus rescue multiple low doses administration.  
Pediatr Res 1992; 31: 326A

Walti H.  
Détreffes respiratoires néonatales par immaturité pulmonaire : Moyens de prévention, traitement par les surfactants exogènes.  
Rapport Euromédecine 94, Montpellier, 1994, 252-253

Walti H, Moriette G, Huon C, Relier JP.  
Curosurf<sup>®</sup> and high-frequency-oscillation (HFO): the new deal?  
Pediatr Res 1995, 37: 244

Walti H, Moriette G, Huon C, Relier JP.  
Effect of surfactant replacement during high frequency oscillation (HFO) in infants with respiratory distress syndrome (RDS).  
Pediatr Res 1995; 37: 244

Walti H, Farhat M, Desfrères L, Relier JP.

Natural exogenous surfactant therapy stimulates the acute phase reaction in premature neonates.

Pediatr Res 1996; 39: 355

Walti H, Polla BS, Bachelet M.

Natural porcine surfactant inhibits superoxide anions and proinflammatory mediators released by stimulated human monocytes.

Pediatr Res 1996; 39: 251

Walti H, Llado J, Bréart G, Egberts J, Bevilacqua G.

Prophylactic administration of natural porcine surfactant (NPS) is a significant factor in reducing the odds for peri-intraventricular hemorrhage (PIVH).

Pediatr Res 1997; 41: 186

Walti H, Llado J, Bréart G, Egberts J, Bevilacqua G.

Prophylactic administration of Curosurf<sup>®</sup> is a significant factor reducing the odds for peri-intraventricular hemorrhage (PIVH).

Biol Neonate 1997; 71 (suppl 1): 54-55

Walti H, Nicolas-Robin A, Assous MV, Davis JM, Polla BS, Bachelet M.

Susceptibility of oxygen-dependent bactericidal defenses to the association of surfactant with superoxide dismutase.

Biol Neonate 2000; 77 (suppl 1): 22

Wang F, Gan XZ, Song GW, Li H.

Influence of pulmonary surfactant (Curosurf<sup>®</sup>) on growth of Haemophilus influenzae type B.

J Appl Clin Pediatr 2002; 31 (suppl 17): 66

Wang F, Gan XZ, Song GW, Li H.

Influence of pulmonary surfactant (Curosurf<sup>®</sup>) on growth of Haemophilus influenzae type B.

Acta Pharmacol Sin 2002; 23: 160

Wauer RR, Evlek Z, Wenzel U, Schmalisch G.

Exogenous surfactant reduces alveolar dead space in infants with respiratory distress syndrome.

Biol Neonate 1999; 76 (suppl 1): 46

Weintraub Z, Waisman D, Danino D, Talmon Y.

Correlation between fluid phase morphology and biological activity of lung surfactant in ventilated, very-low-birth-weight premature babies.

Biol Neonate 2000; 77 (suppl 1): 26

Weir FJ, Littleton P, Carter N, Hamilton PA.

Atrial natriuretic peptide in preterm infants with respiratory distress syndrome treated with surfactant.

Pediatr Res 1991; 30:638

Werner O, Björklund L.

Effects of ventilation with large tidal volumes in the surfactant deficient lung.

Biol Neonate 2002; 82: 279

Xing QS, Zhang ST, Yang Y, Sun B.

Decreases in saturated phosphatidylcholine and surfactant protein A in airway aspirates during open chest operation for congenital heart diseases.

Biol Neonate 1996; 69: 222

Yarakova N.

Preliminary results from the use of Curosurf® in the state institute hospital "Maichin Dom" (SIH), Sofia.

Biol Neonate 1995; 67 (suppl 1): 82-83

Yarakova N, Hristova E.

Comparative study of clinical signs of RDS in the course of surfactant therapy.

Biol Neonate 1995; 67 (suppl 1): 83

Yu XQ, Feet BA, Moen A, Saugstad OD.

Is nitric oxide (NO) involved in surfactant-induced systemic and pulmonary vasodilatation in newborn piglets with surfactant deficiency?

Biol Neonate 1996; 69: 218-219

Zetterberg G, Curstedt T, Eklund A, Forslid J, Hed J.

Effekter av surfaktant på humana leukocyter.

Svenska Läkaresällskapets Riksstämman, Hygiea 1989; 98: 217

Zetterberg G, Curstedt T, Eklund A, Forslid J, Hed J, Hernbrand R.

The effect of purified surfactant on Mac-1 mobilization and reactive oxygen metabolite production of human leucocytes.

Eur J Clin Invest 1989; 19: 57

Zhang H, Zhou ZY, van der Marel H, Meintjes A, Zhu LW, He LX, Sun B.

Intratracheal instillation of a surfactant and gentamycin liposome preparation mitigates bacterial proliferation in ventilated adult rats with Klebsiella pneumonia.

Biol Neonate 2000; 77 (suppl 1): 27-28

Zhao DH, Sun B, Wu ZH, Robertson B.

Alleviation of respiratory dysfunction and failure by surfactant and inhaled nitric oxide in rabbits with endotoxin-induced acute lung injury.

Biol Neonate 1998; 74 (suppl 1): 45

Zhou BH, Sun B, Gu JH, Zhu LW, Fan SZ.

Enhancement of oxygenation by combined surfactant and inhaled nitric oxide in ventilated rabbits with respiratory failure.

Biol Neonate 1997; 71 (suppl 1): 65

Zhou ZH, Zhang H, Zhu LW, Sun B.

Alleviation of pig acute lung injury by surfactant, inhaled nitric oxide, and pressure support ventilation.

Biol Neonate 1999; 76 (suppl 1): 48

Zia MT, Mishra R, Brown K, Hassan M, LaGamma EF.

An "optimal FRC" approach to respiratory distress syndrome and its effects on chronic lung disease of infancy.

Biol Neonate 2002; 81 (suppl 1): 41

**PROCEEDINGS**

Albertsen P, Eschen C, Verder H.

Laryngeal mask used as a guideway for brief access to the intratracheal space in premature infants.

Proceedings of the 8th International Workshop on Surfactant Replacement, Oslo, 1993; 17

Amato M, Hüppi P.

Prevention of symptomatic patent ductus arteriosus with ethamsylate in babies treated with exogenous surfactant.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 19-22

Amato M, Sun B, Robertson B.

Influence of prostaglandin inhibition and lung compliance on pulmonary permeability of immature newborn rabbits.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 15

Amato M, Sun B, Herting E, Hüppi P, Robertson B.

Bilirubin leakage and surfactant inhibition in immature neonatal rabbit lungs.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Amato M, Scherrer R, Schurch S, Bachofen H, Burri PH.

Effect of Immunoglobulin G on surface tension properties of lipid extract surfactant.

12<sup>th</sup> International Workshop on Surfactant Replacement, Stockholm, 1997

Anceschi M, Robertson B, Broccucci L, Luzi P, Zaccardo G, Cosmi E.

Immunochemical and immunohistochemical studies of protein leakage in immature rabbit lungs; effect of surfactant replacement.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 72-77

Anceschi MM, Robertson B, Broccucci L, Luzi P, Zaccardo G, Cosmi EV.

Effect of Curosurf<sup>®</sup> on lung permeability in immature newborn rabbits.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990

Andréasson B, Juvonen P, Rudnicki J, Aborelius M, Wiklund KE, Robertson B, Curstedt T.

A device for nebulizing surfactant during CPAP treatment in newborn infants.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 31

Babnik J.

Analysis of cerebral doppler blood flow velocity wave form before and after surfactant treatment.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 12-13

Babnik J.

Evaluation of surfactant (Curosurf<sup>®</sup>) treatment of severe RDS in comparison to controls.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 35

Berggren P, Robertson B.

Lung morphology in non-survivors from the First Collaborative European Multicenter Trial.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 72-73

Berggren P, Eklind J, Linderholm B, Robertson B.

Bubbles and automated image analysis for evaluation of surfactant inhibition.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 34-35

Berggren P, Corcoran D, Curstedt T, Halliday H, Robertson B.

Microbubble stability in suspensions of Curosurf<sup>®</sup> and Exosurf, and physiological effects of these surfactants in artificially ventilated premature rabbits.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 59

Bevilacqua G, Ermelando VC, Curstedt T, Robertson B.

Early vs late treatment (40% vs 60% Oxygen).

Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 79-80

Bevilacqua G, Parmigiani S, Volante E, Gaioni L, Compagnoni G, Guerrini P, Rondini G, Chirico G, Cosmi EV.

The Italian experience with Curosurf<sup>®</sup>.

Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 32-40

Bevilacqua G.

Surfactant-substitution in RDS; early versus late treatment.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 36-47

Bevilacqua G, Parmigiani S and Trial Participants.

The "early vs late" treatment trial: 2<sup>nd</sup> interim analysis.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 5-12

Bevilacqua G, Robertson B (eds).

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990

Bevilacqua G, Cosmi EV.

Pre-ventilatory versus post-ventilatory surfactant treatment in neonatal respiratory distress syndrome: A multicentre randomized clinical trial.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 64-68

Bevilacqua G, Borsi MC, Faienza C, Gugliotta M, Parmigiani S.

Two years respiratory and neurological follow-up of newborn infants treated with Curosurf<sup>®</sup>.  
Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 69

Bevilacqua G, Parmigiani S.

Italian multicentre controlled study of Curosurf for prophylaxis of respiratory distress syndrome (RDS) (preliminary data).

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 76

Bongrani S, Papotti M, Razzetti R, Robertson B.

Lung gas volume and lung compliance in premature newborn rabbits treated with different doses of Curosurf<sup>®</sup>.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 95-96

Bos AF, Oetomo SB, Okken A.

Immunological response to surfactant treatment in the newborn.

Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 18-19

Büky B, Kovacs A, Jancso G, Gresko M, Nureddin S.

Favourable factors influencing neonatal mortality and the impact of Curosurf<sup>®</sup> treatment in Hungary.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 27

Büky B, Akos K, Anna D, Györgyi J, Robertson B.

Changing parameters of ventilation: its significance in the treatment of preterm infants with respiratory distress syndrome.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Büky B.

Experiences with Curosurf<sup>®</sup> for treatment of neonatal RDS with Grade IV radiological changes.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 74-75

Büky B, Kovach I, Kovacs A, Jancso G.

Suggested protocol for a national surfactant trial in Hungary.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 113-117

Büky B, Csiky M, Gresko M, Jancso G, Kovach I, Kovacs A, Tahy A.

The Hungarian multicenter Curosurf<sup>®</sup> trial.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 9-13

Clarke T.

Dublin experience.

Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 42-49

Clerx A.

Suggested protocol evaluating the combined effect of surfactant replacement and high frequency ventilation for treatment of neonatal RDS.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 124-126

Clercx A, Blum D.

Treatment of moderate to severe RDS with Curosurf<sup>®</sup>: a two years experience in Belgium.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 34

Collaborative European Multicenter Study Group.

Two year follow-up of babies enrolled in European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 1-2

Collaborative European Multicenter Study Group.

The "early versus late" treatment trial: 2nd interim analysis.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 5-12

Collaborative European Multicenter Study Group.

Randomized European multicenter trial of surfactant replacement in neonatal respiratory distress syndrome: single versus multiple doses of Curosurf<sup>®</sup>.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 4

Corcoran D, Halliday HL.

Factors associated with pulmonary haemorrhage following surfactant therapy: a case-control study from Curosurf<sup>®</sup> 4 database.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 30

Corcoran JD, Berggren P, Halliday HL, Robertson B.

The effect of surfactant protein A on microbubble stability measured by automated image analysis of surfactant suspensions.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 29

Corcoran JD, Sheenan O, O'Hare M, Halliday HL.

Changes in tracheal surfactant protein A following treatment with Curosurf<sup>®</sup>.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 28

Corcoran JD, Sheenan O, O'Hare M, Halliday HL.

Appearance of surfactant protein A after treatment with a surfactant which contains only protein B and C.

Proceedings of the 65<sup>th</sup> Annual Meeting of the BPA, 1993; 75

Cosmi EV, La Torre R, Piazze J, Di Iorio R, Bevilacqua G.

In utero surfactant for the prophylaxis of respiratory distress syndrome.

Proceedings of the 12<sup>th</sup> International Workshop on Surfactant Replacement, Stockholm, 1997

Costeloe KL.

The benefit of surfactant replacement therapy in babies less than 25 completed weeks gestation is unclear.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Cowan F.

Acute effects of surfactant administration on cerebral blood flow velocity.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 14

Cowan F, Greisen G, Edwards D, Svenningsen N, van Bel F.

Round table: Cerebral blood flow and oxygenation in surfactant-treated babies.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 34

Curstedt T, Nilsson G, Johansson J, Robertson B.

Biophysical activity of artificial surfactant.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Curstedt T, Johansson, Jörnvall H, Robertson B.

Reconstituted surfactants based on hydrophobic polypeptides (SP-B, SP-C) and natural or synthetic phospholipids.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 92-93

Curstedt T.

Natural porcine surfactant: manufacture and quality control.

International Curosurf Symposium, Rottach-Egern, 1993; 18-21

Dassieu G, Danan C, Mellah D, Agudze E, Janaud JC.

Effect of first dose of surfactant on the pulmonary hemodynamics.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

De Winter JP, van Bel F, Wijnands JBG, van de Bor M, Robertson B, Egberts J.

Cerebral (CBFV) and aortic blood flow velocity (AoBF) in preterm infants during and after surfactant (SF) treatment.

Proceedings of the 5<sup>th</sup> European Workshop on Surfactant Replacement, Sestri Levante, 1990; 43-47

De Winter JP, Egberts J, de Kleine MJK, van Bel F.

The prophylactic administration of Curosurf<sup>®</sup> to preterm infants.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 7-8

De Winter JP, Merth IT, Egberts J, Bruzual IJ, Quanjer PH.

Lung function measurements during the first year of life in control infants and in infants with RDS, who had Curosurf<sup>®</sup>.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 46

Egberts J, Bevilacqua G.

Prophylaxis trial.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 24

Egberts J, de Winter PJ, van Bel F.

Second interim analysis of the prophylactic administration of Curosurf<sup>®</sup> to preterm infants.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 102-107

Egberts J.

Different treatment of respiratory distress syndrome and costs of hospitalization. Theoretical effects.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 69-70

Egberts J, de Winter JP, Sedin G, Broberger U, de Kleine MJK, van Bel F, Robertson B.  
The Dutch-Swedish prophylactic-surfactant trial with Curosurf®.  
Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian,  
1992; 31

Egberts J, Walti H, Bevilacqua G.  
Meta analysis of three “Prophylaxis versus rescue“ trials with Curosurf®.  
Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 19

Fiori RM, Goncalves AL, Segre CAM, Lopes JMA, Marino WT.  
Surfactant replacement therapy: comparison of two dosage approaches.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem,  
1994

Fornasier M, Papotti M, Razzetti R, Bongrani S.  
Effects of Curosurf® and Exosurf on ventilatory parameters and lung gas volume in  
premature newborn rabbits.  
Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian,  
1992; 60

Fornasier M, Papotti M, Razzetti R, Bongrani S.  
Effects of detergents, Exosurf and Curosurf® on alveolar stability in immature newborn  
rabbits.  
Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 44

Fornasier M, Puccini P, Razzetti R, Acerbi D, Bongrani S, Ventura P.  
Protective effects of Curosurf® versus alveolar epithelial injury induced by  
lysophospholipids.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem,  
1994

Gadzinowski J, Szymankiewicz M, Twarowska I, Halliday HL.  
Improved gas exchange after Curosurf® administration in neonates with respiratory  
distress syndrome.  
Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian,  
1992; 36

Gibson AT.  
Surfactant replacement in the extremely low birthweight infant.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem,  
1994

Gibson AT, Wales JKH, Pearse RG.  
Growth impairment in bronchopulmonary dysplasia.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem,  
1994

Gibson AT, Powers HJ, Silvers KM.

Antioxidant status, vitamin C and outcome in premature babies.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Glover R, Stenson B, Wilkie R, Laing I, Tarnow-Mordi W.

Changes in respiratory compliance after surfactant.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 42

Greisen G, Skov L, Bell A.

Suggested new protocol for study of the effect of surfactant therapy on EEG and cerebral blood flow in preterm infants.

Proceedings of the 5<sup>th</sup> Workshop on Surfactant Replacement, Sestri Levante, 1990; 36-38

Greisen G, Skov L, Jacobsen T, Friis-Hansen B.

Acute cerebral effects of surfactant administration.

Proceedings of the 5<sup>th</sup> Workshop on Surfactant Replacement, Sestri Levante, 1990, 35

Greisen G, Lundström K, Albertsen P.

A quality management system for routine surfactant use.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 25

Groneck P.

Changes in lung mechanics following Curosurf<sup>®</sup> treatment in RDS.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 17-29

Groneck P, Soditt V, Koch D.

Evolution of chronic lung disease after surfactant replacement and effects of early dexamethasone treatment.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 23-24

Groneck P, Goetze-Speer B, Speer CP.

Effects of Dexamethasone on interleukin-8 (IL-8) concentrations in pulmonary effluent fluid of ventilated preterm infants at risk for chronic lung disease.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 39

Groneck P, Goetze-Speer B, Schutt-Gerowitt H, Speer CP.

Inflammatory pulmonary response following colonization of the airways with *Ureaplasma urealyticum* in preterm infants at risk for bronchopulmonary dysplasia.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Haddad J, Donato L, Astruc D, Messer J.

Cerebral blood flow velocities before and after transfer to high frequency oscillation ventilation in newborn infants.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Halahakoon CN, McClure BG, Halliday HL, Reid MMcC.

Outcome of very tiny babies treated with surfactant replacement therapy.

Proceedings of the Irish American Paediatric Society, Scientific Abstracts, 1994; 26

Halliday HL, McCord FB.

Surfactant replacement in Belfast.

Proceedings of the 2<sup>nd</sup> Workshop on European Multicentre Trial of Surfactant Replacement in Neonatal RDS, Mantua, 1987

Halliday HL.

Factors determining response to surfactant. Belfast tables.

Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 24-31

Halliday HL.

Hot topics' 88 in neonatology.

Proceedings of the Royal College of Physicians of Edinburgh 1989; 19: 476-477

Halliday HL.

The Curosurf<sup>®</sup> experience in Europe: Follow-up examination of infants treated with Curosurf<sup>®</sup>.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 69-71

Halliday HL, Tubman TRJ.

The role of surfactant deficiency in neonatal respiratory distress.

Proceedings of the 1<sup>st</sup> International Symposium on Neonatal Medicine. Ceske Budejovice, Czechoslovakia, 1989; 5

Halliday HL.

Follow-up data from the first randomized multicenter trial.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 128-137

Halliday HL, Speer CP.

The high versus low dose trial.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 14-23

Halliday HL, Speer CP.

Pilot trial of high versus low dose Curosurf<sup>®</sup> in babies with severe respiratory distress syndrome.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 67

Halliday HL, Tarnow-Mordi WO.

Curosurf<sup>®</sup> versus Exosurf; the design of a new European multicenter trial.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 89

Halliday HL, Tarnow-Mordi WO.

Proposal for a 4<sup>th</sup> Collaborative Multicentre Study of Curosurf<sup>®</sup>.

Proceedings of the 5<sup>th</sup> Workshop on Surfactant Replacement, Sestri Levante, 1990; 89-106

Halliday HL.

Exogenous surfactant for therapy of neonatal RDS: Past, present and future

Proceedings of the VI. International Berlin Symposium: Research in Perinatal Medicine 1991; 28: 41

Halliday HL, Corcoran D, Patterson CC, Tarnow-Mordi W.

Progress with Curosurf 4.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 38-43

Halliday HL.

Does surfactant work in babies of < 750 g?

Proceedings of the Irish American Paediatric Society, Belfast, 1992; 36

Halliday HL.

How should we use surfactant?

Proceedings of Respiratory Disease in Children: New developments, University of London, 1992; 34

Halliday HL, Patterson CC, Corcoran D.

Interim analysis of Curosurf<sup>®</sup> 4: high versus low dose.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 29

Halliday HL, Tarnow-Mordi WO, Patterson CC.

Proposed multicentre trial of Exosurf, Curosurf<sup>®</sup> and early dexamethasone in infants with moderate to severe RDS.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 74

Halliday HL.

Curosurf® trials in Europe.

International Curosurf Symposium, Rottach-Egern, 1993; 25-30

Halliday HL.

Meconium aspiration syndrome treated with natural surfactant.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Halliday HL.

What interventions facilitate weaning from the ventilator? A review of the evidence from systematic reviews.

Proceedings of the 5<sup>th</sup> International Congress on Pediatric Pulmonology, Editions EDK, Paris, 2002; 140

Hallman M, Merritt TA, Anceschi MM, Di Renzo GC, Cosmi EV.

New means to enhance the alveolar stability in the newborn.

International Symposium on Perinatal Biology, Rome, 1988; 47-48

Hamilton P.

The use of surfactant in babies <700g.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Hannslar L, Wiesemann G, Stassen W.

Pulmonary mechanics and ventilation in premature infants after surfactant treatment.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 30

Haumont D, Rössle C, Biver A, Richelle M, Carpentier YA, Robertson B.

Parenteral nutrition and lipid profile in tracheal effluents of babies receiving surfactant for neonatal RDS; a new protocol.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 118-122

Haumont D, Clercx A, Rössele C, Biver A, Carpentier Y.

Modifications of surfactant phospholipid pattern in premature infants treated with Curosurf®. Clinical and nutritional correlations.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 16-17

Haumont D, Richelle M, Franckart G, Carpentier YA.

Fatty acid (FA) pattern imbalances in preterm infants with RDS receiving parenteral nutrition (PN).

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 46

Herin P.

Stockholm experience.

Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 50-52

Herting E.

Surfactant replacement in patients with persistent fetal circulation, hydrops fetalis and severe interstitial emphysema.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 87-91

Herting E, Harms K, Mahn G, Speer CP.

Proteases and antiproteases in airway samples from patients treated with single or multiple doses of Curosurf<sup>®</sup>.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 69-71

Herting E, Compagnone D, Harms K, Speer CP, Gefeller O, Curstedt T, Robertson B, Herin P, G Noack, Kok J, Koppe J, van Sonderen L, Halliday H, McClure G, Reid M, Tubman R, Laufkötter E, Köhler W, Boenisch H, Albrecht K, Hanssler L, Haim M, Oetomo SB, Okken A, Altfeld PC, Groneck P, Kachel W, Relier JP, Walti H.

Factors influencing morbidity and mortality of Curosurf<sup>®</sup> treated infants with severe RDS.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 4

Herting E, Speer CP, Harms K, Curstedt T, Robertson B, Halliday HL.

Neonatal septicaemia following multiple dose surfactant treatment.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 44

Herting E, Speer CP, Harms K, Schiffmann JH, Curstedt T, Robertson B, Halliday HL.

Radiographic changes following surfactant treatment in infants with severe respiratory distress syndrome.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 41

Herting E, Gefeller O, Harms K, Speer CP, Curstedt T, Robertson B.

Intracranial hemorrhages in surfactant treated neonates with severe respiratory distress syndrome (RDS): time of onset and risk factors.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 38

Herting E, Jarstrand C, Rasool O, Curstedt T, Sun B, Robertson B.

Effect of Curosurf<sup>®</sup> on bacterial proliferation in experimental neonatal group B streptococcal pneumonia.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 37

Herting E, Jarstrand C, Curstedt T, Speer CP, Sun B, Robertson B.  
Inflammatory response in experimental neonatal group B streptococcal (GBS) infection is modulated by surfactant.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Herting E, Jarstrand C, Rasool O, Curstedt T, Håkansson S, Robertson B.  
Effect of surfactant and a specific antiserum to type Ia group B streptococci (GBS) on oxidative metabolism of neutrophils (PMN).  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Holt J, Danielsen K, Finne PH, Gronn M, Meberg A, Silberg IE, Okland O, Saugstad OD.  
The Norwegian Curosurf<sup>®</sup> study.  
Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 50

Hüppi P, Amato M.  
Hematologic changes after surfactant treatment in premature babies with respiratory distress syndrome.  
Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 43

Hüppi P, Amato M, Ramseyer V, Stadler B.  
Specific serum antibodies against Curosurf<sup>®</sup>.  
Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 16

Jin HZ, Chen C, Fan SZ, Lin Z, Zhang LE, Ning SB.  
NRDS and ARDS in Shanghai, China.  
Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 40

Kachel W, Müller W, Lasch P, Varnholt V.  
Clinical studies showing limited success of inhaled nitric oxide in treatment of persistent pulmonary hypertension of the newborn.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Kok JH.  
Thyroid function after surfactant treatment.  
Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 20-21

Kok JH, van Sonderen L.  
Thyroid function in babies treated with single or multiple doses of surfactant.  
Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 63-65

Koranyi J, Bekefi D, Alexy M.

Results of Curosurf<sup>®</sup> treatment in county hospitals.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991: 46

Lundström K, Greisen G.

Hemodynamic impairment and ventilatory response during surfactant replacement therapy with 2 versus 6 doses.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 72

Lundström K, Greisen G.

Curosurf<sup>®</sup> treatment in infants treated with nasal CPAP.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 26

Lundstrom KE.

Hemodynamic impairment and EEG suppression following surfactant replacement therapy using 2 versus 6 aliquots.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Mahn G, Speer CP.

Bronchoalveolar activity and concentration of elastase (E),  $\alpha_1$ -proteinaseinhibitor ( $\alpha_1$ -PI) and E- $\alpha_1$ -PI in infants treated with single or multiple doses of Curosurf<sup>®</sup>.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant-Replacement, Göttingen, 1989; 35

Marraro G.

A new protocol for surfactant replacement in infants with ARDS.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 83-87

Marraro G, Casiraghi GM, Riva A.

ARDS treated with surfactant replacement in 3 leukemic children and 1 child affected by rhabdomyosarcoma.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 50

Marraro G, Sarti A.

Supplementary use of natural surfactant in ARDS infants.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 48

Marraro G.

The use of porcine natural surfactant in the treatment of massive inhalation syndrome of limpid amniotic liquid in the newborn.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 49

Marraro G, Casiraghi G, Motta A, Vignati D.  
Pressure regulated, volume controlled (PRVC) vs control ventilation (VC) in prematures treated with natural surfactant.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Marraro G, Casiraghi, Rataggi M.  
Selective natural surfactant supplementation in the treatment of adult monolateral lung pneumonia: case report.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Marraro G, Diomede L, Salmona M, Casiraghi G, Vignati D.  
Broncho-alveolar lavage (B.A.L.) in surfactant evaluation before and after supplementation in newborns and infants.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

McClure, Wilson DC.  
Surfactant and neonatal respiratory support.  
Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 7-12

McCord B, Halliday HL, McClure G, Reid MMcC.  
Cerebral and pulmonary blood flow after surfactant treatment.  
Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 22

Merritt A.  
Surfactant preparations currently used in the USA; problems and perspectives for the future.  
Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 88

Moen A, Rootwelt T, Curstedt T, Robertson B, Saugstad OD.  
Acute blood pressure effects of surfactant replacement in newborn piglets.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Nobilis A, Machay T, Ronaszeki A, Somogyvari Z.  
Changes of lung function during Curosurf<sup>®</sup> therapy.  
Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 14-15

Papagaroufalas C, Koumenidou M, Xanthou M.  
Surfactant replacement therapy for severe secondary RDS due to septic shock in a 15-day-old infant.  
Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 25

Papagaroufalis C, Stamocosta E, Xanthou M.

Clinical comparative study between Alveofact (A) and Curosurf<sup>®</sup> in premature neonates with RDS.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Papagaroufalis C.

Nasal continuous positive airway pressure (NCPAP) following extubation of very low birth weight (VLBW) neonates treated with surfactant.

Proceedings of the 14<sup>th</sup> International Workshop on Surfactant Replacement, Skagen, 1999; 11.

Parmigiani S, Bevilacqua G.

Early versus late treatment trial of Curosurf<sup>®</sup> for neonatal respiratory distress syndrome.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 5-6

Parmigiani S, Gambini L, Bevilacqua G.

Respiratory compliance and resistances 6 months after surfactant.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 51

Robertson B, Herin P (eds).

European multicenter trial of surfactant replacement in neonatal RDS.

Proceedings of the 1<sup>st</sup> Amsterdam Symposium, 1986

Robertson B, Herin P (eds).

Proceedings of the 2<sup>nd</sup> Workshop on European Multicenter Trial of Surfactant Replacement in Neonatal RDS.

Mantua 1987

Robertson B, Herin P.

Proceedings of the 3<sup>rd</sup> Workshop on European Multicenter Trials of Surfactant Replacement in Neonatal RDS.

Belfast, 1988

Robertson B.

Surfactant replacement in neonatal respiratory distress syndrome.

Proceedings of the International Meeting "Drugs in the World". Torino Part II 1989; 263-267

Robertson B, Curstedt T, Grossmann G, Kobayashi T, Suzuki Y.

Monoclonal antibodies to SP-B inhibit surfactant function in artificially ventilated newborn rabbits.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 101-102

Robertson B, Noack G.

Factors determining the clinical response to surfactant treatment in neonatal RDS: multiple regression analysis of data from 165 patients treated with Curosurf<sup>®</sup> 1985-1988.

Proceedings of the 4<sup>th</sup> Workshop on Surfactant Replacement, Göttingen, 1989; 66-67

Robertson B, Bentz R, Berggren P, Curstedt T, Song GW, Sun B.  
Permeability of the immature rabbit lung in relation to surfactant treatment and ventilator settings.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991

Robertson B, Jarstrand C, Berggren P, Johansson M, Rasool O, Sun B.

A new animal model for evaluation of bacterial growth and lung function in neonatal streptococcal pneumonia.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 62

Robertson B.

Surfactant replacement: biophysical and physiological aspects.  
International Curosurf Symposium, Rottach-Egern, 1993; 22-24

Robertson B, Curstedt T, Herting E, Sun B, Akino T, Schäfer K.

Alveolar-to-vascular leakage of SP-A as a parameter of lung injury in ventilated immature rabbits.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 32

Saugstad OD, Gloppestad K, Aasen AO, Curstedt T, Robertson B.

Activation of the kallikrein-kinin system in babies with RDS. No effects of Curosurf<sup>®</sup> treatment.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 31

Saugstad OD, Gloppestad K, Curstedt T, Robertson B.

Washing out of hypoxanthine after treatment with Curosurf<sup>®</sup>.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 32

Schipper JA, van Sonderen L, Koppe JG.

Evaluation of lung function in newborns with respiratory distress syndrome receiving exogenous surfactant therapy.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Schollin J, Andreasson B, Berggren E, Curstedt T, Robertson B, Malmström B, Moa G, Winbladh B.

Aerosol treatment with surfactant in RDS children treated with CPAP.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Schürch S.

Surface properties of Curosurf® studies with the captive bubble method: Adsorption, hysteresis, stability.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 54

Schürch S.

Films absorbed from fresh Curosurf® are highly enriched in DPPC.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 41

Schürch S, Bachofen H.

Surfactant: monolayer or multilayer? Effects of inhibition.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Schürch S, Palmer D, Amato M.

The effect of cholesterol on the surface activity of lipid extract surfactant.

Proceedings of the 12<sup>th</sup> International Workshop on Surfactant Replacement Therapy Stockholm, 1997

Segerer H.

Types of response following Curosurf® substitution in RDS.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 15-16

Segerer H.

Response typing in very low birthweight infants with clinically diagnosed RDS.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 13

Segerer H, van Gelder W, Curstedt T, Obladen M, Lachmann B.

Response to surfactant treatment in surfactant-depleted rabbits is related to administration technique.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 61

Segerer H.

Modes of surfactant administration.

International Curosurf Symposium, Rottach-Egern, 1993; 37-41

Segerer H, Rey M, Kießling Ch, Obladen M.

Effects of different surfactant doses on blood pressure (BP) and cerebral blood flow velocities (CBFVs).

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 18

Segerer H, Scheid A, Wagner M, Obladen M.

Tracheal surfactant infusion during 5 min. is less effective than bolus instillation in rabbits.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Shinwell ES, Zmora E, Karplus M.

Curosurf<sup>®</sup> in Israel.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 59-62

Shinwell ES Zmora E, Karplus M.

Response to exogeneous surfactant: prognostic significance of immediate improvement in a/A ratio after first dose in multiple dose regimen.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 18

Shinwell ES, Zmora E, Levine D, Karplus M.

Initial response to surfactant therapy as a prognostic indicator.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991

Shinwell ES, Zmora E, Karplus M.

Surfactant replacement therapy in non-RDS respiratory failure in the neonate.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 75

Shinwell E, Golan A, Zalstein E, Zmora E, Shinwell E.

Tolazoline for pulmonary hypertension in non-response to surfactant.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 23

Shinwell E, Kuint J.

Prognostic value of response to surfactant.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 22

Shinwell E, Zmora E, Karplus M.

Effect of surfactant replacement therapy on morbidity and mortality in VLBW infants. A national study in Israel.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Sittlington N, Tubman TRJ, Normand C, Halliday HL.

Cost of surfactant treatment in Belfast.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1990; 83-86

Skov L, Bell A, Greisen G.

Acute effect of surfactant administration on cerebral blood flow in the neonate.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 10-13

Skov L.

Cerebral blood flow and plasma hypoxanthine reaction to surfactant treatment.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1994; 30

Slot H, van Sonderen L.

Renal function in babies treated with single or multiple doses of surfactant.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 66

Song GW, Sun B, Curstedt T, Grossmann G, Robertson B.

Effects of amiloride and surfactant on lung liquid clearance in mechanically ventilated newborn rabbits.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 79-81

Song GW, Huang WX, Gan XZ, Curstedt T, Robertson B.

Effect of surfactant replacement in experimental E. coli pneumonia.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Speer CP, Harms K, Müller U, Schröter W, Curstedt T, Robertson B.

Surfactant replacement therapy in preterm infants with respiratory distress syndrome.

Proceedings of the 3<sup>rd</sup> International Workshop of Surfactant Replacement, Belfast, 1988; 41

Speer CP.

Surfactant-therapy in RDS: Single versus multiple doses. First interim analysis of data from 101 patients treated with Curosurf<sup>®</sup>.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 49-53

Speer CP, Robertson B (eds).

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement. Göttingen, 1989

Speer CP.

The single versus multiple doses trial.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 4

Speer CP, Curstedt T, Robertson B.

The variable clinical response to surfactant replacement for neonatal respiratory distress syndrome for neonatal RDS. International Symposium: Surfactant in Clinical Practice.

Proceedings of the Congress, Parma, 1990; 24

Speer CP, Curstedt T, Robertson B, Herin P, Noack G, Kok J, Koppe J, van Sonderen L, Halliday H, McClure G, Reid M, Tubman R, Laufkötter E, Köhler W, Boenisch H, Albrecht K, Hanssler L, Haim M, Oetomo SB, Okken A, Compagnone D, Harms K, Herting E, Altfeld PC, Groneck P, Kachel W, Relier JP, Walti H.

Randomized European multicenter trial of surfactant replacement in neonatal respiratory distress syndrome (RDS).

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 4

Speer CP, Götze B, Curstedt T, Robertson B.

Curosurf<sup>®</sup> and phagocyte function.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 68

Speer CP, Herting E, Harms K.

Comparison of two natural surfactant preparation.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 53-63

Speer CP, Robertson B, Curstedt T, Halliday HL, Herting E

Final results of the randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single vs. multiple doses of Curosurf<sup>®</sup>.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 3

Speer CP, Götze-Speer B.

Modulation of phagocyte function by natural surfactant preparations.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 56

Speer CP, Herting E, Harms K, Rosinski D, Gefeller O.

Neutrophil elastase in tracheal aspirates of infants with respiratory distress syndrome (RDS).

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 57

Speer CP.

Results of European randomized multicenter trial: single versus multiple doses of Curosurf<sup>®</sup>.

International Curosurf Symposium, Rottach-Egern, 1993; 31-36

Speer CP, Gefeller O, Groneck P, Soditt V, Hanssler L, Roll C, Harms K, Herting E, Laufkötter E, Boenisch H, Robertson B.

Comparison of two natural surfactant preparations: results of a five-center randomized pilot-trial.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 21

Speer CP.

Inflammatory mediators in bronchoalveolar secretions of infants with respiratory distress syndrome.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Spragg R, Gilliard N, Merritt A, Richman P, Robertson B, Curstedt T.

Curosurf<sup>®</sup> for ARDS - the San Diego experience.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 82

Spragg RG.

Experience with surfactant treatment of adult respiratory distress syndrome.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 37

Strayer D.

Inhibition of surfactant activity by monoclonal antibodies to the hydrophobic surfactant-associated proteins.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 99-100

Strayer D.

Serum antibodies and surfactant-antisurfactant immune complexes in babies treated with Curosurf<sup>®</sup> in the first randomized trial.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 3

Strayer DS.

Applications of anti-Curosurf<sup>®</sup> antibodies to understanding the biology of alveolar surfactant.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 28-29

Strayer D.

The use of anti-Curosurf<sup>®</sup> antibodies to identify structures important to the regulation of surfactant production.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 55

Strayer D, Shijun Y, Henry H.

Regulation of surfactant production: Receptor proteins recognizing SP-A.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 24

Strayer DS, Herting E, Bo S, Robertson B.

Surfactant protein A protects surfactant from inactivation by fibrinogen in vivo.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Strohmaier W, Müller B, Kneidinger R, Redl H, Schlag G.  
Studies of the potential role of SP-A in surfactant replacement - in vitro and in vivo investigations.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 30-31

Strohmaier W, Ohlinger W, Redl H, Schlag G.

Histologic and radiologic studies on the distribution of exogenous surfactant in rabbit lung.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 52

Sun B, Curstedt T, Robertson B.

Surface properties of Curosurf<sup>®</sup> during long-term cycling in Wilhelmy balance.

Proceedings of the 3<sup>rd</sup> International Workshop on Surfactant Replacement, Belfast, 1988; 16-17

Sun B, Kobayashi T, Curstedt T, Grossmann G, Robertson B.

Application of a new ventilator-multiplethysmograph system for testing efficacy of surfactant replacement in newborn rabbits.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 94

Sun B, Curstedt T, Grossmann G, Robertson B.

Surfactant treatment for experimental meconium aspiration.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990

Sun B, Song GW, Curstedt T, Robertson B

Surfactant replacement therapy in experimental meconium aspiration syndrome.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 78

Sun B, Andersson M, Curstedt T, Robertson B.

Nebulized surfactant (Curosurf<sup>®</sup>) improves blood oxygenation in rats with respiratory failure induced by repeated bronchoalveolar lavage.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 35

Sun B, Chen S, Zhou PH, Fan SZ.

Preterm pregnancy with total parenteral nutrition, respiratory distress syndrome, and surfactant replacement therapy: First case of Curosurf<sup>®</sup>-treated immature newborn infant in China.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 36

Sun B, Herting E, Curstedt T, Robertson B.

Curosurf<sup>®</sup> improves lung function in an adult rat model of meconium aspiration.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 34

Sun B, Sun MY, Yan YL.

Effects of Curosurf® in a premature neonate with severe respiratory distress syndrome. Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 33

Sun B.

Surfactant replacement therapy for severe neonatal hyaline membrane disease. Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Sun B, Robertson B.

Effect of synthetic surfactant (Exosurf) on gas exchange in ventilated adult rats with surfactant deficiency induced by bronchoalveolar lavage. Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Svenningsen N.

Cerebral function and oxygenation monitoring before and after surfactant endotracheal instillation. Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 13

Svenningsen N, Björklund L, Vilstrup C, Werner O.

Lung mechanics in ET-surfactant treated infants (FRC with SF static pressure-volume diagram with interrupter technique). Preliminary observations. Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 36

Svenningsen NW, Saugstad O & the Norwegian Curosurf® study group.

Surfactant in extremely low birth weight (ELBW) infants. Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 43

Svenningsen N, Björklund LJ, Vilstrup CT, Werner O.

Will Curosurf® ET-instillation have any influence on the mechanical properties of the lungs? Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Szymankiewicz M, Gadzinowski J, Breborowicz G.

Curosurf® treatment of babies from Poznan who were enrolled in Curosurf®. Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 42

Tarnow-Mordi W.

Prevention of severe respiratory illness and its consequences in premature infants: protocol for a population-based evaluation of the costs and benefits of surfactant replacement therapy in 3 Scottish health regions. Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 59-65

Tarnow-Mordi W, Wilkie R, Reid E.

Is the clinical management of infants receiving mechanical ventilation or surfactant improved by routine measurement of respiratory compliance?

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 37

Thomas P.

Radiological changes after surfactant instillation.

Proceedings of the 3<sup>rd</sup> International Workshop on European Multicenter Trials of Surfactant Replacement in Neonatal RDS, Belfast, 1988; 23

Tovar JA, Alfonso LF, Sasieta MJ, Ingunza N, Alvarez FJ, Valli i Soler A.

Lung phospholipids in experimental congenital diaphragmatic hernia.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 63

Tubman TRJ, Halliday HL.

Surfactant treatment for respiratory distress syndrome following prolonged rupture of membranes.

Proceedings of the BPA 61<sup>st</sup> Annual Meeting York, 1989; 72: 101

Tubman TRJ, Halliday HL.

Surfactant treatment for respiratory distress syndrome (RDS) following very prolonged rupture of the membranes (PROM).

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 76-78

Tubman TRJ, Halliday HL.

Surfactant replacement in severe neonatal respiratory distress syndrome (RDS): Follow-up at one year.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 69-71

Tubman TRJ, Reid MMcC, McClure BG, Halliday HL.

Surfactant treatment for severe respiratory distress syndrome - experience in Belfast.

Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 79-86

Tubman TRJ, Halliday HL.

Effect of surfactant replacement therapy on dynamic compliance of the respiratory system in neonatal respiratory distress syndrome.

Proceedings of the BPA 62<sup>nd</sup> Annual Meeting, Warwick, 1990; 74: 113

Tubman TRJ, Halliday HL.

Lung compliance measurements following treatment with Curosurf<sup>®</sup>.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 67

Tubman TRJ, Halliday HL, Normand C.

Cost-effectiveness of Curosurf<sup>®</sup> treatment.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 126

Tubman TRJ, Halliday HL, Strayer DS, Berggren P.

Two year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 1-2

Tubman TRJ, Normand C, Halliday HL.

Cost of surfactant replacement for severe neonatal respiratory distress syndrome: results of a randomised controlled trial.

Proceedings of the BPA 62<sup>nd</sup> Annual Meeting, Warwick, 1990; 89: 170

Tubman TRJ, Rankin SJ, Halliday H, Johnston SS.

Surfactant replacement therapy and the incidence of retinopathy of prematurity.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 52

Tubman TRJ.

Surfactant replacement for neonatal respiratory distress syndrome: Cost implications and other considerations.

Proceedings of the Guild of Hospital Pharmacists, 1992; 12

Valls i Soler A, Heredia L, Echevarria, L, Hernaez E, Gastiasoro Cuesta E.

Curosurf<sup>®</sup> in Spain.

Proceedings of the 5<sup>th</sup> International Workshop on Surfactant Replacement, Sestri Levante, 1990; 48-58

Valls i Soler A.

Tratamiento del Síndrome del Distrés Respiratorio neonatal con surfactante natural exógeno

Proceedings of the XIII. Spanish Congress of Perinatal Medicine. Tenerife, 1991; 151-158

Valls i Soler A, Lizarraga M, Lopez Heredia J, Roman L, Hernaez E, Gastiasoro E.

Effectiveness of clinical use of Curosurf<sup>®</sup> in severe RDS. A case-control study.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 26-27

Valls i Soler A, Lopez Heredia J, Roman L, Gastiasoro E.

A simplified method to administer Curosurf<sup>®</sup>. Proposal for the "side-hole" multicenter clinical trial.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 73

Valls i Soler A, Robertson B (eds).

Proceedings of the 7th International Workshop on Surfactant Replacement. San Sebastian, 1992

Valls i Soler A, Lopez Heredia J.

The "side-hole" pilot study. Progress report.

Proceedings of the 8th International Workshop on Surfactant Replacement, Oslo, 1993; 47

Valls i Soler A, Alfonso L, Arnaiz A, Alvarez JL, Tovar J.

Surfactant (SF) dysfunction and therapy in experimental and clinical congenital diaphragmatic hernia.

Proceedings of the 9th International Workshop on Surfactant Replacement, Jerusalem, 1994

Valls i Soler A, Hernáez E, Quintana JM, Román L, López Heredia J, Gastiasoro E.

Immediate oxygenation response to Curosurf® administration predicts survival of preterm neonates with RDS.

Proceedings of the 9th International Workshop on Surfactant Replacement, Jerusalem, 1994

Vandenbussche G, Clercx A, Curstedt T, Johansson J, Jörnvall H, Ruyschaert JM.

Structure and orientation of SP-C and SP-B in membranes of surfactant lipids.

Proceedings of the 7th International Workshop on Surfactant Replacement, San Sebastian, 1992; 53

Veiner-Magnazi T, Yanai N, Shniur A, Penikov M, Reich D.

Lamellar body concentration in amniotic fluid as a method of prediction of neonatal respiratory distress syndrome.

Proceedings of the 9th International Workshop on Surfactant Replacement, Jerusalem, 1994

Verder H.

Surfactant treatment in spontaneously breathing babies with RDS: protocol for a new randomized trial.

Proceedings of the 4th International Workshop on Surfactant Replacement, Göttingen, 1989

Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbesen F, Greisen G, Hobolth N, Holm V, Jacobsen T, Johansen KH, Kamper J, Lange A, Mølgaard C, Nathan E, Nielsen F, Pedersen-Bjergaard L, Peitersen B, Robertson B, Skov L, Svenningsen N, Tegllund L.

The Danish protocol for surfactant replacement in patients with RDS requiring ventilatory support by nasal-CPAP.

Proceedings of the 5th International Workshop on Surfactant Replacement, Sestri Levante, 1990; 107-112

Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbesen F, Greisen G, Hobolth N, Holm V, Jacobsen T, Johansen KH, Kamper J, Lange A, Mølgaard C, Nathan E, Nielsen F, Pedersen-Bjergaard L, Peitersen B, Robertson B, Skov L, Svenningsen N, Tegllund L.

Curosurf<sup>®</sup> replacement for RDS in infants treated with nasal-CPAP. Status after the pilot study.

Proceedings of the 6<sup>th</sup> International Workshop on Surfactant Replacement, Héviz, 1991; 47-50

Verder H, Albertsen P, Robertson B, Curstedt T, Agertoft L, Andersen O, Christensen NC, Ebbesen F, Djernes B, Greisen G, Hertel J, Hobolt N, Holm V, Jacobsen T, Johansen KH, Kamper J, Lange A, Lundström K, Mølgaard C, Nathan E, Nielsen F, Pedersen-Bjergaard L, Peitersen B, Skov L, Svenningsen N.

Treatment of RDS with nasal-CPAP and Curosurf<sup>®</sup>. Danish-Swedish randomized multicenter study. Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 71

Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundström K, Jacobsen T, Agertoft L, Hobolth N, Djernes B, Grytter C, Hertel J, Holm V, Hansen US, Kamper J, Johansen KH, Nathan E, Lange A, Peitersen B, Pedersen-Bjergaard L, Skov L, Svenningsen N, Curstedt T, Bertelsen A, Vestergaard A, Petersen E.

Treatment of RDS with nasal-CPAP and Curosurf<sup>®</sup>. Final results from the Danish-Swedish randomized multicenter study.

Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 20

Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B, Agertoft L, Christensen MF, Djernes B, Hertel J, Johansen KH, Kaad P-H, Nathan E, Peitersen B, Svenningsen N.

Early administration of Curosurf<sup>®</sup> to babies with RDS <30 wk's of gestation treated with early nasal-CPAP. A new protocol for a randomized multicenter study.

Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Walti H, Boule M, Moriette G, Relier JP.

Pulmonary functional outcome at one year of age in infants treated with natural porcine surfactant at birth.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 51

Walti H, Parat S, Paris J, Breard G, Relier JP.

A comparison of surfactant replacement as prophylactic and rescue therapy with porcine natural surfactant extract (Curosurf<sup>®</sup>) in newborns of less than 31 weeks' gestation. A background analysis and description of the trial.

Proceedings of the 6<sup>th</sup> European Workshop on Surfactant Replacement, Héviz, 1991; 44-45

Walti H, Paris J, Breart G, Relier JP.

Porcine surfactant replacement therapy in neonates of less than 31 week's gestation: a randomized trial of prophylaxis versus rescue multiple low doses administration.

Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 32

Walti H, Clamadieu C, Moriette G, Relier JP  
Curosurf® and HFOV: the new deal.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Weintraub Z, Shnitzer S, Lanir A, Gottfried V, Gershon D.  
Thermo-chemiluminescence of exogenous surfactants (Curosurf®, Survanta, Exosurf, phosphatidylcholine), and natural lung surfactant and its use in clinics and research.  
Proceedings of the 9<sup>th</sup> International Workshop on Surfactant Replacement, Jerusalem, 1994

Wijnands H, van Bel F, Ruys J, Egberts H.  
First results of the randomized clinical trial of prophylactic treatment with Curosurf® in very preterm babies.  
Proceedings of the 4<sup>th</sup> International Workshop Surfactant Replacement, Göttingen, 1989; 48

Wilkie RA, Bryan MH, Tarnow-Mordi W.  
Selection of infants for surfactant replacement by measuring respiratory compliance.  
Proceedings of the 4<sup>th</sup> International Workshop on Surfactant Replacement, Göttingen, 1989; 97-98

Wilson DC, Scrimgeour CM, Halliday HL, Reid M, McClure G, Rennie MJ.  
Causes of prolonged undernutrition in the surfactant treated extremely-low-birthweight infant.  
Proceedings of the 7<sup>th</sup> International Workshop on Surfactant Replacement, San Sebastian, 1992; 45

Winbladh B, Berggren E, Dahlström A, Gentz J.  
Experience with nebulized surfactant.  
Proceedings of the 8<sup>th</sup> International Workshop on Surfactant Replacement, Oslo, 1993; 45

### **Acknowledgment:**

The editors thank Carola Wolpert, Würzburg for the careful preparation of the bibliography.